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CHAPTER 1 
INTRODUCTION 
 
The number of human immunodeficiency virus (HIV) infected people is 
large and widespread. The Joint United Nations Programme on HIV/AIDS 
(UNAIDS) released the 2008 UNAIDS report on the global acquired 
immunodeficiency syndrome (AIDS) epidemic, stating that an estimated 30-36 
million people are living with HIV worldwide. More than 20 million people have 
died. Most of the individuals with this disease reside in developing nations [54,72]. 
The HIV-infected patients need timely and lifelong medical treatment in order to 
live. The expense of such treatment is even high in those lesser developed 
nations [14,17,18,57]. Additionally, there are not enough physicians with HIV/AIDS 
expertise to properly prescribe the appropriate and potentially life-saving drugs. 
This shortage leads to a significant number of deaths. Prescribing the right drugs 
can increase the HIV-infected patients’ lifespan. 
1.1    Problem Statement 
The challenge in treating most diseases is to optimize medical decision-
making. HIV/AIDS is an extremely severe disease. An HIV/AIDS patient has 
individual characteristics such as genetic traits, reaction to the side effects of 
drugs, and overall prognosis. Many symptoms and diagnoses are vague in their 
definitions and hard to measure. Treatment outcomes are also subjective, with 
some degree of uncertainty. To address treatment decisions for an individual 
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patient, a clinician gathers all these variables into a clinical decision process and 
then a treatment decision is judged. Expert opinions play a significant role in 
optimizing treatment outcomes for specific patients. Many variables and factors 
involved in the medical treatment could cause physicians with inconsistent 
treatment decision-making. 
In HIV/AIDS treatment, the highly active antiretroviral therapy (HAART) is 
an efficient therapy that can improve a patient’s mortality and morbidity [38]. A 
combination of two or three drugs from three drug classes, nucleoside reverse 
transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors 
(NNRTIs), and protease inhibitors (PIs), is used in HAART to suppress the viral 
load caused by HIV-infected CD4+ cells. When infected, the CD4+ cells are 
unable to signal the immune response cells (i.e., cytotoxic lymphocytes) in order 
to eliminate infection. The patient can retain low viral load and high population of 
CD4+ cells that would be the ideal clinical situation in HIV therapy. The desired 
drugs should provide such results with a minimum of side effects and toxicities 
(e.g., [38] listed common side effects and toxicities of anti-HIV drugs). Modeling 
the interaction between the viral load, CD4+ cells and the immune response cells 
was studied widely. That study included [35,37,43], [49]-[51], and their models 
were based on differential equations. 
Clinical studies as well as empirical studies demonstrate that the patient 
must be strict with medication adherence to achieve levels of low viral load and 
high CD4+ cells. Taking less than 75-80% of the regimen prescription is 
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considered as poor adherence, causing an underestimate of treatment effect. The 
patient’s individual characteristics and the treatment regimen affect patient 
adherence. Additionally, [40] provided other factors associated with patient 
adherence. 
The technical approaches that contribute to treatment decision-supporting, 
especially in HIV/AIDS treatment, mainly include statistical methods [35]-[37], 
expert systems [8,10,48], and fuzzy discrete event systems theory [22,25,31,34]. 
The statistical methods were employed to estimate the unknown parameters in 
HIV dynamic models based on differential equations. Bayesian approach 
[35,36,39,42] is a powerful statistical method to estimate dynamic parameters for 
complex HIV dynamic models without closed-form solutions available, but it is 
complicated in application. Conversely, the expert system approach sometimes 
referred to as knowledge-based approach is designed using either rule-based or 
case-based reasoning methods to emulate the performance of treatment 
professionals. In the expert system the representation of knowledge is intuitive 
and reasoning sequences of decisions are understandable. The expert system 
usually employs the probability theory to describe the uncertainties of clinical 
parameter characteristics. When merging to artificial neural network [8,9,15], the 
expert system gained profit on self-learning capabilities being able to handle 
frequent update of existing knowledge or inclusion of new knowledge. The expert 
system could be combined with fuzzy set theory [1]-[3] (e.g., [47,71]). That theory 
provided the expert system capable of handling the uncertainties in form of fuzzy 
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rules and memberships. The physician knowledge is subjective, and a consensus 
among a group of individual physicians is difficult and rarely achieved. Extracting 
and representing the consensus knowledge from diverse opinions into a usable 
form like the IF-THEN rules for the expert system would be complicated and 
costly. 
Recently, the theory of fuzzy discrete event systems (FDES) [12,13] was 
established and studied with the retrospective HIV/AIDS patients for the treatment 
regimen selection [22], [25]-[27], [31]. FDES theory merges the fuzzy system 
technology with the discrete event systems (DES) technology [4]. The DES is 
used to model a system which is described by sequences of events that involves 
changes of system states. Theoretically, the changes of the states would be 
occupied completely when the corresponding events take place. An evaluation of 
the state change can be mathematically described by a transition function (e.g., a 
partial function). A deterministic automaton can be used as a model of DES. On 
the other hand, a model of FDES is represented by a fuzzy automaton. FDES 
allows partial changes of states when the event occurs. The transition function 
involving fuzzy logic operations (e.g., max-product, max-min) will be employed to 
describe such changes of states. For example, for a partial change of states, in 
the medical field, saying a patient’s illness is bad would be vague because the bad 
condition may mean something different for different people. After a treatment 
event (e.g., prescribing a drug), the patient’s illness seems to be improved, which 
is between bad and fair state. The incomplete change of the illness states will 
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associate partially with corresponding states (i.e., saying 40% bad state and 60% 
fair state) in a state transition matrix.  Such uncertainties and vagueness of the 
patient’s illness state and state transition can be handled by the FDES but not the 
DES,  showing that FDES is capable of handling a system with uncertainties and 
vagueness of the state and state transition. 
The HIV/AIDS treatment regimen selection system is an interesting 
example of clinical applications achieved using FDES approach. Some important 
features of the application in concise details are given in the next session. This 
FDES-based system provided intuitive physical meanings of the parameter 
representation. The sequence process from beginning to end is easy, conceptual 
understanding for people. However, the situation of collecting consensuses may 
be undergone in difficult environments, especially in the biomedical field, and so 
may not be successful. This potential focused our attentions on how to correct this 
situation. Moreover, the HIV/AIDS epidemic is a global problem. Most of those 
suffering from this epidemic live in poor countries where the expertise of the 
physicians is limited and so the prescribed treatment is inefficient. The FDES-
based system could provide a significant tool for HIV/AIDS treatment decisions. 
1.2   Fuzzy Discrete Event System (FDES) in HIV/AIDS Treatment Regimen 
Selection System 
In the antiretroviral therapy, two major concerns in drug selection are 
choosing ones with sufficient ability to suppress the HIV replication and those that 
minimize side effects. Complying with these goals would slow down viral 
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resistance in HIV/AIDS patients with the proper doses, thus prolonging their lives. 
The combination of drugs used in antiretroviral therapy (i.e., HAART) for HIV-
infected patients is called a regimen. The HIV/AIDS specialists can prescribe 
proper regimens for specific characteristics of the patients. However, the 
prescriptions of the appropriate regimens could be inconsistent if the specialists 
deal with similar characteristics of patients time after time. The support system for 
treatment regimen selection (i.e., FDES-based system) providing a solution for 
such problem would be preferred by those specialists. In the FDES-based system, 
FDES theory was applied in HIV/AIDS treatment regimen selection system [22] 
being implemented in Fuzzy Finite State Models block illustrated in Figure 1.1. 
Three regimens were prescribed to patients. Each regimen consisted of Combivir 
(CBV) and one another drug, Efavirenz (EFV), Nevirapine (NVP), or Abacavir 
(ABC), shown in Table 1.1 with corresponding percentages of four clinic-
considered parameters. Potency of the regimen, expected patient adherence to 
the regimen, adverse events (side effects and toxicities), and future drug options 
due to failure of the current regimen were the clinical parameters used in the 
model that needed to be defined and balanced by an HIV/AIDS specialist. 
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Figure 1.1: Block diagram of the FDES-based regimen selection system 
 
Table 1.1: Values of four clinical parameters of the three HIV/AIDS  
treatment regimens 
 Potency Adherence Adverse Events 
Future Drug 
Options 
Regimen 1: 
CBV+EFV 90% 80% 20% 60% 
Regimen 2: 
CBV+NVP 85% 85% 20% 65% 
Regimen 3: 
CBV+ABC 80% 90% 10% 85% 
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1.2.1 Fuzzy Sets in HIV/AIDS Treatment System 
In the application of FDES theory to the HIV/AIDS treatment regimen 
selection system, four clinical parameters were primarily used in optimizing an 
antiretroviral treatment regimen for HIV-infected patients. These parameters are 
the regimen’s expected potency, the patient’s expected adherence along with the 
regimen, adverse events (e.g., side effects, toxicities) caused by the regimen, and 
future drug options due to the drug-resistance that develops from the current 
regimen.  
Potency parameter is used to indicate a regimen capable of suppressing 
the HIV replication. As shown in Table 1.1, the measure of potency uses the 
percentage of patients who achieve clinical trials of plasma HIV RNA below a 
baseline (i.e., less than 400 copies/mL) after 48 weeks of treatment. Adherence is 
complicated and involves various factors that a patient faces in order to comply 
with the antiretroviral therapy. Effectively, at least 95% of the prescribed regimen 
doses are recommended for the patients to get desired outcomes of the treatment 
[55]. However, the HIV/AIDS studies indicate patients follow, at most, only 70% of 
prescribed regimens. Insufficient adherence cannot maintain suppression of HIV 
replication in an appropriate way and furthermore causes rapid development of 
drug-resistant HIV.  
Adherence was defined as the expected percentage of doses of regimen 
prescribed by HIV/AIDS specialists that the patient would take faithfully each 
week. Adverse events were defined as the risk in the form of the undesired side 
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effects and toxicities to the patient under the regimen. Some medical information 
and physical behavior were considered, involving, for example, patient’s age, 
gender, cholesterol, blood pressure, diseases like diabetes or hepatitis, etc. 
Finally, if the current regimen failed to maintain the suppression of HIV RNA 
replication and led to the development of resistance to the regimen, what is the 
feasibility that new regimens would be available for effective antiretroviral 
treatment? That is the definition of the clinical parameters of future drug options. 
In the FDES system, each of four parameters was fuzzified by type-1 fuzzy 
sets defined according to HIV/AIDS specialists’ knowledge as well as the clinical 
literatures. These type-1 fuzzy sets served to represent specialists’ consensus. 
Unfortunately, more often in clinical practice, specialists with distinct knowledge 
and expertise may have a difficult time reaching a consensus. As an example, the 
fuzzy sets “Medium” and “High” shown in Figure 1.2 are two fuzzy variables for the 
regimen’s future drug options parameter. The other three clinical parameters; 
potency, “Medium” and “High”; adherence: “Challenging”, “Moderate”, and “Easy”; 
and adverse events: “Very low”, “Low”, and “Medium”, were fuzzified using similar 
type-1 fuzzy sets. 
 
 
 
 
 
  
10 
 
Figure 1.2: Two type-1 fuzzy sets defined for future drug options in the FDES 
system. In case of regimen 2, after fuzzification of the 65%, 0.9560 and 
0.4111 are obtained as memberships for “Medium” and “High”. 
 
1.2.2 FDES-Based Model for HIV/AIDS Treatment System 
A fuzzy automaton can be used to model the FDES describing various 
parameters available and their potential output. The Fuzzy Finite State Model, a 
part in HIV/AIDS treatment system in Figure 1, is an example of the use of the 
fuzzy automaton.  Generally, the fuzzy automaton (G) [7,12,13,16], [19]-[21], [23] 
can be expressed as ),,,( 0qQG δΣ= . The formula describes how a state in the 
system changes from a current one to the next one when an event occurs. The 
current state q is a vector q=[v1, v2, …, vn] in the fuzzy state space Q=[0, 1]n, 
where ]1,0[∈iv  is the membership grade of the state i possibly taken in the 
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system. The Qq ∈0  is the initial state vector. An event kσ  is in the set of events 
}...,,,{ 21 mσσσ=Σ  represented by a state transition matrix [ ]
nn
k
ij
k
×
= σσ , 
where ]1,0[∈kijσ states the chance of the system shifting from state i to state j when 
the event takes place. Consequently, the occurrence of the event kσ causes the 
update of the current state vector q. This state transition would be described byδ . 
The update (next) state vector 'q can be computed by kqq σo=' , where o  a fuzzy 
logic operation is defined by δ . 
The FDES model may consist of N fuzzy automata: G1 G 2 … G N. Their 
corresponding state vectors and event sets are denoted by q1 q 2 … q N and Σ1 Σ2 
… ΣN , respectively. For instance, there were four automata in the FDES-based 
regimen selection system. Each was modeled for each of the clinical parameters. 
The state vectors could be either 1×3 vector or 1×4 vector, for instance, 
adherence state vector has four components: initial, challenging, moderate, and 
easy, with the initial state vector represented by [1 0 0 0]. (Numbers in the second, 
third, and fourth place are membership grade for “Challenging”, “Moderate”, and 
“Easy”, respectively). Since prescribing a regimen referred to the occurrence of 
events in the system, thus each of the four sets would have three events (three 
given regimens). 
1.2.3 Optimization in the FDES-Base Treatment System  
All the events in the FDES-based system can be assumed to be either 
disabled and/or enforced. Controllable events are events that can be disabled, 
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whereas enforceable events are those events that can be enforced. To optimize 
FDES is to disable some controllable events and/or enforce some enforceable 
events. The forward-looking tree was employed for an optimal control online 
shown in Figure 1.3. After each of the events occurs, the controller will assess the 
possible consequent state of the system and determine which events are to be 
disabled and/or enforced. 
 
q-state
q'-state
q0-initial state
i-th step
i+1-th step
-eventσ
 
Figure 1.3: For FDES, q and q′ in an example forward-looking tree 
for optimal control synthesis are fuzzy states represented by a 
vector containing the fuzzy state vectors. 
 
Each node in the forward-looking tree for an FDES represents a fuzzy 
state. The fuzzy state (node) q in Figure 1.3 is a vector containing the fuzzy state 
vectors: ]...,,,[ 21 Nqqqq = . Occurrence of an event leads to movement of a fuzzy 
state. In Figure 1.3 the occurrence of the event σ  causes the movement of the 
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fuzzy state q to a new fuzzy state: ]...,,,[' ''2'1 Nqqqq = , where 'iq  is obtained by 
either σoii qq =' , iG∈σ or ii qq =' , iG∉σ . 
Let h be a node in the forward-looking tree and designed as ),( sqh = , 
where q is the corresponding fuzzy state (vector of the fuzzy state vectors) and s 
is the sequence of events leading to the expected node from the initial fuzzy state 
q0. Furthermore, each node in the forward-looking tree can be calculated for the 
performance index, cost measure or other specified measurements. The 
effectiveness measure and cost measure are two common measurements for a 
branch as defined for its terminal nodes in the forward-looking tree for the FDES 
in HIV/AIDS treatment system. The effectiveness measure and cost measure for a 
node ),( sqh =  can be expressed as )],...,,,([),()( 21 sqqqfsqfhE N==  and 
)],...,,,([),()( 21 sqqqgsqghC N== , respectively, where f and g are the functions.  
For the HIV/AIDS treatment, the term of optimization used is to maximize 
the effectiveness of the expected treatment regimens for a given cost of the 
treatment regimen. Therefore, the optimization problem for characterized state or 
node h of the forward-looking tree for the HIV/AIDS treatment system can be 
expressed as 
    ),(max
)(
hE
hTr
 such that LhC <)(          (1.1) 
where Tr(h) is the forward-looking tree beginning at node h, L is a given number of 
the limited cost, and LhC <)( is the constraint of cost persistently maintaining 
during the optimization execution.  
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The level of the complex optimization depends upon the length of the 
forward-looking tree Tr(h). A node which is several levels apart from the beginning 
would have more complexity of optimization. Usually for the HIV/AIDS treatment, 
one or two levels of the optimization which corresponds to one or two rounds of 
the treatment are desired. A treatment is considered to be the same round of the 
treatment if the drug or regimen is used without changing.  
1.3 Issues on Representations of Physicians’ Expertise in FDES-Based 
HIV/AIDS Treatment Regimen Selection System 
As the compilation of many complicated factors, the FDES-based system 
can be considered to be the complex treatment system. All these factors were 
constructed based on the specialists’ knowledge and experience as well as clinical 
literatures.  Extracting knowledge and experience from specialist domains is a 
significant task. It is not easy for the specialists to express their opinions 
quantitatively. Accurate conversion of the expertise domains into a useable form 
for the system is a technical difficulty that the system developer encounters. In the 
FDES-based framework, point estimates (crisp numbers) and type-1 fuzzy sets 
are the FDES-useable forms describing subjectivity and imprecision in specialists’ 
knowledge and experience.  
In the knowledge acquisition for regimen’s characteristics, the HIV/AIDS 
specialist was asked to estimate and give a percentage of clinical parameters for 
all regimens used in the medical treatment, for example, such as those shown in 
Table 1.1. The percentages represented the specialist’s best point estimates of 
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the regimen’s anticipated clinical parameters. As seen, these numbers were 
uncertainties, as no such true values existed in the literature. If the specialist was 
allowed to use interval numbers (e.g., potency is [80%, 90%] for regimen 2), fuzzy 
numbers (e.g., potency is about 85%) or fuzzy sets, it would be a more realistic 
representation of the specialist’s knowledge. 
Since the absolute truth in HIV/AIDS treatment is mysterious and unknown, 
inequality respective to individual specialists’ opinions should be potentially 
mentioned. This inequality is an issue when specialists in the team have different 
opinions. For example, specialist A’s opinion on the potency of regimen 2 is 82%, 
whereas specialist B’s opinion is 88%. To meet the requirements for the FDES-
based system, the compromising consensus must be conducted. The specialists’ 
agreement would be 85% potency of regimen 2. If they insist on their own 
numbers, the potency consensus would not be achieved. The FDES-based 
system could not work under this situation.  
Furthermore, the interval value [80%, 90%] or the fuzzy number, around 
85%, would represent remarkably the diverse opinions. The issue is similar when 
the HIV/AIDS specialists define the fuzzy sets for the four clinical parameters. For 
instance, the fuzzy sets in Figure 1.2 represented the consensus of the specialists’ 
opinions describing the future drug options parameter characteristic of the system 
changing from initial state to “High” or “Medium” state. Failing to reach consensus 
and insisting on using different fuzzy sets cannot be handled by the current FDES-
based system. The issue may exist in the specialist domains dealing with equal 
  
16 
respective expertise among differences. Without doubt, such a problem of 
obtaining consensuses occurs in the biomedical field. The second issue seems to 
be a conflict of consensus achievement that would cause the first order fuzzy sets 
(i.e., type-1 fuzzy set) insufficient representation of the specialists’ knowledge. 
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(a) 
 
(b) 
Figure 1.4: Type-2 fuzzy sets in EFDES system as defined, for example, for future 
drug options: (a) the primary memberships with footprints of uncertainty of the 
type-2 fuzzy sets “Medium” and “High”, (b) the secondary membership function for 
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the fuzzy set “Medium” at future drug options of 65% is triangular (solid line) or 
rectangular (dotted line) as assumed the fuzzy sets is an interval type-2 fuzzy set. 
 
To handle this situation and accomplish the knowledge acquisition of such 
specialists’ distinct opinions, the higher order fuzzy sets need to be utilized. Type-
2 fuzzy set, one order higher than type-1 fuzzy set, can be described by a 
membership function of memberships over an entire universe of discourse which 
is called a secondary membership function. The membership function is now 
called a primary membership function. Type-2 fuzzy set [6,11,30,53,54,67,68] 
contains an infinite number of type-1 fuzzy sets (i.e., the primary membership 
functions) creating a footprint of uncertainty (FOU) [6,52] as shown in Figure 
1.4(a) that would characterize diversities and uncertainties of the specialists’ 
knowledge. The footprint of uncertainty can be described by an upper primary 
membership function and a lower primary membership function which bind 
countless type-1 membership functions. A second membership function shown in 
Figure 1.4(b) can be defined over the primary membership grades at a particular 
value of the universe of discourse (i.e., at 65% future drug options). A type-2 fuzzy 
set which has equal secondary memberships is named an interval type-2 fuzzy 
set.  
Type-3 fuzzy set [6] is one order higher than type-2 fuzzy set. A third 
membership function can be defined over the second memberships in the same 
manner as defining the secondary membership function over the primary 
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memberships. The higher the order of the fuzzy set, the more complicated the 
system. At present, the type-3 or higher orders fuzzy sets have not been 
implemented in practice. 
Alternatively, if type-1 fuzzy set could be derived as a 2-D function: y=f(x)), 
then type-2 fuzzy set would be derived as a 3-D function: z=f(x,y). The one 
dimension beyond type-1 fuzzy set for type-2 fuzzy set could be supplemented for 
capturing the specialists’ different opinions. Therefore, type-2 fuzzy set is the 
simplest among higher order fuzzy sets and would be effective enough to be 
applied to such a task. Thus the current FDES-based framework needs to be 
expanded in order to deal with type-2 fuzzy sets. The theory of the extended 
FDES (EFDES) is an approach in handling type-2 fuzzy sets to capture such 
specialists’ knowledge. The development of the new HIV/AIDS treatment regimen 
system under the implementation of the EFDES theory is significantly concerned 
as a new aspect of the decision-supporting system. The EFDES theory utilizes 
type-2 fuzzy sets to parameters or factors considered with imprecision and 
uncertainties applying not only for medical fields but others as well. 
As is known, the update of the HIV/AIDS treatment guidelines several times 
per year would reflect the treatment complexity. Approval of new antiretroviral 
regimens for the treatment, for example, would cause such updates. For the new 
approved regimens, the knowledge acquisition process will be required for the 
decision-supporting system. At this point, the system with the capacity of self-
learning will be preferable. As mentioned above, another issue on performance of 
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the new system under the EFDES theory would arise. The skepticism issue is that 
under the EFDES-based framework, whether the HIV/AIDS treatment regimen 
selection system constructed with or without the capability of self-learning could 
handle the diversities and uncertainties of specialists’ knowledge and could 
provide as such a good performance. 
The way to disclose or key this skepticism problem is to construct such an 
EFDES-base decision-supporting system with or without self-learning function 
using the patients’ medical information and specialist domains implemented in the 
FDES-based system as the basis of system data; the performance of the EFDES-
based system can be verified.  
1.4 Extended Fuzzy Discrete Event System (EFDES) Theory [24,33] 
The EFDES theory can be modeled by a fuzzy automaton (G) which is 
mathematically expressed as ),,,( 0qδΣQG = , where Q is the set of fuzzy state 
vectors. The k-th fuzzy state vector kq ( Qk ∈q ) is mathematically represented as 
kq ][ 21 Nkkk VVV L= , where N is the total number of fuzzy states and ikV  is a 
fuzzy set with the universe of discourse [0, 100%]. Fuzzy state 0q  is an initial 
fuzzy state vector. Σ  is the set of fuzzy events. A fuzzy event jσ , ( Σj ∈σ ), is a 
fuzzy state transition matrix. The matrix is in the form of 
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where mnj A , Nnm ≤≤ ,1 , is a fuzzy set characterizing the transition from one state 
(m-state), to another state (n-state) when the j-th event occurs. The universe of 
discourse of mnj A  ranges from 0 to 100% on the x-axis and the corresponding 
membership ranges from 0 to 1 on the y-axis. M is the total number of possible 
events. 
δ  is a transition mapping that describes how to obtain a new fuzzy state 
vector from a current fuzzy state vector and a fuzzy event transition matrix. It can 
be mathematically represented as QQ →Σo:δ , where o is a fuzzy logic operation 
[1,5,28,69,70] (e.g., max-product() and max-min() etc). Thus, the new fuzzy state 
vector is determined from 1k k j+ =q q σo .  Since the max-product operation is 
desirable for the EFDES-based system, the equation becomes )max(1 jkk σqq ×=+  
in which nk V1+  is determined by 
   
( )
( )NnjNknjknjk
in
j
i
k
Nin
k
AVAVAV
AVV
×××=
×=
≤≤
+
,...,,max
max
2211
1
1
,        (1.3) 
where ×  refers to product() operation. 
Like the FDES theory used in the HIV/AIDS treatment regimen selection, 
the EFDES theory will be implemented in the Fuzzy Finite State Model named 
Extended Fuzzy Finite State Models. Similar to the FDES-based system, the fuzzy 
state model of the EFDES-based system consists of four fuzzy automata, each of 
which corresponds to one of the four parameters, i.e., potency, adherence, 
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adverse events, and future drug options. The fuzzy states of the automata are 
defined as follows: the fuzzy automaton for potency has three states: initial, 
medium, and high; the fuzzy automaton for adherence has four states: initial, 
challenging, moderate, and easy; the fuzzy automaton for adverse events has four 
states: initial, very low, low, and medium; the fuzzy automaton for future drug 
options has three states: initial, medium, and high. The interpretation of each 
state, except initial state, should be associated with the corresponding parameters 
of regimens. For example, the “high” state in the fuzzy automaton for potency 
means the anticipated high potency of the regimen. A fuzzy event occurs when a 
treatment regimen is prescribed for a patient. This prescription leads to a 
transition of a fuzzy state vector from the current fuzzy state to the next fuzzy 
state. A detailed computational example of the fuzzy automata will be discussed 
later in the next chapter. 
1.5 Adaption of EFDES Theory into FDES-Based HIV/AIDS Treatment 
Regimen Selection System 
As in the previous section, the potential issues could have faced the current 
FDES-based HIV/AIDS treatment regimen selection system in which the 
specialists’ domains of knowledge were captured in the form of the consensuses 
(i.e., estimated points for the clinical parameter characteristic of the treatment 
regimens and type-1 fuzzy sets for the treatment regimen’s clinical parameter 
definitions) that may not be achieved as usual. The FDES-based system was 
discussed in the literature by [22], which provided the great details in the 
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implementation of the theory of fuzzy discrete event system to the HIV/AIDS 
treatment regimen selection system. Conducting the clinical parameters (e.g., 
regimen’s potency) in the useable forms for the system was demonstrated in the 
paper along with the forward-looking tree as an optimal control online approach 
discussed by [22] as well. The regimen effectiveness neglecting the treatment cost 
was the considered factor used for the optimization utilized with the genetic 
algorithm. The FDES-based system employed the 35 retrospective patients’ 
medical information in the evaluation of the performance of the system. 
In order to overcome such possible conflicts, the FDES-based system 
needs to be modified and generalized into the EFDES-based system. [24,33] 
demonstrated how to extend the FDES theory to the EFDES theory. The EFDES 
theory uses the fuzzy automaton as a model. Unlike the FDES, the elements in 
fuzzy state vectors could be crisp numbers in [0, 1], interval numbers, or fuzzy 
sets in general in which the prior two could be treated as special cases. [24,33] 
provided illustrative examples on how to obtain the fuzzy event transition matrices 
when applying the EFDES theory to the HIV/AIDS treatment regimen selection 
system. As in the examples in the next chapter (i.e., three different situations), two 
cases utilized the type-2 fuzzy sets  with either crisp numbers or fuzzy sets to 
capture diversities and uncertainties of the specialists’ knowledge and experience 
in determining the fuzzy event transition matrices.  
The system capable of self-learning is preferred significantly, as frequent 
updates of the information, such as the HIV/AIDS treatment in which guidelines 
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change several times in each year and the new regimens become available, as 
well. Paper [31] discussed the FDES-based system with self-learning ability that 
could be achieved by adjusting parameter weights via the Optimizer. In the paper 
four regimens were involved in learning for the system used in the initial round of 
the HIV/AIDS treatment regimen selection. The information of the experts’ 
knowledge on those regimens and patients’ clinical data used in the FDES-based 
system would be implemented into the EFDES-based system in order to evaluate 
the system performance. 
1.6 Research Objectives 
Representing a consensus of physician experts’ domains of knowledge with 
a useable form by utilizing type-1 fuzzy set in the HIV/AIDS treatment regimen 
selection system that is less acceptable in term of human sense and has a chance 
of being unachievable among respective experts’ distinct opinions, this 
dissertation presents the utilization of EFDES theory and type-2 fuzzy set to 
handle the consensus of the experts’ distinct opinions used in the system 
providing more realistic representation of expert knowledge and as good as the 
system performance of utilizing type-1 fuzzy set. 
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CHAPTER 2 
EFDES-BASED HIV/AIDS TREATMENT REGIMEN SELECTION SYSTEM 
  
Developing the FDES-based regimen selection system, HIV/AIDS 
specialists must compromise to reach consensus in terms of the parameter values 
and the type-1 fuzzy sets (e.g., Table 1.1 and Figure 1.1). If different specialists 
insist on using different parameter values or different fuzzy sets, then an FDES 
system cannot be constructed. To accommodate such needs, type-2 fuzzy sets [6, 
30] provide a solution. This solution led recently to development of an extended 
fuzzy discrete event system (EFDES) theory [33]. It is capable of handling a 
parameter value in the form of type-1 fuzzy set or interval and a type-1 fuzzy set in 
the form of a type-2 fuzzy set. In this research work, we will employ the EFDES 
theory to investigate seven distinct scenarios shown in Table 2.1. For the 
specialist domains, either type-1 fuzzy sets or type-2 fuzzy sets are used to 
represent the definitions of clinical parameters, whereas crisp numbers, interval 
numbers, type-1 fuzzy sets and type-2 fuzzy sets are served to represent the 
parameter characteristics of the regimens.  
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Table 2.1: Specialist Domains in the FDES and EFDES-Based System 
 
Fuzzy Set Type for 
the Clinical 
Parameter 
Definitions 
Value Type 
for the Clinical 
Parameter 
Characteristics 
FDES theory Type-1 fuzzy sets Crisp numbers 
EFDES theory   
Scenario 1 Type-1 fuzzy sets Interval numbers 
Scenario 2 Type-1 fuzzy sets Type-1 fuzzy sets 
Scenario 3 Type-1 fuzzy sets Type-2 fuzzy sets 
Scenario 4 Type-2 fuzzy sets Crisp numbers 
Scenario 5 Type-2 fuzzy sets Interval numbers 
Scenario 6 Type-2 fuzzy sets Type-1 fuzzy sets 
Scenario 7 Type-2 fuzzy sets Type-2 fuzzy sets 
 
2.1 EFDES-Based HIV/AIDS Treatment Regimen Selection System 
The block diagram of the EFDES-based HIV/AIDS treatment regimen 
selection system is illustrated in Figure 2.1. Its structure is similar to the FDES-
based system as mentioned in the Introduction. The major difference between the 
EFDES-based system and the FDES-based system is that the EFDES theory is 
now used to implement the Extended Fuzzy Finite State Models shown in Figure 
2.1. Concisely, each block of the EFDES-based system will be explained as 
follows.  
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Rule-based
Treatment Objective
Classifier
Extended Fuzzy
Finite State Models
Regimen Selection
Optimizer
Patient's Medical
Information
Ranking of Treatment Regimen
Made by
Specialist 1 ...   Specialist N
Optimized Regimen
for Patient
 
Figure 2.1: Block diagram of the EFDES-based HIV/AIDS treatment 
regimen selection system 
 
2.1.1 Rule-Based Treatment Objective Classifier 
The task of the rule-based classifier is to map a patient to one of the 32 
objectives based on his/her medical condition. Each objective is a combination of 
the four clinical parameters. Potency, adherence, adverse events and future drug 
options are the clinical parameters which an HIV/AIDS specialist considers when 
assigning which regimen to prescribe. Each clinical parameter is composed of 
stated variables: “medium” and “high” for potency, “challenging”, “moderate”, and  
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Table 2.2: Patient’s 32 clinical treatment objectives [22,31] 
Objective 
class no. Potency Adherence 
Adverse 
events 
Future drug 
options 
1 High Easy Medium High 
2 High Easy Medium Medium 
3 High Easy Low High 
4 High Easy Low Medium 
5 High Easy Very low High 
6 High Easy Very low Medium 
7 High Moderate Medium High 
8 High Moderate Medium Medium 
9 High Moderate Low High 
10 High Moderate Low Medium 
11 High Moderate Very low High 
12 High Moderate Very low Medium 
13 High Challenging Medium High 
14 High Challenging Medium Medium 
15 High Challenging Low High 
16 High Challenging Low Medium 
17 High Challenging Very low High 
18 High Challenging Very low Medium 
19 Medium Easy Medium High 
20 Medium Easy Medium Medium 
21 Medium Easy Low High 
22 Medium Easy Low Medium 
23 Medium Easy Very low High 
24 Medium Easy Very low Medium 
25 Medium Moderate Medium High 
26 Medium Moderate Low High 
27 Medium Moderate Very low High 
28 Medium Moderate Very low Medium 
29 Medium Challenging Medium High 
30 Medium Challenging Low High 
31 Medium Challenging Very low High 
32 Medium Challenging Very low Medium 
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“easy” for adherence, “very low”, “low”, and “medium” for adverse events and 
“medium” and “high” for future drug options, called a treatment objective. 
Practically, there are a total of 32 clinical treatment objectives. Four combinations 
are excluded because of the absurd situation in the treatment. For instance, the 
second treatment objective is the combination of “high” potency, “easy” 
adherence, “medium” adverse events and “medium” future drug options. The 
complete list of the treatment objectives is displayed in Table 2.2. The rules used 
by the classifier were constructed with the help of the HIV/AIDS specialists as a 
document according to [22] in which only two specialists were involved.  
In the classifier the patient’s CD4+ cell counts and HIV RNA level 56,58] 
were used to determine the regimen’s expected potency and future drug options 
needed. The rules for these two clinical parameters applied from [22,29] as 
follows are: 
• Potency 
 If a patient’s CD4+ counts <50 cell/µL, then high expected potency of the 
regimen is desired. 
If a patient’s CD4+ counts from 50 to 200 cell/µL, and a patient’s HIV RNA 
>100,000 copies/ml, then high expected potency of the regimen is desired. 
If a patient’s CD4+ counts from 50 to 200 cell/µL, and a patient’s HIV RNA 
<100,000 copies/ml, then either high or medium expected potency of the regimen 
is desired. 
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If a patient’s CD4+ counts > 200 cell/µL, and a patient’s HIV RNA ≥100,000 
copies/ml, then high expected potency of the regimen is desired. 
If a patient’s CD4+ counts > 200 cell/µL, and a patient’s HIV RNA <100,000 
copies/ml, then medium expected potency of the regimen is desired. 
• Future drug options 
If a patient’s CD4+ counts ≥ 350 cell/µL, then high expected future drug 
options of the regimen is desired. 
If a patient’s CD4+ counts from 200 to 350 cell/µL, and a patient’s HIV RNA 
<100,000 copies/ml, then high expected future drug options of the regimen is 
desired. 
If a patient’s otherwise conditions, then medium expected future drug 
options of the regimen is desired. 
In order to classify a patient into which regimen’s expected adherence, we 
need to answer questions about the criteria involving the patient’s behavior and 
medical information. There are 5 questions to be asked: 1) if a patient’s age is 
less than 25 year old, 2) if a patient is homeless, 3) if a patient uses any illegal or 
narcotic drugs or excessive alcohol, 4) if a patient has a mental illness, and 5) if a 
patient missed more than one clinic visit in the last year. The number of questions 
with which the corresponding patient complies is used to determine the adherence 
characteristic. Following are the rules used as guidelines for the regimen’s 
expected adherence. 
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• Adherence 
If a patient complies with two or more questions, then easy expected 
adherence of the regimen is desired. 
If a patient complies with only one question, then either easy or moderate 
expected adherence of the regimen is desired. 
If a patient complies with no questions, then any expected adherence of the 
regimen characteristic is desired. 
• Adverse events 
One of three treatment characteristics of adverse events (i.e., medium, low 
and very low) the classifier assigns as the regimen’s expected adverse events for 
a treatment objective deals with a patient’s risk of diseases, which include 
diabetes, hepatitis and cardiovascular disease. The patient with one or both of 
diabetes and hepatitis diseases will be avoided classifying with regimen’s medium 
expected adverse events.  
 
 
 
 
 
 
 
 
  
32 
Table 2.3: Cardiovascular Disease Risk Assessment Scoring 
Risk points 
Risk Factor 
Men Women 
<34 -1 -9 
35-39 0 -4 
40-44 1 0 
45-49 2 3 
50-54 3 6 
55-59 4 7 
60-64 5 8 
65-69 6 8 
Age, years 
70-74 7 8 
<160 -3 -2 
160-199 0 0 
200-239 1 1 
240-279 2 2 
Total cholesterol, 
mg/dL 
≥280 3 3 
<35 2 5 
35-44 1 2 
45-49 0 1 
50-59 0 0 
HDL cholesterol, 
mg/dL 
≥60 -2 -3 
<120 0 -3 
120-129 0 0 
130-139 1 1 
140-159 2 2 
Systolic blood 
pressure, mm Hg 
≥160 3 3 
No 0 0 Diabetes Yes 2 4 
No 0 0 Smoking Yes 2 2 
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Table 2.4: Risk Estimates for Cardiovascular Disease as Determined 
Framingham Scoring 
Below Moderately 
above Age 
average risk 
average risk 
average risk 
High risk 
years man woman man woman man woman man woman 
30-34 <1 <4 1 4 2-4 5 >4 >5 
35-39 <3 <5 3 5 4-6 6-7 >6 >7 
40-44 <4 <6 4 6 5-6 7-8 >6 >8 
45-49 <6 <7 6 7 6 8-10 >7 >10 
50-54 <6 <9 7 9 8 10-12 >8 >12 
55-59 <8 <10 8 10 9 11-15 >9 >15 
60-64 <9 <11 9 11 10 12-16 >10 >16 
65-69 <10 <12 10 12 11 13-16 >11 >16 
70-74 <11 <13 11 13 12 14-16 >12 >16 
 
The risk estimates of cardiovascular disease is derived by using the 
Framingham risk score [73,74] obtained by assessing the risk points of all risk 
factors shown in Table 2.3 that the individual associates with the risk of the 
cardiovascular disease. Then Table 2.4 is used to label the risk of the scores. For 
example, a 44-year male patient with a Framingham risk score of 4 will be labeled 
with average risk for the cardiovascular disease. With the risk label, the patient will 
be classified using the rules as follows: 
If a patient is below average risk, then any adverse events of the regimen 
characteristic is desired. 
If a patient is average risk, then either low or very low expected adverse 
events of the regimen is desired. 
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 If a patient is above average risk, then very low expected adverse events 
of the regimen is desired. 
Finally, all risks of diabetes, hepatitis and cardiovascular disease need to 
be evaluated to adopt which one has the most impact. 
As mentioned above in the rules for an individual’s clinical parameters, 
those rules need to meet clinical rules in order to classify a patient into a treatment 
objective. The clinical rules are 
If potency is high, then adherence is either moderate or challenging 
If potency is medium, then adherence is either easy or moderate 
If potency is high, then adverse events are either medium or low 
If potency is medium, then adverse events are very low 
If a patient’s adherence complies with at least one issue, then future drug 
options must be high. 
In case of conflicts, potency must be the first priority choice. The second 
priority is adherence mapping with the easiest adherence level available. The last 
priority is adverse events mapping with the lowest adverse events level available. 
2.1.2 Extended Fuzzy Finite State Models  
The fuzzy finite state models for the FDES-based system describe the 
sequences of the change of states when the corresponding events occur. In the 
HIV/AIDS treatment, a naïve patient’s state will change partially from a pre-treated 
state (an initial state) to a treated state (a next state) when an event of receiving a 
particular regimen happens. Correspondingly, the four clinical fuzzy state vectors 
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(parameters) of the model change to new fuzzy state vectors through fuzzy state 
transition matrices. The characteristics of the clinical parameters and the 
definitions of the corresponding state variables (e.g., the vertical line of the 
characteristic of the future drug options for regimen 2 and the fuzzy set definitions 
in Figure 1.1) are needed to construct the fuzzy state transition matrix. The new 
fuzzy state vector is determined by applying a fuzzy logic operation on the current 
fuzzy state with the fuzzy state transition matrix. This change of fuzzy states can 
be modeled by a fuzzy automaton. [13,22,25] provide great details. 
2.1.3 Regimen Selection Optimizer 
In the EFDES-based system, the interesting optimization issue is to 
maximize the expected HIV/AIDS treatment effectiveness without considering the 
treatment cost [41]. Therefore, at the nodes of the forward-looking tree, the L 
could be assumed to be infinity. We merely implemented an effectiveness 
measure introduced in [22,25] in order to search for regimens that best match 
those selected by the AIDS specialists for the 32 treatment objectives. The 
effectiveness measure (E) is computed in terms of the weighted average of the 
state vectors. It can be mathematically expressed by 
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where SP, SA, SE and SF are the next fuzzy state vectors for potency, adherence, 
adverse events and future drug options, respectively, whereas def () is 
defuzzification operation [6,56,57,63,64] which generates a crisp number (i.e., the 
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middle point of the interval) from each of the fuzzy elements (i.e., the intervals) of 
the fuzzy state vectors and wP, wA, wE and wF are their corresponding weight 
vectors. The weight vector for a parameter is the same regardless of regimens.  
To demonstrate an example, assume the regimen 2 with the scenario 4 of 
the specialist domains is prescribed to a patient classified to one of 32 treatment 
objectives saying “high” potency, “moderate” adherence, “medium” adverse 
events, and “high” future drug options. Let the fuzzified next fuzzy state vectors for 
potency, adherence, adverse events, and future drug options respectively be 
SP=[Z [0.3246 0.5460] [0.9802 1.000]],  
SA=[Z [0.0889 0.1977] [0.4578 0.7066] [0.9802 1.000]], 
SE=[Z [0.4867 0.7261] [0.9523 0.9785] [0.7827 0.9559]],  
SF=[Z [0.8968 0.9801] [0.3411 0.4867]]. 
where Z is the singleton fuzzy number 0. Then the defuzzification of the next fuzzy 
state vectors can be obtained as  
def(SP)=[0 0.4353 0.9901],  
def(SA)=[0 0.1433 0.5822 0.9901],  
def(SE)=[0 0.6064 0.9654 0.8693],   
def(SF)=[0 0.9384 0.4139]. 
Furthermore, assume that the weight vectors for “high” potency is wP=[0 
0.2031 0.7969], for “moderate” adherence wA=[0 0.1484 0.6523 0.1992], for 
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“medium” adverse events wE=[0 0.2422 0.3086 0.4492], and for “high” future drug 
options wF=[0 0.1836 0.8164]. The effectiveness measure for the regimen 2 with 
the scenario 4 of the specialist domains applied to the patient can be determined 
using the equation (2.1). 
E=[0 0.4353 0.9901][0 0.2031 0.7969]T 
  +[0 0.1433 0.5822 0.9901][0 0.1484 0.6523 0.1992]T 
        +[0 0.6064 0.9654 0.8693][0 0.2422 0.3086 0.4492]T 
  +[0 0.9384 0.4139][0 0.1836 0.8164]T 
                     = 2.8212 
For each treatment objective, three effectiveness measure values can be 
computed: E1 for regimen 1, E2 for regimen 2 and E3 for regimen 3. They are used 
by the models to rank the three regimens. The regimen with the highest value is 
the first choice regimen and the lowest value is the last choice. 
To rank the three regimens, we need to adjust the 10 weight vectors for the four 
parameters. There are 26 adjustable weights (i.e., 22333322 ×+×+×+× ) used 
for computing the effectiveness measures. The goal of the regimen selection 
optimizer is to search for a set of 26 weights that make the rankings of the three 
regimens made by the models best match those made by the specialists for the 
32 treatment objectives. The 26 weights were arranged for the 32 treatment 
objectives regarding Table 2.2, as shown in Table 2.5.
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Table 2.5: Optimal weight vectors for four parameters for 32 treatment objectives  
Optimal weight vector for four clinical parameters Treatment 
Objective 
No. Potency, (wP) Adherence, (wA) Averse Events, (wE) Future Drug   Options , (wF) 
1 [ 0 W1 W2 ] [ 0 W5 W8 W11 ] [ 0 W14 W17 W20 ] [ 0 W23 W24 ] 
2 [ 0 W1 W2 ] [ 0 W5 W8 W11 ] [ 0 W14 W17 W20 ] [ 0 W25 W26 ] 
3 [ 0 W1 W2 ] [ 0 W5 W8 W11 ] [ 0 W15 W18 W21 ] [ 0 W23 W24 ] 
4 [ 0 W1 W2 ] [ 0 W5 W8 W11 ] [ 0 W15 W18 W21 ] [ 0 W25 W26 ] 
5 [ 0 W1 W2 ] [ 0 W5 W8 W11 ] [ 0 W16 W19 W22 ] [ 0 W23 W24 ] 
6 [ 0 W1 W2 ] [ 0 W5 W8 W11 ] [ 0 W16 W19 W22 ] [ 0 W25 W26 ] 
7 [ 0 W1 W2 ] [ 0 W6 W9 W12 ] [ 0 W14 W17 W20 ] [ 0 W23 W24 ] 
8 [ 0 W1 W2 ] [ 0 W6 W9 W12 ] [ 0 W14 W17 W20 ] [ 0 W25 W26 ] 
9 [ 0 W1 W2 ] [ 0 W6 W9 W12 ] [ 0 W15 W18 W21 ] [ 0 W23 W24 ] 
10 [ 0 W1 W2 ] [ 0 W6 W9 W12 ] [ 0 W15 W18 W21 ] [ 0 W25 W26 ] 
11 [ 0 W1 W2 ] [ 0 W6 W9 W12 ] [ 0 W16 W19 W22 ] [ 0 W23 W24 ] 
12 [ 0 W1 W2 ] [ 0 W6 W9 W12 ] [ 0 W16 W19 W22 ] [ 0 W25 W26 ] 
13 [ 0 W1 W2 ] [ 0 W7 W10 W13 ] [ 0 W14 W17 W20 ] [ 0 W23 W24 ] 
14 [ 0 W1 W2 ] [ 0 W7 W10 W13 ] [ 0 W14 W17 W20 ] [ 0 W25 W26 ] 
15 [ 0 W1 W2 ] [ 0 W7 W10 W13 ] [ 0 W15 W18 W21 ] [ 0 W23 W24 ] 
16 [ 0 W1 W2 ] [ 0 W7 W10 W13 ] [ 0 W15 W18 W21 ] [ 0 W25 W26 ] 
17 [ 0 W1 W2 ] [ 0 W7 W10 W13 ] [ 0 W16 W19 W22 ] [ 0 W23 W24 ] 
18 [ 0 W1 W2 ] [ 0 W7 W10 W13 ] [ 0 W16 W19 W22 ] [ 0 W25 W26 ] 
19 [ 0 W3 W4 ] [ 0 W5 W8 W11 ] [ 0 W14 W17 W20 ] [ 0 W23 W24 ] 
20 [ 0 W3 W4 ] [ 0 W5 W8 W11 ] [ 0 W14 W17 W20 ] [ 0 W25 W26 ] 
21 [ 0 W3 W4 ] [ 0 W5 W8 W11 ] [ 0 W15 W18 W21 ] [ 0 W23 W24 ] 
22 [ 0 W3 W4 ] [ 0 W5 W8 W11 ] [ 0 W15 W18 W21 ] [ 0 W25 W26 ] 
23 [ 0 W3 W4 ] [ 0 W5 W8 W11 ] [ 0 W16 W19 W22 ] [ 0 W23 W24 ] 
24 [ 0 W3 W4 ] [ 0 W5 W8 W11 ] [ 0 W16 W19 W22 ] [ 0 W25 W26 ] 
25 [ 0 W3 W4 ] [ 0 W6 W9 W12 ] [ 0 W14 W17 W20 ] [ 0 W23 W24 ] 
26 [ 0 W3 W4 ] [ 0 W6 W9 W12 ] [ 0 W15 W18 W21 ] [ 0 W23 W24 ] 
27 [ 0 W3 W4 ] [ 0 W6 W9 W12 ] [ 0 W16 W19 W22 ] [ 0 W23 W24 ] 
28 [ 0 W3 W4 ] [ 0 W6 W9 W12 ] [ 0 W16 W19 W22 ] [ 0 W25 W26 ] 
29 [ 0 W3 W4 ] [ 0 W7 W10 W13 ] [ 0 W14 W17 W20 ] [ 0 W23 W24 ] 
30 [ 0 W3 W4 ] [ 0 W7 W10 W13 ] [ 0 W15 W18 W21 ] [ 0 W23 W24 ] 
31 [ 0 W3 W4 ] [ 0 W7 W10 W13 ] [ 0 W16 W19 W22 ] [ 0 W23 W24 ] 
32 [ 0 W3 W4 ] [ 0 W7 W10 W13 ] [ 0 W16 W19 W22 ] [ 0 W25 W26 ] 
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A genetic algorithm in MATLAB’s Direct Search Toolbox is employed to 
perform the task. The objective function 332211 MMMf α+α+α= , where Mi (i=1, 2, 3) 
is how many the first-choice, second-choice and third-choice regimens ranked by 
the models match those ranked by the two specialists. αi represents the relative 
importance and we use α1=1, α2=0.01 and α3=0.001. In clinical practice, the first 
choice is much more important than the other two choices. To terminate the 
optimization process when running the genetic algorithm, either the tolerative 
changing of the objective function value or the number of generations can be 
conditionally applied. We prefer the latter in which the termination condition is set 
to 1,600 generations. That is, the optimization process stops after 1,600 
generations. f represents agreement between the models and the AIDS 
specialists. 
After the 26 optimal weights are obtained, the rankings of the three 
regimens for the 32 treatment objectives can be made using these weights. As a 
result, the EFDES models establish a table of regimen choices for the 32 objective 
classes. Once a patient is classified into an objective, his/her treatment regimen 
can be found in the table. 
2.2 Genetic Algorithm 
Genetic algorithm is an optimization algorithm inspired by the process 
observed in natural selection. Genetic algorithm attempts to duplicate the process 
and utilize it for solving optimization problems. Genetic algorithm performs random 
searches through a given set of individuals to find the best one with respect to a 
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given criteria expressed in terms of an objective function or usually  regarded as a 
fitness function. The individuals with better fitness values will contribute to the next 
population. From the current population the individuals are randomly selected to 
be parents in order to produce the children for the next generation. A genetic 
algorithm will modify a population of individuals from generation to the next 
generation. This successive process provides population evolvement toward an 
optimal solution. 
Genetic algorithm uses three kinds of rules to create the next generation; 
selection rules choose the individuals as parents contributing to the population for 
the next generation. Crossover rules merge two parents to create children for the 
next generation, and mutation rules make random change to parents to form 
children.  
This research implements the genetic algorithm in MATLAB’s Direct Search 
Toolbox. There are three types of children that the algorithm creates for the next 
generation: elite children, crossover children, and mutation children.  
Elite children are the individuals with the best fitness values in the current 
generation. These individuals grant privilege to the next generation.  
Crossover children are created by combining pairs of parents in the current 
population. The crossover function selects the gene and its coordinate from one of 
the two parents to form the child gene at the same position. There are 26 
adjustable weights which need to be optimized in this research. Each of them is in 
the form of a string of 8-bit binary numbers. The connection of these strings 
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provides a 208-bit-long string that represents a weight vector or an individual. With 
the crossover fraction of 0.5, the child receives the first half, 104-bit string, from 
one of two parents and the second half from the other. We use the crossover 
fraction of 0.75 for weight optimizing in this research. 
Mutation children are the children who receive the mutative genes from 
their parents. To create mutation children, the algorithm provides random change 
of the parent genes. We use the algorithm default setting that adds a random 
vector from a Gaussian distribution to the parent vectors. 
2.3 Fuzzy Sets for the Representation of the Specialist Domains 
2.3.1 Defined Fuzzy Set Types of Four Clinical Parameters 
According to [22], the type-1 fuzzy sets defined for the four clinical 
parameters in the FDES-based treatment regimen system took advantage of 
semi-Gaussian functions which could provide modest changes of the membership 
grades. In this research of the EFDES-based treatment regimen system, those 
defined type-1 fuzzy sets will be employed and regarded as the references for the 
upper and lower primary membership functions used to define type-2 fuzzy sets 
with the secondary membership grades.  
The interval type-2 fuzzy set is a specific type-2 fuzzy set with a unit 
secondary membership grade that is the one for the investigation. Generally, the 
upper and lower primary membership functions are used to describe the type-2 
fuzzy set. The area bounded by these two primary membership functions creates 
a footprint of uncertainty (FOU). Mathematical representations for the boundaries 
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of the footprint of uncertainties for the four clinical parameters are ordinarily listed 
in Table 2.6 and theirs corresponding graphical representations of the type-2 fuzzy 
sets when ∆m equals to 2% are shown in Figure 2.2 as well. As ∆m equals to 
zero, the interval type-2 fuzzy sets reduces to the type-1 fuzzy sets. 
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Table 2.6: Boundary membership Functions of the Foot of Uncertainties of the 
type-2 fuzzy sets for the Four Clinical Parameters 
Clinical Parameters Boundary Functions of FOU 
High 




∆±=≤
∆±=>





 −−
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85,,1
2
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1
 
 
 
 
Potency 
Medium 




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(a)               (b) 
 
 
(c)                  (d) 
 
Figure 2.2: Graphical representations of the FOUs of the corresponding type-2 
fuzzy sets with ∆m being 2% according to Table 2.6. Also, an example 
demonstration of the fuzzification process shown in (d) in which the black area of 
FOU fuzzified from the “High” future drug options and the characteristic of future 
drug options for a particular regimen represented by the interval type-2 fuzzy set 
and its FOU shown as a shade of the triangular shape with ∆x being 5% and ∆w 
being 4%. 
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2.3.2 Fuzzy Sets for the Parameter Characteristic of the Regimen 
In order to express the specialist domains of the clinical parameter 
characteristics of the particular regimens, not only including crisp numbers used in 
the FDES-based system, but also extending to interval numbers, type-1 fuzzy sets 
and type-2 fuzzy sets that will be employed in the EFDES-based system. The 
fuzzy sets or the fuzzy numbers are constructed based on the estimated value 
(crisp) of the clinical characteristics of the regimens as the center points. Note that 
the interval numbers are not the fuzzy numbers but can be treated as a special 
case of the fuzzy numbers. These symmetrical shapes of the fuzzy numbers are 
illustrated in Figure 2.3 with specific variables that we use to assign values 
hereafter. For example, the interval number with ∆v being 10% for the regimen 2 
will refer to [80%, 90%] for potency, [80%, 90%] for adherence, [15%, 25%] for 
adverse events, and [60%, 70%] for the future drug options as illustrated in Figure 
2.3 (a). Jointly, ∆x and ∆w are used to specify FOU of the symmetrical triangular 
type-2 fuzzy sets. Shown in Figure 2.3 (c) is FOU of future drug options for the 
regimen 2 with ∆x being 5% and ∆w being 4% and FOUs of other parameters for 
the regimen 2 use the same values as well. As ∆w equals to zero, the interval 
type-2 fuzzy sets reduces to the type-1 shown in Figure 2.3 (b). 
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(a) 
 
(b) 
 
(c) 
Figure 2.3: Specific variables used to describe the fuzzy numbers of the clinical 
characteristics of the regimens. (a) ∆v used for the interval numbers (i.e., a special 
case of the fuzzy numbers), (b) ∆x used for symmetrical triangular type-1 fuzzy 
sets, and (c) ∆x and ∆w used for FOU of the symmetrical type-2 fuzzy sets. 
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2.4 Determine the Fuzzy Event Transition Matrices in Different Situations 
of Specialists’ Knowledge Representations 
Four clinical parameters need to be models by four fuzzy automata. Seven 
scenarios need to be investigated in the EFDES-based regimen selection system. 
As the special case of the EFDES-based system, the case of the FDES-based 
system (i.e., type-1 fuzzy sets for definitions of parameters and crisp numbers for 
regimens characteristics) was clearly explained in detailed information [22] that 
then will be ignored here. In the seven different scenarios, we merely demonstrate 
that the fuzzy automata for future drug options are the combinations of the clinical 
parameter definitions in the forms of type-1 fuzzy sets and type-2 and the 
parameter characteristics in the forms of crisp number, interval number, type-1 
fuzzy set and type-2 fuzzy set. Only regimen 2 is used in computing the fuzzy 
event transition matrices. 
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2.4.1 Type-1 Fuzzy Sets for the Parameter Definitions and Interval 
Numbers for the Parameter Characteristics (scenario 1) 
 
Figure 2.4: Determining the fuzzy event transition matrix for regimen 2 
under the scenario 1 
 
In this scenario an interval number instead of a crisp number is considered 
to describe diverse experts’ opinions on the clinical factors. The crisp number can 
be a consensus of the experts’ opinions but not each of them. The distinct 
opinions with different crisp numbers can be windowed into the interval number in 
which the opinions have the same weights. The interval number used in the 
EFDES-based system is illustrated in Figure 2.4. Its center at the value of the 
parameter characteristic value in Table 1.1 and ∆v equals to 10% for regimen 2 
which is the one in Figure 2.4. The fuzzy operation named fuzzification is 
processed to these two clinical parameters. The fuzzy sets for fuzzification for 
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future drug options are type-1 fuzzy sets. Their mathematical definitions ( FHµ for 
“High” and FMµ for “Medium”) are  
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In the EFDES-based system, the initial state vectors in the fuzzy automata 
have similar initial conditions. For instance, the fuzzy automaton for future drug 
options has the initial state vector ]11[q0 ZZ/= , where 1/1 and Z are singleton 
fuzzy numbers 1 and 0, respectively. The change of a patient’s states occurs 
when he/she follows a regimen. 
The fuzzy state transition matrix for future drug options for the first-round 
treatment is  
High
Medium
Initial
ZZZ
ZZZ
FFZ
HighMediumInitial










=
13
1
12
1
1σ  
where 121F  and 131F  are type-1 fuzzy sets representing the transition of fuzzy 
states from the Initial state to the Medium state and High state, respectively. 
Figure 2.4 will be utilized to obtain 131F . The dark and thick curve in the 
figure is its membership function:  
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which is the result of applying the standard fuzzy intersection to the fuzzy set 
“High” and the interval number depicted in Figure 2.4 over the universe of 
discourse ranging from 50 to 100. According to [33], the range of )(xFHxµ , which is 
from 0.2494 to 0.6067, will be assigned as the domain of fuzzy set for 131F . This is 
a special case involving only the domain of the fuzzy set (i.e., the interval [0.2494, 
0.6067]). This result is because the membership of 131F is calculated or obtained 
from the secondary membership of )(xFHxµ , which can be regarded as 1 since 
)(xFHxµ is a type-1 fuzzy set. So, 131F  is the interval [0.2494, 0.6067]. We do the 
same procedure in order to obtain 121F . Finally, the fuzzy state transition matrix is 
[ ] [ ]










=
ZZZ
ZZZ
.,,Z 606702494.018009.0
σ1 . 
Consequently, we compute the next state by 
[ ] [ ][ ]6067.0,2494.018009.0σqq 101 ,Z== o  
The same process can be applied to other regimens as well as to other 
fuzzy automata: potency, adherence, and adverse events. 
The result of interval numbers in the fuzzy state vectors need to be reduced 
to crisp numbers. We use the middle point of the interval [45] for this purpose. 
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This result is the case for the next six scenarios. Then the fuzzy state vectors are 
ready for the Regimen Selection Optimizer. 
2.4.2 Type-1 Fuzzy Sets for the Parameter Definitions and Type-1 
Fuzzy Sets for the Parameter Characteristics (Scenario 2) 
 
Figure 2.5: Determining the fuzzy event transition matrix for regimen 2 
under the scenario 2 
 
A fuzzy number instead of a crisp number used in FDES-based system is 
employed to describe diverse experts’ opinions on the clinical factors. The fuzzy 
number in this scenario for the EFDES-based system is a symmetrical triangular 
type-1 fuzzy set as illustrated in Figure 2.5. Its center is the value of the parameter 
characteristic value in Table 1.1 and ∆x equals to 5% for regimen 2 that is the one 
in Figure 2.5. The fuzzy sets for fuzzification for future drug options are type-1 
fuzzy sets, and their mathematical definitions are the same shown in scenario 1. 
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Initial state vector ]11[q0 ZZ/=  and the fuzzy state transition matrix are the 
same for the first-round treatment.  
High
Medium
Initial
ZZZ
ZZZ
FFZ
HighMediumInitial










=
13
1
12
1
1σ  
Figure 2.5 will be utilized to obtain 131F . The dark and thick curve in the 
figure is its membership function:  
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µ ,        (2.4) 
which is the result of applying the standard fuzzy intersection (i.e., min()) to the 
fuzzy set “High” and the fuzzy number depicted in Figure 2.4 over the universe of 
discourse ranging from 50 to 100. According to [33], the range of )(xFHxµ , which is 
from 0 to 0.5052, will be assigned as the domain of fuzzy set for 131F . This domain 
is a special case involving only the domain of the fuzzy set (i.e., the interval [0, 
0.5052]). This result is because the membership of 131F is calculated or obtained 
from the secondary membership of )(xFHxµ , which can be regarded as 1, since 
)(xFHxµ is a type-1 fuzzy set. Therefore, 131F  is the interval [0, 0.5052]. We use the 
same procedure in order to obtain 121F . Finally, the fuzzy state transition matrix is 
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[ ] [ ]










=
ZZZ
ZZZ
.,.,Z 505200950900
σ1 . 
Consequently, we compute the next state by 
[ ] [ ][ ]5052.0,0950900σqq 101 .,Z== o  
2.4.3 Type-1 Fuzzy Sets for the Parameter Definitions and Type-2 
Fuzzy Sets for the Parameter Characteristics (Scenario 3) 
 The symmetrical triangular type-1 fuzzy set in the scenario is not adequate 
to capture the diverse experts’ opinions if they have their own triangular type-1 
fuzzy sets on clinical factors. The conflict made by different experts can be 
managed by employing a type-2 fuzzy set with equal second membership grades 
(i.e., interval type-2). The type-2 fuzzy set can be thought of as blurring the 
triangular type-1 fuzzy set in the scenario 2, and it creates an FOU. The FOUs 
shown in Figure 2.6 for future drug options are bounded by the lower and upper 
primary membership functions whose mathematical expressions are equation 
(2.5) and equation (2.6), with ∆v and ∆w being 5% and 2%, respectively, as 
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Figure 2.6: Determining the fuzzy event transition matrix for regimen 2 
under the scenario 3 
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where )(xTriµ and )(xTriµ are the respective upper and lower primary membership 
functions for the type-2 fuzzy set  used to describe the diverse experts’ opinions 
on the clinical parameter characteristics. 
In this scenario, the experts agree upon the type-1 fuzzy sets of the clinical 
parameter definitions. To obtain 121F  and 131F , we have to process the fuzzy 
operation of the symmetrical triangular type-2 fuzzy set and the type-1 fuzzy sets 
for “Medium” and “High”, respectively. Applying the fuzzy intersection on the type-
2 fuzzy set and the type-1 fuzzy set for “High”, it results in an FOU which is the 
deep dark region shown in Figure 2.6. The FOU is bounded by the upper primary 
membership function in equation (2.7) and the lower primary membership function 
in equation (2.8) described below: 
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where FHy  and FHy  are the respective upper and lower primary membership 
functions of  “High” for future drug options of regimen 2. 
Unlike the first two scenarios, the range of the primary membership grades 
of the type-2 fuzzy set (the dark region in Figure 2.6) assigned for the domain of 
fuzzy set for 131F , as well as the membership function, can be determined by using 
the height type-reducer method [6,30]. The membership function for the reduced 
type-1 fuzzy set ))(( yψ  can be represented by 
     ),(sup)( yxy xϕψ = ,          (2.9) 
where y is the primary membership grade and ϕ is the secondary membership 
function of the type-2 fuzzy set, the result of applying a fuzzy intersection on two 
fuzzy sets. The ()supx operation gives the highest grades of ),( yxϕ for x in the 
universe of discourse. 
Applying equation (2.9) to the type-2 fuzzy set (the dark region for “High” in 
Figure 2.6) over the universe of discourse for x from 50 to 100 will result in the 
value of the primary grade changing from 0 to 0.5359 and the corresponding 
membership grade equal to 1. Therefore, 131F can be represented by the interval [0, 
0.5359]. We employ the same procedure for “Medium” and yield its associated 
interval [0, 0.9527] for 121F . 
Hence, the fuzzy state transition matrix is represented as 
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









=
ZZZ
ZZZ
Z ]5359.0,0[]9527.0,0[
σ1 .  
The next state vector can be determined by 
[ ]]5359.0,0[]9527.0,0[σqq 101 Z== o . 
2.4.4 Type-2 Fuzzy Sets for the Parameter Definitions and Crisp 
Numbers for the Parameter Characteristics (Scenario 4) 
The experts are allowed to define individually the state using different type-
1 fuzzy sets. The diverse definitions made by different experts can be captured by 
a type-2 fuzzy set with equal second membership grades. The type-2 fuzzy set 
can be thought of blurring the type-1 fuzzy set in the scenario 1, and it creates an 
FOU. The FOUs of “High” and “Medium” shown in Figure 2.7 for future drug 
options are bounded by the lower and upper primary membership functions whose 
mathematical expressions are equation (2.10) and equation (2.11) with ∆m being 
2%. 
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Figure 2.7: Determining the fuzzy event transition matrix for regimen 2 
under the scenario 4 
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where )(xFHµ and )(xFHµ are the respective upper and lower primary membership 
functions for “High” and  )(xFMµ and )(xFMµ are the upper and lower primary 
membership functions for “Medium”, respectively. 
In this scenario, the experts agree upon the crisp numbers of the clinical 
parameters. To obtain 121F  and 131F , we draw a vertical line at a parameter value 
(i.e., 65% future drug options in Figure 2.7). The intersections of the line and the 
lower and upper primary membership functions of the two type-2 fuzzy sets create 
two intervals: one for “Medium” and the other for “High”. These intervals are the 
ranges of the primary membership grades for “Medium” and “High” and so will be 
used as the domains of fuzzy sets for 121F and 131F , respectively. The membership 
grades for 121F and 131F over those range equal to 1. We normally represent this 
kind of a type-1 fuzzy set (i.e., an interval type-1 fuzzy set) by its domain of the 
fuzzy set. Hence, in Figure 2.7 the interval [0.8968, 0.9801] for “Medium” is for 
12
1F   and the interval [0.3411, 0.4867] for “High” is for 131F . We therefore obtain the 
fuzzy state transition matrix, 
[ ] [ ]










=
ZZZ
ZZZ
.,..,.Z 48670341109801089680
σ1 . 
Consequently, the next state vector is  
[ ] [ ][ ]4867.0,3411.09801089680σqq 101 .,.Z== o . 
 
  
60 
2.4.5 Type-2 Fuzzy Sets for the Parameter Definitions and Interval 
Numbers for the Parameter Characteristics (Scenario 5) 
 
Figure 2.8: Determining the fuzzy event transition matrix for regimen 2 
under the scenario 5 
 In this scenario, the type-2 fuzzy sets employed in scenario 4 are preferred 
to capture the distinct experts’ opinions on the clinical parameter definitions for 
future drug options as shown in Figure 2.7. The interval number employed in 
scenario 1 is used to represent the range largely over the deviation of experts’ 
opinions on the clinical factors for a regimen. This number is the combination of 
the scenario 1 and the scenario 4 as illustrated in Figure 2.8. The interval type-2 
fuzzy set is described by the FOU with unity of the secondary membership grade. 
The FOUs of “High” and “Medium” for future drug options are bounded by the 
lower and upper primary membership functions whose mathematical expressions 
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are the same equation (2.10) and equation (2.11), with ∆m being 2%. The interval 
number of which ∆v equals 10% for regimen 2 shown in Figure 2.8 has a center at 
the value of the parameter characteristic value in Table 1.1.  
 Applying the fuzzy intersection on the interval number and the type-2 fuzzy 
set for “High”, its result is an FOU which is the deep dark region shown in Figure 
2.8. The foot of uncertainty is bounded by the upper primary membership function 
in equation (2.12) and the lower primary membership function in equation (2.13) 
given below: 
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where )(xFHµ and )(xFHµ are the respective upper and lower primary membership 
functions for “High”, and  )(xFMµ and )(xFMµ are the upper and lower primary 
membership functions for “Medium”, respectively. 
Applying equation (2.9) to the type-2 fuzzy set with the FOU (the dark 
region for “High” in Figure 2.8) over the universe of discourse for x from 50 to 100 
will result in the value of the primary grade changing from 0.1976 to 0.6863 and 
the corresponding membership grade equals 1. Therefore, 131F can be represented 
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by the interval [0.1976, 0.6863]. We construct the same procedure for the 
“Medium” and yield its associated interval [0.7264, 1] for 121F . 
Hence, the fuzzy state transition matrix is represented as 
 










=
ZZZ
ZZZ
Z ]1,7264.0[]6863.0,1976.0[
σ1 .  
The next state vector can be determined by 
[ ]]1,7264.0[]6863.0,1976.0[σqq 101 Z== o . 
2.4.6 Type-2 Fuzzy Sets for the Parameter Definitions and Type-1 
Fuzzy Sets for the Parameter Characteristics (Scenario 6) 
 
Figure 2.9: Determining the fuzzy event transition matrix for regimen 2 
under the scenario 6 
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This scenario is the combination of scenario 2 and scenario 4. While the 
consensus of the diverse definitions of state is defined by type-2 fuzzy sets, the 
clinical parameters for a regimen are defined as symmetrical triangular type-1 
fuzzy sets. Applying the fuzzy intersection on the triangular type-1 fuzzy set and 
the type-2 fuzzy set for “High”, it results in an FOU which is the deep dark region 
shown in Figure 2.9. The FOU is bounded by the upper primary membership 
function in equation (2.14) and the lower primary membership function in equation 
(2.15) given below: 
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where FHy  and FHy  are the respective upper and lower primary membership 
functions of  “High” for future drug options of regimen 2. 
The range of the primary membership grades of the type-2 fuzzy set (the 
dark region in Figure 2.9) assigned for the domain of fuzzy set for 131F as well as 
the membership function can be determined by using the height type-reducer 
  
64 
method expressed in the equation (2.9). As the interval type-2 fuzzy set has the 
secondary membership grade of the interval type-2 fuzzy set equals 1, the 
equation (2.9) will determine the highest primary membership grade for each 
value of x in the universe of discourse. 
Applying equation (2.9) to the type-2 fuzzy set (the dark region for “High” in 
Figure 2.6) over the universe of discourse for x from 50 to 100 will result in the 
value of the primary grade changing from 0 to 0.5718 and the corresponding 
membership grade equal to 1. Therefore, 131F can be represented by the interval [0, 
0.5718]. We employ the same procedure for the “Medium” and yield its associated 
interval [0, 0.9812] for 121F . 
Hence, the fuzzy state transition matrix is represented as 
 










=
ZZZ
ZZZ
Z ]5718.0,0[]9812.0,0[
σ1 .  
The next state vector can be determined by 
[ ]]5718.0,0[]9812.0,0[σqq 101 Z== o . 
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2.4.7 Type-2 Fuzzy Sets for the Parameter Definitions and Type-2 
Fuzzy Sets for the Parameter Characteristics (Scenario 7) 
 
Figure 2.10: Determining the fuzzy event transition matrix for regimen 2 
under the scenario 7 
This scenario is the combination of scenario 3 and scenario 4. While the 
consensus of the diverse definitions of parameter state is defined by type-2 fuzzy 
sets, the clinical parameters for a regimen are defined as symmetrical triangular 
type-2 fuzzy sets. Their FOUs are depicted in Figure 2.10 and their boundary 
functions, the upper primary membership function and the lower primary 
membership function, have mathematical expressions in scenario 3 (equation 
(2.5) and (2.6)) and scenario 4 (equation (2.10) and (2.11)) for the clinical 
parameter and the definitions of parameter state, respectively. 
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Applying the fuzzy intersection on the triangular type-2 fuzzy set and the 
type-2 fuzzy set for “High” results in an FOU which is the deep dark region shown 
in Figure 2.10. The FOU is bounded by the upper primary membership function in 
equation (2.16) and the lower primary membership function in equation (2.17) 
given below: 
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where FHy  and FHy  are the respective upper and lower primary membership 
functions of  “High” for future drug options of regimen 2. 
The equation (2.9) for the height type-reducer method is used to determine 
the range of the primary membership grades of the type-2 fuzzy set (the dark 
region in Figure 2.10) assigned for the domain of fuzzy set for 131F , as well as the 
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membership function. The second membership grade of the interval type-2 fuzzy 
set is 1. 
Applying equation (2.9) to the type-2 fuzzy set (the dark region for “High” in 
Figure 2.10) over the universe of discourse for x from 50 to 100 will result in the 
value of the primary grade changing from 0 to 0.5987 and the corresponding 
membership grade equal to 1. Therefore, 131F can be represented by the interval [0, 
0.5987]. We employ the same procedure for the “Medium” and yield its associated 
interval [0, 0.9818] is for 121F . 
Hence, the fuzzy state transition matrix is represented as 
 










=
ZZZ
ZZZ
Z ]5987.0,0[]9818.0,0[
σ1 .  
The next state vector can be determined by 
[ ]]5987.0,0[]9818.0,0[σqq 101 Z== o . 
2.5 Retrospective patient data 
The patient database [22, 31] was from the HIV/AIDS center founded in 
1994. Clinical information of More than 4500 patients was collected. Since 1998 
various highly active antiretroviral therapy regimens have been provided to 
patients. Clinical information of 35 patients used in this research was from the 98 
treatment-naïve patients who received one of three treatment regimens for 
antiretroviral therapy at the AIDS clinical center in 2001. The data of all 35 
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patients was extracted from the database shown in Table 2.7-2.8. Table 2.10 was 
the regimen-choice of three treatment regimens for the 32 treatment objectives 
assigned by specialist A and B individually.  
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Table 2.7: 35 retrospective patients with their clinical information of physicians, 
CD4+ counts, HIV RNA, age, gender, and homelessness treated at AIDS Clinical 
Center in 2001 
Patient CD4+ HIV RNA Age 
No. 
Physician (cell/µL) (copies/mL) (years) Gender Homeless 
1 PHYSICIAN 1 81 8500 35 Male No 
2 EXPERT A 777 15000 32 Female No 
3 PHYSICIAN 2 64 300 36 Male No 
4 EXPERT B. 63 750000 55 Male No 
5 PHYSICIAN 3 210 60000 49 Male No 
6 PHYSICIAN 2 350 10000 48 Female No 
7 EXPERT A 512 100000 38 Male No 
8 PHYSICIAN 2 50 375000 49 Male No 
9 EXPERT B. 180 8500 48 Male No 
10 PHYSICIAN 1 10 85000 34 Male No 
11 EXPERT A 380 15000 36 Male No 
12 PHYSICIAN 4 532 125000 24 Male Yes 
13 PHYSICIAN 2 48 175000 42 Male No 
14 PHYSICIAN 5 135 400000 51 Male No 
15 PHYSICIAN 1 164 30000 45 Male No 
16 PHYSICIAN 6 288 225000 40 Female No 
17 PHYSICIAN 7 255 30000 32 Male No 
18 PHYSICIAN 4 440 25000 35 Male No 
19 PHYSICIAN 7 315 100000 33 Male No 
20 PHYSICIAN 3 575 15000 23 Male No 
21 PHYSICIAN 5 306 40000 40 Male No 
22 PHYSICIAN 8 714 750000 27 Male No 
23 EXPERT B. 480 6500 44 Female No 
24 PHYSICIAN 1 575 35000 25 Female No 
25 EXPERT B. 510 275000 33 Male No 
26 PHYSICIAN 6 644 3500 49 Male Yes 
27 EXPERT B. 656 2000 44 Male No 
28 EXPERT B. 45 725000 27 Male No 
29 PHYSICIAN 9 81 275000 43 Female No 
30 EXPERT B. 50 10000 40 Male No 
31 PHYSICIAN 10 24 150000 42 Male No 
32 PHYSICIAN 3 11 250000 38 Male No 
33 EXPERT A 342 2500 38 Male No 
34 PHYSICIAN 11 40 750000 70 Male No 
35 EXPERT B. 162 100000 43 Male No 
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Table 2.8: 35 retrospective patients with their clinical information of behavior on 
illegal drugs or alcohol, mental illness problems, clinic visits, smoking, diabetes, 
and hepatitis B treated at AIDS Clinical Center in 2001 
Clinic visit 
Patient No. Active 
abuse 
Mental 
illness Missed >1 
Smoking Diabetes Hepatitis B 
1 Yes No No Yes No No 
2 No No No No No No 
3 No No No No No No 
4 No Yes No No No No 
5 Yes No No Yes No No 
6 Yes Yes Yes No No No 
7 Yes No Yes No No No 
8 No No No No No No 
9 No No No No No No 
10 Yes No No Yes No Yes 
11 No No Yes No No No 
12 Yes No No No No No 
13 Yes Yes No No No No 
14 Yes No Yes Yes Yes Yes 
15 No No No Yes No No 
16 Yes No No Yes Yes No 
17 No No No Yes No No 
18 Yes Yes No Yes No No 
19 No No No Yes No No 
20 No No Yes No No No 
21 Yes Yes Yes Yes No No 
22 Yes No Yes Yes No No 
23 Yes No No Yes No No 
24 No No No No No No 
25 Yes Yes No Yes No No 
26 No Yes No No No No 
27 No No No Yes No No 
28 Yes No No Yes Yes No 
29 Yes No No Yes No No 
30 No No No No No No 
31 No No No No No No 
32 No No No No No No 
33 No No No No No Yes 
34 No No No No No No 
35 No Yes No No No No 
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Table 2.9: 35 retrospective patients with their clinical information of hepatitis C, 
total cholesterol, HDL cholesterol, blood pressure, and given medicines treated at 
AIDS Clinical Center in 2001 
Cholesterol HDL Blood Pressure 
Patient No. Hepatitis C (mg/dL) (mg/dL) (mm Hg) Medications 
1 Yes <100 <20 147 Regimen 3 
2 No 144 44 105 Regimen 3 
3 No 223 69 132 Regimen 3 
4 No <100 <20 99 Regimen 3 
5 No 166 43 138 Regimen 3 
6 Yes 107 34 113 Regimen 3 
7 No 165 <20 114 Regimen 3 
8 No <100 <20 131 Regimen 3 
9 No 198 53 136 Regimen 1 
10 No 156 <20 122 Regimen 3 
11 No 142 45 121 Regimen 3 
12 No 189 62 126 Regimen 3 
13 No <100 <20 120 Regimen 3 
14 No 159 36 141 Regimen 3 
15 No <100 <20 120 Regimen 1 
16 No 154 43 119 Regimen 3 
17 No 196 56 154 Regimen 2 
18 No 129 <20 110 Regimen 3 
19 No <100 <20 132 Regimen 3 
20 No <100 <20 120 Regimen 1 
21 No 139 33 137 Regimen 3 
22 No 168 34 95 Regimen 3 
23 Yes 133 52 112 Regimen 3 
24 No 149 <20 135 Regimen 3 
25 No <100 <20 118 Regimen 3 
26 No 172 35 139 Regimen 2 
27 No 141 30 118 Regimen 3 
28 No 108 <20 105 Regimen 3 
29 No <100 <20 133 Regimen 3 
30 No <100 <20 105 Regimen 3 
31 No 192 32 115 Regimen 1 
32 No 143 <20 104 Regimen 3 
33 No 171 42 134 Regimen 3 
34 No 163 21 160 Regimen 2 
35 No <100 <20 115 Regimen 3 
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Table 2.10: Regimens assigned by AIDS expert A and B for the preferable 
regimen-choices regarding the 32 treatment objectives   
Treatment Objectives 1st choice 2nd choice 3rd choice 
Potency Adherence Adverse Events 
Future Drug 
Options 
Expert 
A 
Expert 
B 
Expert 
A 
Expert 
B 
Expert 
A 
Expert 
B 
High Easy Medium High 1 3 2 1 3 2 
High Easy Medium Medium 1 1 2 2 3 3 
High Easy Low High 1 3 3 1 2 2 
High Easy Low Medium 1 1 2 2 3 3 
High Easy Very Low High 1 3 3 1 2 2 
High Easy Very low Medium 1 3 2 1 3 2 
High Moderate Medium High 1 3 2 1 3 2 
High Moderate Medium Medium 1 1 2 2 3 3 
High Moderate Low High 1 3 2 1 3 2 
High Moderate Low Medium 1 1 2 2 3 3 
High Moderate Very Low High 1 3 2 1 3 2 
High Moderate Very low Medium 1 3 2 1 3 2 
High Challenging Medium High 1 3 2 1 3 2 
High Challenging Medium Medium 1 1 2 2 3 3 
High Challenging Low High 1 3 2 1 3 2 
High Challenging Low Medium 1 1 2 2 3 3 
High Challenging Very Low High 1 3 2 1 3 2 
High Challenging Very low Medium 1 3 2 1 3 2 
Medium Easy Medium High 3 3 1 2 2 1 
Medium Easy Medium Medium 1 3 2 2 3 1 
Medium Easy Low High 3 3 2 2 1 1 
Medium Easy Low Medium 1 3 2 2 3 1 
Medium Easy Very Low High 3 3 1 2 2 1 
Medium Easy Very Low Medium 1 3 2 2 3 1 
Medium Moderate Medium High 3 3 1 2 2 1 
Medium Moderate Low High 3 3 1 2 2 1 
Medium Moderate Very Low High 3 3 1 2 2 1 
Medium Moderate Very Low Medium 1 3 2 2 3 1 
Medium Challenging Medium High 3 3 1 1 2 2 
Medium Challenging Low High 3 3 1 1 2 2 
Medium Challenging Very Low High 3 3 1 2 2 1 
Medium Challenging Very Low Medium 1 3 2 2 3 1 
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2.6 Simulation Results 
The EFDES-based regimen selection system was implemented by using 
MATLAB. The medical information on the same 35 patients used in the FDES-
based system was put into the system. We did experiments under the seven 
scenarios and evaluated the system’s performance in terms of retrospectively 
matching the 35 patients’ actual prescriptions. Twelve of the 35 patients were 
treated by the two HIV/AIDS experts. These two expert physicians involved in the 
system development (e.g., weighting the regimens for each of 32 treatment 
objectives).  The remaining 23 patients were treated by 11 HIV/AIDS experts 
without contributing to system training, those results in the mean and standard 
deviation of patients per expert being 2 and 1.97, respectively.  
The results are shown in Table 2.11, 2.11, 2.12 and Table 2.14, where the 
meanings of ∆m, ∆x, ∆w, and ∆v are given above (e.g., Figure 2.2 and Figure 2.3). 
Table 2.15 contains all seven scenarios that provide the patients’ details of 
regimens experimentally assigned by the system against the historical 
prescriptions.  
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Table 2.11: First-choice regimens assigned by the EFDES-based system model 
against the actual regimens given to the 35 patients under scenario 1, 2, and 3   
Assigned Regimens 
The EFDES- Based System Model 
Scenario 1 Scenario 2 Scenario 3 
∆v (%) ∆x (%) ∆x, ∆w (%) 
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2 6 10 1 3 5 1,2 3,2 3,4 5,2 5,4 
1 23 3 3 3 3 3 3 3 3 3 3 3 3 3 3 
2 23 3 3 3 3 3 3 3 3 3 3 3 3 3 3 
3 10 3 1 1 1 1 1 1 1 1 1 1 1 1 1 
4 9 3 1 3 3 3 3 3 3 3 3 3 3 3 3 
5 23 3 3 3 3 3 3 3 3 3 3 3 3 3 3 
6 23 3 3 3 3 3 3 3 3 3 3 3 3 3 3 
7 23 3 3 3 3 3 3 3 3 3 3 3 3 3 3 
8 9 3 1 3 3 3 3 3 3 3 3 3 3 3 3 
9 10 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
10 9 3 1 3 3 3 3 3 3 3 3 3 3 3 3 
11 23 3 3 3 3 3 3 3 3 3 3 3 3 3 3 
12 23 3 3 3 3 3 3 3 3 3 3 3 3 3 3 
13 9 3 1 3 3 3 3 3 3 3 3 3 3 3 3 
14 9 3 1 3 3 3 3 3 3 3 3 3 3 3 3 
15 10 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
16 9 3 1 3 3 3 3 3 3 3 3 3 3 3 3 
17 23 2 3 3 3 3 3 3 3 3 3 3 3 3 3 
18 23 3 3 3 3 3 3 3 3 3 3 3 3 3 3 
19 24 3 1 3 1 1 1 1 1 3 1 1 1 1 1 
20 23 1 3 3 3 3 3 3 3 3 3 3 3 3 3 
21 23 3 3 3 3 3 3 3 3 3 3 3 3 3 3 
22 23 3 3 3 3 3 3 3 3 3 3 3 3 3 3 
23 23 3 3 3 3 3 3 3 3 3 3 3 3 3 3 
24 23 3 3 3 3 3 3 3 3 3 3 3 3 3 3 
25 23 3 3 3 3 3 3 3 3 3 3 3 3 3 3 
26 23 2 3 3 3 3 3 3 3 3 3 3 3 3 3 
27 23 3 3 3 3 3 3 3 3 3 3 3 3 3 3 
28 9 3 1 3 3 3 3 3 3 3 3 3 3 3 3 
29 9 3 1 3 3 3 3 3 3 3 3 3 3 3 3 
30 23 3 3 3 3 3 3 3 3 3 3 3 3 3 3 
31 10 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
32 10 3 1 1 1 1 1 1 1 1 1 1 1 1 1 
33 23 3 3 3 3 3 3 3 3 3 3 3 3 3 3 
34 10 2 1 1 1 1 1 1 1 1 1 1 1 1 1 
35 9 3 1 3 3 3 3 3 3 3 3 3 3 3 3 
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Table 2.12: First-choice regimens assigned by the EFDES-based system model 
against the actual regimens given to the 35 patients under scenario 4 and 5   
Assigned Regimens 
The EFDES- Based System Model 
Scenario 4 Scenario 5 
∆m (%) ∆m, ∆v (%) 
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1 2 3 1,2 1,6 1,10 2,2 2,6 2,10 3,2 3,6 3,10 
1 23 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 
2 23 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 
3 10 3 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
4 9 3 1 3 3 3 3 3 3 3 3 3 3 3 3 3 
5 23 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 
6 23 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 
7 23 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 
8 9 3 1 3 3 3 3 3 3 3 3 3 3 3 3 3 
9 10 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
10 9 3 1 3 3 3 3 3 3 3 3 3 3 3 3 3 
11 23 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 
12 23 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 
13 9 3 1 3 3 3 3 3 3 3 3 3 3 3 3 3 
14 9 3 1 3 3 3 3 3 3 3 3 3 3 3 3 3 
15 10 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
16 9 3 1 3 3 3 3 3 3 3 3 3 3 3 3 3 
17 23 2 3 3 3 3 3 3 3 3 3 3 3 3 3 3 
18 23 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 
19 24 3 1 3 1 1 1 1 1 1 1 1 1 1 1 1 
20 23 1 3 3 3 3 3 3 3 3 3 3 3 3 3 3 
21 23 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 
22 23 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 
23 23 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 
24 23 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 
25 23 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 
26 23 2 3 3 3 3 3 3 3 3 3 3 3 3 3 3 
27 23 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 
28 9 3 1 3 3 3 3 3 3 3 3 3 3 3 3 3 
29 9 3 1 3 3 3 3 3 3 3 3 3 3 3 3 3 
30 23 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 
31 10 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
32 10 3 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
33 23 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 
34 10 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
35 9 3 1 3 3 3 3 3 3 3 3 3 3 3 3 3 
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Table 2.13: First-choice regimens assigned by the EFDES-based system model 
against the actual regimens given to the 35 patients under scenario 6 
Assigned Regimens 
The EFDES- Based System Model 
Scenario 6 
∆m, ∆x (%) 
 
 
Pa
tie
n
t N
o
.
 
 
 
O
bje
ct
iv
e
s 
 
 
G
iv
e
n
 
R
e
gi
m
e
n
s 
 
 
Ex
pe
rt 
A 
 
 
Ex
pe
rt 
B 
1,1 1,3 1,5 2,1 2,3 2,5 3,1 3,3 3,5 
1 23 3 3 3 3 3 3 3 3 3 3 3 3 
2 23 3 3 3 3 3 3 3 3 3 3 3 3 
3 10 3 1 1 1 1 1 1 1 1 1 1 1 
4 9 3 1 3 3 3 3 3 3 3 3 3 3 
5 23 3 3 3 3 3 3 3 3 3 3 3 3 
6 23 3 3 3 3 3 3 3 3 3 3 3 3 
7 23 3 3 3 3 3 3 3 3 3 3 3 3 
8 9 3 1 3 3 3 3 3 3 3 3 3 3 
9 10 1 1 1 1 1 1 1 1 1 1 1 1 
10 9 3 1 3 3 3 3 3 3 3 3 3 3 
11 23 3 3 3 3 3 3 3 3 3 3 3 3 
12 23 3 3 3 3 3 3 3 3 3 3 3 3 
13 9 3 1 3 3 3 3 3 3 3 3 3 3 
14 9 3 1 3 3 3 3 3 3 3 3 3 3 
15 10 1 1 1 1 1 1 1 1 1 1 1 1 
16 9 3 1 3 3 3 3 3 3 3 3 3 3 
17 23 2 3 3 3 3 3 3 3 3 3 3 3 
18 23 3 3 3 3 3 3 3 3 3 3 3 3 
19 24 3 1 3 1 1 1 1 1 1 1 1 1 
20 23 1 3 3 3 3 3 3 3 3 3 3 3 
21 23 3 3 3 3 3 3 3 3 3 3 3 3 
22 23 3 3 3 3 3 3 3 3 3 3 3 3 
23 23 3 3 3 3 3 3 3 3 3 3 3 3 
24 23 3 3 3 3 3 3 3 3 3 3 3 3 
25 23 3 3 3 3 3 3 3 3 3 3 3 3 
26 23 2 3 3 3 3 3 3 3 3 3 3 3 
27 23 3 3 3 3 3 3 3 3 3 3 3 3 
28 9 3 1 3 3 3 3 3 3 3 3 3 3 
29 9 3 1 3 3 3 3 3 3 3 3 3 3 
30 23 3 3 3 3 3 3 3 3 3 3 3 3 
31 10 1 1 1 1 1 1 1 1 1 1 1 1 
32 10 3 1 1 1 1 1 1 1 1 1 1 1 
33 23 3 3 3 3 3 3 3 3 3 3 3 3 
34 10 2 1 1 1 1 1 1 1 1 1 1 1 
35 9 3 1 3 3 3 3 3 3 3 3 3 3 
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Table 2.14: First-choice regimens assigned by the EFDES-based system model 
against the actual regimens given to the 35 patients under scenario 7   
Assigned Regimens 
The EFDES- Based System Model 
Scenario 7 
∆m, ∆x, ∆w (%) 
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1,1,2 1,3,2 1,3,4 1,5,2 1,5,4 2,1,2 2,3,2 2,3,4 
1 23 3 3 3 3 3 3 3 3 3 3 3 
2 23 3 3 3 3 3 3 3 3 3 3 3 
3 10 3 1 1 1 1 1 1 1 1 1 1 
4 9 3 1 3 3 3 3 3 3 3 3 3 
5 23 3 3 3 3 3 3 3 3 3 3 3 
6 23 3 3 3 3 3 3 3 3 3 3 3 
7 23 3 3 3 3 3 3 3 3 3 3 3 
8 9 3 1 3 3 3 3 3 3 3 3 3 
9 10 1 1 1 1 1 1 1 1 1 1 1 
10 9 3 1 3 3 3 3 3 3 3 3 3 
11 23 3 3 3 3 3 3 3 3 3 3 3 
12 23 3 3 3 3 3 3 3 3 3 3 3 
13 9 3 1 3 3 3 3 3 3 3 3 3 
14 9 3 1 3 3 3 3 3 3 3 3 3 
15 10 1 1 1 1 1 1 1 1 1 1 1 
16 9 3 1 3 3 3 3 3 3 3 3 3 
17 23 2 3 3 3 3 3 3 3 3 3 3 
18 23 3 3 3 3 3 3 3 3 3 3 3 
19 24 3 1 3 1 1 1 1 1 1 1 1 
20 23 1 3 3 3 3 3 3 3 3 3 3 
21 23 3 3 3 3 3 3 3 3 3 3 3 
22 23 3 3 3 3 3 3 3 3 3 3 3 
23 23 3 3 3 3 3 3 3 3 3 3 3 
24 23 3 3 3 3 3 3 3 3 3 3 3 
25 23 3 3 3 3 3 3 3 3 3 3 3 
26 23 2 3 3 3 3 3 3 3 3 3 3 
27 23 3 3 3 3 3 3 3 3 3 3 3 
28 9 3 1 3 3 3 3 3 3 3 3 3 
29 9 3 1 3 3 3 3 3 3 3 3 3 
30 23 3 3 3 3 3 3 3 3 3 3 3 
31 10 1 1 1 1 1 1 1 1 1 1 1 
32 10 3 1 1 1 1 1 1 1 1 1 1 
33 23 3 3 3 3 3 3 3 3 3 3 3 
34 10 2 1 1 1 1 1 1 1 1 1 1 
35 9 3 1 3 3 3 3 3 3 3 3 3 
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Table 2.14: (continued) First-choice regimens assigned by the EFDES-based 
system against the actual regimens given to the 35 patients under scenario 7   
Assigned Regimens 
The EFDES- Based System Model 
Scenario 7 
∆m, ∆x, ∆w (%) 
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2,5,2 2,5,4 3,1,2 3,3,2 3,3,4 3,5,2 3,5,4 
1 23 3 3 3 3 3 3 3 3 3 3 
2 23 3 3 3 3 3 3 3 3 3 3 
3 10 3 1 1 1 1 1 1 1 1 1 
4 9 3 1 3 3 3 3 3 3 3 3 
5 23 3 3 3 3 3 3 3 3 3 3 
6 23 3 3 3 3 3 3 3 3 3 3 
7 23 3 3 3 3 3 3 3 3 3 3 
8 9 3 1 3 3 3 3 3 3 3 3 
9 10 1 1 1 1 1 1 1 1 1 1 
10 9 3 1 3 3 3 3 3 3 3 3 
11 23 3 3 3 3 3 3 3 3 3 3 
12 23 3 3 3 3 3 3 3 3 3 3 
13 9 3 1 3 3 3 3 3 3 3 3 
14 9 3 1 3 3 3 3 3 3 3 3 
15 10 1 1 1 1 1 1 1 1 1 1 
16 9 3 1 3 3 3 3 3 3 3 3 
17 23 2 3 3 3 3 3 3 3 3 3 
18 23 3 3 3 3 3 3 3 3 3 3 
19 24 3 1 3 1 1 1 1 1 1 1 
20 23 1 3 3 3 3 3 3 3 3 3 
21 23 3 3 3 3 3 3 3 3 3 3 
22 23 3 3 3 3 3 3 3 3 3 3 
23 23 3 3 3 3 3 3 3 3 3 3 
24 23 3 3 3 3 3 3 3 3 3 3 
25 23 3 3 3 3 3 3 3 3 3 3 
26 23 2 3 3 3 3 3 3 3 3 3 
27 23 3 3 3 3 3 3 3 3 3 3 
28 9 3 1 3 3 3 3 3 3 3 3 
29 9 3 1 3 3 3 3 3 3 3 3 
30 23 3 3 3 3 3 3 3 3 3 3 
31 10 1 1 1 1 1 1 1 1 1 1 
32 10 3 1 1 1 1 1 1 1 1 1 
33 23 3 3 3 3 3 3 3 3 3 3 
34 10 2 1 1 1 1 1 1 1 1 1 
35 9 3 1 3 3 3 3 3 3 3 3 
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Table 2.15: Comparison of 35 patients’ prescribed regimen with those assigned by 
the EFDES-based system 
  
∆m ∆x ∆w ∆v 
Number of  first-
choice regimens 
matched with 
prescribed regimens 
for the 35 patients 
      2% 28 
      6% 28 Scenario 1 
      10% 28 
  1%     28 
  3%     28 Scenario 2 
  5%     29 
  1% 2%   28 
  3% 2%   28 
  3% 4%   28 
  5% 2%   28 
Scenario 3 
  5% 4%   28 
1%       28 
2%       28 Scenario 4 
3%       28 
1%     2% 28 
1%     6% 28 
1%     10% 28 
2%     2% 28 
2%     6% 28 
2%     10% 28 
3%     2% 28 
3%     6% 28 
Scenario 5 
3%     10% 28 
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Table 2.15: (continued) Comparison of 35 patients’ prescribed regimen with those 
assigned by the EFDES-based system 
  
∆m ∆x ∆w ∆v 
Number of  first-
choice regimens 
matched with 
prescribed regimens 
for the 35 patients 
1% 1%   
  28 
1% 3%   
  28 
1% 5%   
  28 
2% 1%   
  28 
2% 3%   
  28 
2% 5%   
  28 
3% 1%   
  28 
3% 3%   
  28 
Scenario 6 
3% 5%   
  28 
1% 1% 2% 
  28 
1% 3% 2% 
  28 
1% 3% 4% 
  28 
1% 5% 2% 
  28 
1% 5% 4% 
  28 
2% 1% 2% 
  28 
2% 3% 2% 
  28 
2% 3% 4% 
  28 
2% 5% 2% 
  28 
2% 5% 4% 
  28 
3% 1% 2% 
  28 
3% 3% 2% 
  28 
3% 3% 4% 
  28 
3% 5% 2% 
  28 
Scenario 7 
3% 5% 4% 
  28 
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2.7 Discussion 
Specialist A treated patient numbers 2, 7, 11 and 33, whereas the specialist 
B treated the patient numbers 4, 9, 23, 25, 27, 28, 30 and 35. The clinical 
information of 35 retrospective patients is in Table 2.7-2.10. In all seven 
scenarios, the first-choice treatment regimens computed by the EFDES system 
match the regimens selected by the two specialists for the 12 patients 100% of 
times. This result may indicate that the system captures and represents the 
diverse knowledge of these two specialists well.  
As shown in the result tables, most agreement between the computer and 
the actual prescriptions is 80% (28 out of 35), exempting scenario 2 with ∆x being 
5% which is 82.9% (29 out of 35). To obtain such high numbers of 29 first-choice 
matching regimens, the system assigned the right regimen (i.e., regimen 3) to 
patient number 19 with the treatment objective: “medium” potency, “easy’ 
adherence, “very low” adverse events, and “medium” future drug options. Under 
other scenarios, patient number 19 was assigned with regimen 1 instead. 
Unfortunately, this case has never again been observed since the first time. 
Basically, an initial condition value for the genetic algorithm is randomly generated 
which takes time to initiate the right one. It will take even more time when dealing 
with a large dimension of the initial values like the one in the EFDES-based 
system. The system normally provides 80% matching.  
The uncertainties of the fuzzy state vectors like those in the seven 
scenarios need to be represented in a form of the certainties done by 
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defuzzification and then will be used for the Regimen Selection Optimizer. For 
instance, ])]5052.0,0[]9509.0,0[([Zdef is [0 0.4754 0.2526], according to 
equation (2.3.1.2) for the future drug options for regimen 2 (Figure 2.4) in scenario 
2 and the corresponding normalized state vector is [0 0.6530 0.3470]. While the 
normalized state vector for the future drug options for the FDES-based in Figure 
1.1 is [0 0.6993 0.3007], the closest normalized state vector [0 0.6963 0.3037] is 
obtained from scenario 4 when ∆x equals 1% and the farthest normalized state 
vector [0 0.6209 0.3791] is obtained from scenario 6 when ∆m and ∆x equal 3% 
and 5%, respectively. The system model shows that the Regimen Selection 
Optimizer for the EFDES-based system is able to handle at least those ranges of 
uncertainties in Table 2.11. For example, normalized state vectors for future drug 
options for regimen 2 are in the range from [0 0.6209 0.3791] to [0 0.6963 0.3037] 
that result in the same number of matching regimens (28 out of 35).  
The normal level of performance is a bit lower than the FDES-based 
system, which is 82.9% (29 out of 35). However, that level shows the benefit of 
the EFDES system providing the domain experts with the ability to use their 
individual diverse knowledge and expertise. The equality respective is kept to 
those experts. 
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CHAPTER 3 
SELF-LEARNING EFDES-BASED HIV/AIDS TREATMENT REGIMEN 
SELECTION SYSTEM 
  
The EFDES-based HIV/AIDS treatment selection system with static mode 
(i.e., without self-learning mode) is a part of the research work. It has been studied 
and experimented, as the results have shown in the previous chapter. An 
adaptation of the HIV disease to a new environment would be remarkable as 
recognized by the revising of the HIV/AIDS treatment every few years. How to 
adapt the ability of self-learning to the system would be another challenging task. 
The theory of self-learning for the fuzzy discrete event system would be 
contributed in the development of the EFDES-based system with self-learning.  
Adding a self-learning ability to the EFDES-based system will make the 
system even more useful where the evaluation of the HIV/AIDS treatment 
changes rapidly. The EFDES-based system with self-learning will be developed, 
and the complete system will then be used as an HIV/AIDS treatment decision-
supporting system that will give huge benefits to those clinical institutes with 
limited numbers of the HIV/AIDS specialists. 
3.1  EFDES-Based HIV/AIDS Regimen Selection System with Self-Learning 
The approach of the self-learning system will utilize the theory of the self-
learning fuzzy discrete system [31]. There will be four regimens involved in the 
system for self-learning. Each of them has the same four clinical parameters: 
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potency, adherence, adverse events, and future drug options. As mentioned in the 
previous chapter, without regarding the initial state, there are two states (e.g., 
medium and high) for potency, three for adherence, three for adverse events and 
two for future drug options. Theoretically, the combinations of the four clinical 
parameters generate 36 treatment objectives, but only 32 treatment objectives 
exist clinically. One of them will be labeled on a patient when classified. Which 
regimen to be assigned will be the one with the highest effectiveness measure 
computed by the system. Under the EFDES-based system, in general, the 
fuzzification of a fuzzy state vector of which components can be a type-1 fuzzy set 
or an interval number may need defuzzification into a crisp state vector in order to 
compute the effectiveness measure. The mathematical expression of the 
effectiveness measure (E) for the j-th regimen regarding the h-th treatment 
objective can be defined in a form of the function as 
,41,1),,...,( 11 <<≤≤⋅⋅= nPkWSWSfE nknhnjkjhhj           (3.1) 
where f is a function. Shnj is a new fuzzy state vector when an event occurs (i.e., 
prescribing a regimen), which is obtained by performing fuzzy logic operation (i.e., 
max-product) to the current fuzzy state vector with a state transition matrix. The 
four clinical parameters considered are indicated by n and Pn is the number states 
of the corresponding parameter (e.g., P1=2 for medium and high for potency). 
Finally, Wkn is the weight vector corresponding to Shnj. 
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The linear function in the form of the weighted average of clinical 
parameters will be utilized as a predicting function. With the same significant given 
to all clinical parameters, the linear function can be expressed as 
0
4
1
CWSE
n
knhnjhj +⋅=∑
=
          (3.2) 
where C0 is a constant offset. 
In the equation (3.2), only the weight vector Wkn will be considered as a 
part of the system to be learned. The self-learning EFDES-based system can be 
adapted as shown in Figure 3.1. In order to prove the adapted system model, sets 
of data need to be acquired for the system training.  There are four data-learning 
settings. Their criteria of these various data settings are in the following section. 
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Figure 3.1: Block diagram of the EFDES-based HIV/AIDS treatment 
selection system with self-learning 
 
3.2  Settings for the Self-Learning System Evaluation  
As from the clinical data base as well as in [31], the four treatment 
regimens, the three regimens in Table 1.1 and the regimen which consisted of 
Combivir (CBV) and Nelfinavir (NEV), will be used for the self-learning system. 
Table 3.1 provides the clinical parameter characteristics of these four treatment 
regimens. Each of the four regimens with points individually given by two AIDS 
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experts for all 32 treatment objectives in Table 3.2-3.3 would be data for data-
learning setting. The AIDS experts rated the four regimens following the 
instruction of a 10-point scoring with increments of 0.5. The highest score is 10. 
The experts’ preference of regimens for the treatment objective was indicated in 
the form of scores rated among the four regimens. The regimen with the highest 
score was the most preferable as the first choice. In the case of the same scores, 
one of the regimens involved was selected randomly. 
 
Table 3.1: Four clinical parameters of the four HIV/AIDS treatment regimens 
 Potency Adherence Adverse Events 
Future Drug 
Options 
Regimen 1: 
CBV+NEV 85% 55% 30% 80% 
Regimen 2: 
CBV+EFV 90% 80% 20% 60% 
Regimen 3: 
CBV+NVP 85% 85% 20% 65% 
Regimen 4: 
CBV+ABC 80% 90% 10% 85% 
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Table 3.2: Regimens assigned by AIDS experts A and B for the preferable scores 
of regimen 1 and regimen 2 regarding the 32 treatment objectives. Also marked 
are the 10 selected treatment objectives used in Learning Setting 3 [31]   
Treatment Objectives Regimen 1 Regimen 2 
Potency Adherence Adverse Events 
Future Drug 
Options 
Expert 
A 
Expert 
B 
Expert 
A 
Expert 
B 
10 Selected 
Objectives 
for Learning 
Setting 3 
High Easy Medium High 5.5 6.0 7.0 4.0 X 
High Easy Medium Medium 6.5 3.0 9.0 9.0  
High Easy Low High 5.5 3.5 6.5 5.0  
High Easy Low Medium 6.5 4.0 8.5 8.5  
High Easy Very Low High 5.0 3.0 6.5 7.0  
High Easy Very low Medium 6.0 2.0 8.5 8.0 X 
High Moderate Medium High 6.5 7.0 8.0 6.0 X 
High Moderate Medium Medium 6.5 7.0 10.0 9.0  
High Moderate Low High 6.5 7.0 7.5 5.0  
High Moderate Low Medium 7.5 6.0 9.5 8.5  
High Moderate Very Low High 3.0 3.0 7.5 5.0  
High Moderate Very low Medium 7.0 3.0 9.5 8.0 X 
High Challenging Medium High 7.5 9.0 8.0 4.0 X 
High Challenging Medium Medium 8.5 7.0 10.0 9.0  
High Challenging Low High 7.5 7.5 7.5 4.0  
High Challenging Low Medium 8.5 6.5 9.5 9.0  
High Challenging Very Low High 7.0 3.0 7.5 5.0  
High Challenging Very low Medium 8.0 3.0 9.5 8.0 X 
Medium Easy Medium High 6.5 7.0 7.0 4.5 X 
Medium Easy Medium Medium 7.5 5.0 9.0 8.0  
Medium Easy Low High 6.5 5.0 6.5 4.0  
Medium Easy Low Medium 7.5 2.0 8.5 8.0  
Medium Easy Very Low High 3.0 3.0 6.5 4.5  
Medium Easy Very Low Medium 7.0 3.0 8.5 7.0 X 
Medium Moderate Medium High 7.5 9.0 8.0 3.5  
Medium Moderate Low High 7.5 7.5 7.5 3.5 X 
Medium Moderate Very Low High 7.0 3.0 7.5 3.5  
Medium Moderate Very Low Medium 8.0 3.0 9.5 8.0  
Medium Challenging Medium High 8.5 9.0 8.0 6.0  
Medium Challenging Low High 8.5 9.0 7.5 4.0  
Medium Challenging Very Low High 8.0 3.0 7.5 3.5  
Medium Challenging Very Low Medium 9.0 6.0 9.5 8.0 X 
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Table 3.3: Regimens assigned by AIDS experts A and B for the preferable scores 
of regimen 3 and regimen 4 regarding the 32 treatment objectives. Also marked 
are the 10 selected treatment objectives used in Learning Setting 3 [31]   
Treatment Objectives Regimen 3 Regimen 4 
Potency Adherence Adverse Events 
Future Drug 
Options 
Expert 
A 
Expert 
B 
Expert 
A 
Expert 
B 
10 Selected 
Objectives 
for Learning 
Setting 3 
High Easy Medium High 6.5 3.5 6.5 9.0 X 
High Easy Medium Medium 8.5 8.5 6.5 8.0  
High Easy Low High 6.0 4.5 6.5 9.0  
High Easy Low Medium 8.0 8.0 6.5 7.0  
High Easy Very Low High 5.5 6.0 6.0 9.0  
High Easy Very low Medium 7.5 7.5 6.0 8.5 X 
High Moderate Medium High 7.5 5.0 6.5 8.5 X 
High Moderate Medium Medium 9.5 8.5 7.5 8.0  
High Moderate Low High 7.0 4.0 6.5 9.0  
High Moderate Low Medium 9.0 8.0 6.5 7.5  
High Moderate Very Low High 6.5 4.0 6.0 9.0  
High Moderate Very low Medium 8.5 7.5 6.0 8.5 X 
High Challenging Medium High 7.5 3.5 6.5 8.5 X 
High Challenging Medium Medium 9.5 8.5 6.5 6.5  
High Challenging Low High 7.0 3.5 6.5 9.0  
High Challenging Low Medium 9.0 8.5 6.5 7.0  
High Challenging Very Low High 6.5 4.0 6.5 8.5  
High Challenging Very low Medium 8.5 7.5 6.5 9.0 X 
Medium Easy Medium High 7.0 5.0 8.0 9.5 X 
Medium Easy Medium Medium 9.0 8.5 8.0 9.0  
Medium Easy Low High 6.5 3.0 8.0 9.5  
Medium Easy Low Medium 8.5 8.5 8.0 9.5  
Medium Easy Very Low High 6.0 5.0 7.5 9.5  
Medium Easy Very Low Medium 8.0 7.5 7.5 9.5 X 
Medium Moderate Medium High 8.0 4.0 8.0 9.5  
Medium Moderate Low High 7.5 4.0 8.0 9.5 X 
Medium Moderate Very Low High 7.0 4.0 7.5 9.5  
Medium Moderate Very Low Medium 9.0 8.0 7.5 9.5  
Medium Challenging Medium High 8.0 5.0 8.0 9.5  
Medium Challenging Low High 7.5 3.5 8.0 9.5  
Medium Challenging Very Low High 7.0 4.0 7.5 9.5  
Medium Challenging Very Low Medium 9.0 8.0 7.5 9.5 X 
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There are four data-learning settings as follows which will be conducted to 
evaluate the EFDES- based system’s prediction capabilities. 
• Data-learning setting 1 
In this data setting 1, a set of three regimens would be drawn from the pool 
of the four regimens. Thus, it provides 4 sets of the three regimens contributing 
with the consensus choices of specialist A and B or the individual choices of 
specialist A and B for all the 32 treatment objectives that the system would learn 
from and then predict the choices of the undrawn regimen regarding the 32 
treatment objectives. For instance, the system would predict the choice of the 
regimen 1 for all 32 treatment objectives after learning the set of [Regimen 2, 
Regimen 3, Regimen 4]. Eventually, these four sets consisted of [Regimen 2, 
Regimen 3, Regimen 4], [Regimen 1, Regimen 3, Regimen 4], [Regimen 1, 
Regimen 2, Regimen 4], and [Regimen 1, Regimen 2, Regimen 3].  
• Data-learning setting 2 
In this data setting 2, a set of two regimens would be drawn from the pool 
of the four regimens. Thus, it provides 6 sets of the two regimens contributing with 
the consensus choices of specialist A and B or the individual choices of specialist 
A and B regarding the 32 treatment objectives that the system would learn from 
and then predict the choices of the undrawn regimen for all the treatment 
objectives. For instance, the system would predict the choice of the Regimen 1 for 
all 32 treatment objectives after learning each of two different sets; [Regimen 2, 
Regimen 3] and [Regimen 2, Regimen4]. These six sets consisted of [Regimen 1, 
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Regimen 2], [Regimen 1, Regimen 3], [Regimen 1, Regimen 4], [Regimen 2, 
Regimen 3], [Regimen 2, Regimen 4], and [Regimen 3, Regimen 4]. 
• Data-learning setting 3 
In this data setting 3, a set of two regimens would be drawn from the pool 
of the three regimens: Regimen 2, Regimen 3, and Regimen 4. That drawing 
provides 3 sets of the two regimens contributing with the consensus choices of 
specialist A and B regarding ten selected treatment objectives that the system 
would learn from and then predict the choices of the undrawn regimens for 32 
treatment objectives. Those treatment objectives marked in the last column in 
Table 3.2-3.3 were the selected treatment objectives used for this learning setting. 
The system would predict the choice of Regimen 2, Regimen 3, and Regimen 4 
for all the 32 treatment objectives after learning the set of [Regimen 3, Regimen 
4], [Regimen 2, Regimen4], and [Regimen 2, Regimen3], respectively. 
• Data-learning setting 4 
In this data setting 4, it would be the same as the data setting 3. There were 
three sets of two regimens drawn from the pool of the three regimens: Regimen 2, 
Regimen 3, and Regimen 4. The system would learn each of these three sets 
under the 32 treatment objectives and then predict the choices of regimens for the 
35 retrospective patients under their treatment objectives involved. 
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Table 3.4: Rankings of the consensus of AIDS experts A & B for the four regimens 
regarding the 32 treatment objectives  
Treatment Objectives Rankings of Consensus of  Experts A & B 
Potency Adherence Adverse Events 
Future Drug 
Options Regimen 1 Regimen 2 Regimen 3 Regimen 4 
High Easy Medium High 3 2 4 1 
High Easy Medium Medium 4 1 2 3 
High Easy Low High 4 2 3 1 
High Easy Low Medium 4 1 2 3 
High Easy Very Low High 4 2 3 1 
High Easy Very low Medium 4 1 2 3 
High Moderate Medium High 3 1 4 2 
High Moderate Medium Medium 4 1 2 3 
High Moderate Low High 2 3 4 1 
High Moderate Low Medium 3 1 2 4 
High Moderate Very Low High 4 2 3 1 
High Moderate Very low Medium 4 1 2 3 
High Challenging Medium High 1 3 4 2 
High Challenging Medium Medium 3 1 2 4 
High Challenging Low High 1 3 4 2 
High Challenging Low Medium 3 1 2 4 
High Challenging Very Low High 4 2 3 1 
High Challenging Very low Medium 4 1 2 3 
Medium Easy Medium High 2 4 3 1 
Medium Easy Medium Medium 4 2 1 3 
Medium Easy Low High 2 3 4 1 
Medium Easy Low Medium 4 3 2 1 
Medium Easy Very Low High 4 2 3 1 
Medium Easy Very Low Medium 4 2 3 1 
Medium Moderate Medium High 2 4 3 1 
Medium Moderate Low High 2 4 3 1 
Medium Moderate Very Low High 4 2 3 1 
Medium Moderate Very Low Medium 4 1 2 3 
Medium Challenging Medium High 1 3 4 2 
Medium Challenging Low High 1 3 4 2 
Medium Challenging Very Low High 2 3 4 1 
Medium Challenging Very Low Medium 4 1 2 3 
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3.3  Performance Evaluation with Simulation  
To learn the information on the four clinical parameters assigned by the 
AIDS experts A and B shown in Table 3.2 and Table 3.3, it needed to be in the 
form of score rankings used by the genetic algorithm. Four rankings of the 
regimen for each of the 32 treatment objectives would create a table of expert 
choices for the weight optimizer to search the weights so that it would provide the 
most possible matching of the first-choice regimens assigned by the  system and  
selected by the expert individually. 
 The consensus scores of the distinct scores rated by two AIDS experts 
were calculated in the manner done in [31]. Each score of the individual expert 
was divided by the corresponding standard deviation. We then needed to 
calculate the average score for every treatment objective and every regimen. 
There would be the results of 128 average scores of the two experts for the 32 
treatment objectives and the four regimens. These average scores represented 
the consensus of the two experts and were converted to rankings. The score 
rankings of the consensus of experts A and B is shown in Table 3.4. The highest 
average score was ranked as 1 and the lowest average score was ranked as 4.  
 The exact agreements among two AIDS experts on regimen choice for the 
treatment objectives were derived from Table 3.2 and Table 3.3, and their 
measures under various settings were shown in Table 3.5. Also, the agreement 
between each of the experts and their consensus from Table 3.4 were included in 
Table 3.5. The EFDES system performance was evaluated under four various 
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learning settings as imitating medical situations which would be encountered. 
Basically, these situations would arise as new regimens become available. The 
system would predict the new regimens based on clinical information for existing 
available regimens provided by AIDS experts. The first two learning settings 
occupied all completed information for the existing regimens provided by the 
experts. The performance prediction after the system learned these two settings 
were shown in Table 3.6-3.14. Learning setting 3 occupied some information for 
the existing regimens provided by the experts. After learning, the system 
generated the prediction results shown in Table 3.15-3.17. Learning setting 4 
involved 35 historical treatment patients. The prediction results against the given 
regimens to the patients after learning setting 4 was learned shown in Table 3.18-
3.26. The corresponding optimal weight vectors were shown in Table 3.27-3.32. 
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Table 3.5: Measures of exact agreement between two experts and measure of 
exact agreement between each of the two experts and their consensus under 
various prescribing conditions. 
Prescribing 
Exact 
agreement 
between all 4 
regimens 
3 of the 4 
regimens 
(excluding 
Regimen 1) 
3 of the 4 
regimens 
(excluding 
Regimen 2) 
3 of the 4 
regimens 
(excluding 
Regimen 3) 
3 of the 4 
regimens 
(excluding 
Regimen 4) 
Mean rate 
expert A and 
expert B 37.5% 46.9% 46.9% 37.5% 50.0% 43.8% 
expert A and 
consensus of 
experts A&B 
62.5% 65.6% 78.1% 65.6% 75.0% 69.4% 
expert B and 
consensus of 
experts A&B 
68.8% 75.0% 68.8% 68.8% 75.0% 71.3% 
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Table 3.6: Prediction results achieved after the EFDES-based system learned 
under condition of learning setting 1 compared with expert A’s choices. 
Scenario 
Accuracy of  System-prediction Choices 
vs. 
Expert A’s Choices 
 ∆m ∆x ∆w ∆v 
Predicting 
Regimen 1 
 using 
Regimen 
2, 3 & 4 
Predicting 
Regimen 2 
 using 
Regimen 
1, 3 & 4 
Predicting 
Regimen 3 
using 
Regimen 
1, 2 & 4 
Predicting 
Regimen 4 
 using 
Regimen 
1, 2 & 3 
Mean 
prediction 
   6% 30 (93.8%) 30 (93.8%) 32 (100%) 26 (81.3%) 29.5 (92.2%) 
Scenario 1  
   10% 31 (96.9%) 29 (90.6%) 32 (100%) 26 (81.3%) 29.5 (92.2%) 
 3%   29 (90.6%) 29 (90.6%) 32 (100%) 26 (81.3%) 29.0 (90.6%) 
Scenario 2 
 5%   29 (90.6%) 29 (90.6%) 32 (100%) 26 (81.3%) 29.0 (90.6%) 
 3% 4%  32 (100%) 29 (90.6%) 28 (71.9%) 26 (81.3%) 28.8 (89.8%) 
Scenario 3 
 5% 4%  31 (96.9%) 29 (90.6%) 32 (100%) 26 (81.3%) 29.5 (92.2%) 
1%    30 (93.8%) 29 (90.6%) 32 (100%) 26 (81.3%) 29.3 (91.4%) 
Scenario 4 
2%    30 (93.8%) 32 (100%) 32 (100%) 26 (81.3%) 30.0 (93.8%) 
1%   6% 31 (96.9%) 29 (90.6%) 32 (100%) 32 (100%) 31.0 (96.9%) 
1%   10% 32 (100%) 31 (96.9%) 32 (100%) 26 (81.3%) 30.3 (94.5%) 
2%   6% 30 (93.8%) 29 (90.6%) 32 (100%) 32 (100%) 30.8 (96.1%) 
Scenario 5 
2%   10% 30 (93.8%) 32 (100%) 32 (100%) 32 (100%) 31.5 (98.4%) 
1% 3%   30 (93.8%) 29 (90.6%) 32 (100%) 26 (81.3%) 29.3 (91.4%) 
1% 5%   32 (100%) 29 (90.6%) 32 (100%) 26 (81.3%) 29.8 (93.0%) 
2% 3%   30 (93.8%) 31 (96.9%) 30 (93.8%) 26 (81.3%) 29.3 (91.4%) 
Scenario 6 
2% 5%   31 (96.9%) 30 (93.8%) 28 (87.5%) 26 (81.3%) 28.8 (89.8%) 
1% 3% 4%  29 (90.6%) 28 (87.5%) 32 (100%) 26 (81.3%) 28.8 (89.8%) 
1% 5% 4%  29 (90.6%) 29 (90.6%) 32 (100%) 26 (81.3%) 29.0 (90.6%) 
2% 3% 4%  29 (90.6%) 31 (96.9%) 32 (100%) 26 (81.3%) 29.5 (92.2%) 
Scenario 7 
2% 5% 4%  29 (90.6%) 29 (90.6%) 32 (100%) 26 (81.3%) 29.0 (90.6%) 
Average 30.2 (94.4%) 29.7 (92.7%) 31.5 (98.4%) 26.9 (84.1%) 29.6 (92.4%) 
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Table 3.7: Prediction results achieved after the EFDES-based system learned 
under condition of learning setting 1 compared with expert B’s choices 
Scenario 
Accuracy of  System-prediction Choices 
vs. 
Expert B’s Choices 
 ∆m ∆x ∆w ∆v 
Predicting 
Regimen 1 
 using 
Regimen 
2, 3 & 4 
Predicting 
Regimen 2 
 using 
Regimen 
1, 3 & 4 
Predicting 
Regimen 3 
using 
Regimen 
1, 2 & 4 
Predicting 
Regimen 4 
 using 
Regimen 
1, 2 & 3 
Mean 
prediction 
   6% 32 (100%) 30 (93.8%) 31 (96.9%) 32 (100%) 31.3 (97.7%) 
Scenario 1  
   10% 31 (96.9%) 30 (93.8%) 32 (100%) 32 (100%) 31.3 (97.7%) 
 3%   32 (100%) 32 (100%) 30 (93.8%) 32 (100%) 31.5 (98.4%) 
Scenario 2 
 5%   32 (100%) 30 (93.8%) 31 (96.9%) 32 (100%) 31.3 (97.7%) 
 3% 4%  31 (96.9%) 32 (100%) 32 (100%) 30 (93.8%) 31.3 (97.7%) 
Scenario 3 
 5% 4%  32 (100%) 32 (100%) 31 (96.9%) 32 (100%) 31.8 (99.2%) 
1%    32 (100%) 32 (100%) 32 (100%) 32 (100%) 32.0 (100%) 
Scenario 4 
2%    31 (96.9%) 30 (93.8%) 32 (100%) 32 (100%) 31.3 (97.7%) 
1%   6% 32 (100%) 32 (100%) 32 (100%) 29 (90.6%) 31.3 (97.7%) 
1%   10% 32 (100%) 31 (96.9%) 31 (96.9%) 29 (90.6%) 30.8 (96.1%) 
2%   6% 31 (96.9%) 32 (100%) 32 (100%) 29 (90.6%) 31.0 (96.9%) 
Scenario 5 
2%   10% 32 (100%) 32 (100%) 32 (100%) 32 (100%) 32.0 (100%) 
1% 3%   32 (100%) 26 (81.3%) 28 (87.5%) 32 (100%) 29.5 (92.2%) 
1% 5%   32 (100%) 32 (100%) 32 (100%) 31 (96.9%) 31.8 (99.2%) 
2% 3%   31 (96.9%) 28 (87.5%) 32 (100%) 28 (87.5%) 29.8 (93.0%) 
Scenario 6 
2% 5%   31 (96.9%) 32 (100%) 32 (100%) 32 (100%) 31.8 (99.2%) 
1% 3% 4%  32 (100%) 28 (87.5%) 30 (93.8%) 31 (96.9%) 30.3 (94.5%) 
1% 5% 4%  32 (100%) 30 (93.8%) 30 (93.8%) 31 (96.9%) 30.8 (96.1%) 
2% 3% 4%  32 (100%) 32 (100%) 32 (100%) 32 (100%) 32.0 (100%) 
Scenario 7 
2% 5% 4% 
 
32 (100%) 30 (93.8%) 32 (100%) 31 (96.9%) 31.3 (97.7%) 
Average 31.7 (99.1%) 30.7 (95.8%) 31.3 (97.8%) 31.1 (97.0%) 31.2 (97.5%) 
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Table 3.8: Prediction results achieved after the EFDES-based system learned 
under condition of learning setting 1 compared with the consensus of experts A&B 
Scenario 
Accuracy of  System-prediction Choices 
vs. 
Consensus of Experts A & B 
 ∆m ∆x ∆w ∆v 
Predicting 
Regimen 1 
 using 
Regimen 
2, 3 & 4 
Predicting 
Regimen 2 
 using 
Regimen 
1, 3 & 4 
Predicting 
Regimen 3 
using 
Regimen 
1, 2 & 4 
Predicting 
Regimen 4 
 using 
Regimen 
1, 2 & 3 
Mean 
prediction 
   6% 31 (96.9%) 31 (96.9%) 31 (96.9%) 31 (96.9%) 31.0 (96.9%) 
Scenario 1  
   10% 31 (96.9%) 30 (93.8%) 31 (96.9%) 29 (90.6%) 30.3 (94.5%) 
 3%   28 (87.5%) 31 (96.9%) 31 (96.9%) 30 (93.8%) 30.0 (93.8%) 
Scenario 2 
 5%   31 (96.9%) 31 (96.9%) 31 (96.9%) 29 (90.6%) 30.5 (95.3%) 
 3% 4%  31 (96.9%) 30 (93.8%) 31 (96.9%) 28 (87.5%) 30.0 (93.8%) 
Scenario 3 
 5% 4%  31 (96.9%) 29 (90.6%) 30 (93.8%) 28 (87.5%) 29.5 (92.2%) 
1%    30 (93.8%) 30 (93.8%) 31 (96.9%) 29 (90.6%) 30.0 (93.8%) 
Scenario 4 
2%    29 (90.6%) 30 (93.8%) 31 (96.9%) 29 (90.6%) 29.8 (93.0%) 
1%   6% 31 (96.9%) 30 (93.8%) 31 (96.9%) 30 (93.8%) 30.5 (95.3%) 
1%   10% 31 (96.9%) 31 (96.9%) 31 (96.9%) 28 (87.5%) 30.3 (94.5%) 
2%   6% 31 (96.9%) 30 (93.8%) 31 (96.9%) 28 (87.5%) 30.0 (93.8%) 
Scenario 5 
2%   10% 31 (96.9%) 30 (93.8%) 31 (96.9%) 31 (96.9%) 30.8 (96.1%) 
1% 3%   31 (96.9%) 30 (93.8%) 31 (96.9%) 29 (90.6%) 30.3 (94.5%) 
1% 5%   31 (96.9%) 29 (90.6%) 31 (96.9%) 30 (93.8%) 30.3 (94.5%) 
2% 3%   31 (96.9%) 31 (96.9%) 31 (96.9%) 28 (87.5%) 30.3 (94.5%) 
Scenario 6 
2% 5%   30 (93.8%) 29 (90.6%) 29 (90.6%) 28 (87.5%) 29.0 (90.6%) 
1% 3% 4%  30 (93.8%) 29 (90.6%) 31 (96.9%) 29 (90.6%) 29.8 (93.0%) 
1% 5% 4%  31 (96.9%) 29 (90.6%) 29 (90.6%) 28 (87.5%) 29.3 (91.4%) 
2% 3% 4%  30 (93.8%) 29 (90.6%) 30 (93.8%) 29 (90.6%) 29.5 (92.2%) 
Scenario 7 
2% 5% 4% 
 
30 (93.8%) 31 (96.9%) 30 (93.8%) 30 (93.8%) 30.3 (94.5%) 
Average 30.5 (95.3%) 30.0 (93.8%) 30.7 (95.8%) 29.1 (90.8%) 30.1 (93.9%) 
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Table 3.9: Prediction results for Regimen 1 and Regimen 2 achieved after the 
EFDES-based system learned under condition of learning setting 2 compared with 
expert A’s choices 
Accuracy of  System-prediction Choices 
vs.  
Expert A’s Choices Scenario 
Predicting 
 ∆m ∆x ∆w ∆v 
Regimen 
1 
 using 
Regimen 
2 & 3 
Regimen 
1 
 using 
Regimen 
2 & 4 
Regimen 
1 
 using 
Regimen 
3 & 4 
Regimen 
2 
 using 
Regimen 
1 & 3 
Regimen 
2 
 using 
Regimen 
1 & 4 
Regimen 
2 
 using 
Regimen 
3 & 4 
   6% 31(96.9%) 32(100%) 32(100%) 31(96.9%) 32(100%) 32(100%) 
Scenario 1  
   10% 31(96.9%) 32(100%) 32(100%) 32(100%) 32(100%) 32(100%) 
 3%   31(96.9%) 32(100%) 32(100%) 31(96.9%) 32(100%) 32(100%) 
Scenario 2 
 5%   31(96.9%) 32(100%) 32(100%) 31(96.9%) 32(100%) 32(100%) 
 3% 4%  31(96.9%) 32(100%) 32(100%) 31(96.9%) 32(100%) 32(100%) 
Scenario 3 
 5% 4%  31(96.9%) 32(100%) 32(100%) 31(96.9%) 32(100%) 32(100%) 
1%    31(96.9%) 32(100%) 32(100%) 32(100%) 32(100%) 32(100%) 
Scenario 4 
2%    32(100%) 31(96.9%) 32(100%) 31(96.9%) 32(100%) 32(100%) 
1%   6% 31(96.9%) 32(100%) 32(100%) 31(96.9%) 32(100%) 32(100%) 
1%   10% 32(100%) 32(100%) 32(100%) 31(96.9%) 32(100%) 32(100%) 
2%   6% 32(100%) 32(100%) 32(100%) 31(96.9%) 32(100%) 32(100%) 
Scenario 5 
2%   10% 32(100%) 32(100%) 32(100%) 31(96.9%) 32(100%) 32(100%) 
1% 3%   32(100%) 32(100%) 32(100%) 31(96.9%) 32(100%) 32(100%) 
1% 5%   31(96.9%) 32(100%) 32(100%) 31(96.9%) 32(100%) 32(100%) 
2% 3%   31(96.9%) 32(100%) 32(100%) 31(96.9%) 32(100%) 32(100%) 
Scenario 6 
2% 5%   31(96.9%) 32(100%) 32(100%) 31(96.9%) 32(100%) 32(100%) 
1% 3% 4%  32(100%) 32(100%) 32(100%) 31(96.9%) 32(100%) 32(100%) 
1% 5% 4%  31(96.9%) 32(100%) 32(100%) 31(96.9%) 32(100%) 32(100%) 
2% 3% 4%  31(96.9%) 32(100%) 32(100%) 31(96.9%) 32(100%) 32(100%) 
Scenario 7 
2% 5% 4% 
 
31(96.9%) 32(100%) 32(100%) 31(96.9%) 32(100%) 32(100%) 
Average 31.3(97.8%) 31.9(99.8%) 32(100%) 31.1(97.2%) 31.8(99.4%) 32(100%) 
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Table 3.10: Prediction results for Regimen 3 and Regimen 4 achieved after the 
EFDES-based system learned under condition of learning setting 2 compared with 
expert A’s choices 
Accuracy of  System-prediction Choices 
vs. 
Expert A’s Choices Scenario 
Predicting 
 ∆m ∆x ∆w ∆v 
Regimen 
3 
 using 
Regimen 
1 & 2 
Regimen 
3 
 using 
Regimen 
1 & 4 
Regimen 
3 
 using 
Regimen 
2 & 4 
Regimen 
4 
 using 
Regimen 
1 & 2 
Regimen 
4 
 using 
Regimen 
1 & 3 
Regimen 
4 
 using 
Regimen 
2 & 3 
   6% 32(100%) 31(96.9%) 32(100%) 32(100%) 32(100%) 32(100%) 
Scenario 1  
   10% 32(100%) 32(100%) 32(100%) 32(100%) 32(100%) 32(100%) 
 3%   32(100%) 31(96.9%) 32(100%) 32(100%) 32(100%) 32(100%) 
Scenario 2 
 5%   31(96.9%) 32(100%) 32(100%) 32(100%) 32(100%) 32(100%) 
 3% 4%  32(100%) 31(96.9%) 32(100%) 32(100%) 32(100%) 32(100%) 
Scenario 3 
 5% 4%  31(96.9%) 32(100%) 32(100%) 32(100%) 32(100%) 32(100%) 
1%    32(100%) 32(100%) 32(100%) 32(100%) 32(100%) 32(100%) 
Scenario 4 
2%    31(96.9%) 32(100%) 32(100%) 32(100%) 32(100%) 32(100%) 
1%   6% 32(100%) 29(90.6%) 32(100%) 32(100%) 32(100%) 32(100%) 
1%   10% 32(100%) 31(96.9%) 32(100%) 32(100%) 32(100%) 32(100%) 
2%   6% 32(100%) 31(96.9%) 32(100%) 32(100%) 32(100%) 32(100%) 
Scenario 5 
2%   10% 32(100%) 32(100%) 32(100%) 32(100%) 32(100%) 32(100%) 
1% 3%   32(100%) 32(100%) 31(96.9%) 32(100%) 32(100%) 32(100%) 
1% 5%   32(100%) 32(100%) 32(100%) 32(100%) 32(100%) 32(100%) 
2% 3%   31(96.9%) 31(96.9%) 32(100%) 32(100%) 32(100%) 32(100%) 
Scenario 6 
2% 5%   31(96.9%) 31(96.9%) 32(100%) 32(100%) 32(100%) 32(100%) 
1% 3% 4%  31(96.9%) 31(96.9%) 32(100%) 32(100%) 32(100%) 32(100%) 
1% 5% 4%  31(96.9%) 31(96.9%) 32(100%) 32(100%) 32(100%) 30(93.8%) 
2% 3% 4%  32(100%) 32(100%) 30(93.8%) 32(100%) 32(100%) 32(100%) 
Scenario 7 
2% 5% 4% 
 
31(96.9%) 31(96.9%) 32(100%) 32(100%) 32(100%) 32(100%) 
Average 31.6(98.8%) 31.4(98.0%) 31.9(99.5%) 32(100%) 32(100%) 31.9(99.7%) 
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Table 3.11: Prediction results for Regimen 1 and Regimen 2 achieved after the 
EFDES-based system learned under condition of learning setting 2 compared with 
expert B’s choices 
Accuracy of  System-prediction Choices 
vs. 
Expert B’s Choices Scenario 
Predicting 
 ∆m ∆x ∆w ∆v 
Regimen 
1 
 using 
Regimen 
2 & 3 
Regimen 
1 
 using 
Regimen 
2 & 4 
Regimen 
1 
 using 
Regimen 
3 & 4 
Regimen 
2 
 using 
Regimen 
1 & 3 
Regimen 
2 
 using 
Regimen 
1 & 4 
Regimen 
2 
 using 
Regimen 
3 & 4 
   6% 32(100%) 32(100%) 31(96.9%) 32(100%) 31(96.9%) 32(100%) 
Scenario 1  
   10% 32(100%) 32(100%) 32(100%) 32(100%) 32(100%) 32(100%) 
 3%   32(100%) 31(96.9%) 31(96.9%) 32(100%) 32(100%) 32(100%) 
Scenario 2 
 5%   32(100%) 31(96.9%) 31(96.9%) 32(100%) 31(96.9%) 32(100%) 
 3% 4%  32(100%) 32(100%) 31(96.9%) 32(100%) 32(100%) 30(93.8%) 
Scenario 3 
 5% 4%  32(100%) 32(100%) 31(96.9%) 32(100%) 32(100%) 32(100%) 
1%    32(100%) 32(100%) 32(100%) 32(100%) 32(100%) 32(100%) 
Scenario 4 
2%    32(100%) 31(96.9%) 32(100%) 32(100%) 32(100%) 32(100%) 
1%   6% 32(100%) 31(96.9%) 31(96.9%) 32(100%) 32(100%) 32(100%) 
1%   10% 32(100%) 32(100%) 32(100%) 32(100%) 31(96.9%) 32(100%) 
2%   6% 32(100%) 32(100%) 32(100%) 32(100%) 32(100%) 32(100%) 
Scenario 5 
2%   10% 32(100%) 31(96.9%) 32(100%) 32(100%) 32(100%) 32(100%) 
1% 3%   32(100%) 32(100%) 32(100%) 32(100%) 32(100%) 30(93.8%) 
1% 5%   32(100%) 32(100%) 32(100%) 32(100%) 32(100%) 32(100%) 
2% 3%   32(100%) 31(96.9%) 32(100%) 32(100%) 32(100%) 32(100%) 
Scenario 6 
2% 5%   32(100%) 31(96.9%) 32(100%) 32(100%) 32(100%) 28(87.5%) 
1% 3% 4%  32(100%) 32(100%) 32(100%) 32(100%) 32(100%) 32(100%) 
1% 5% 4%  32(100%) 32(100%) 32(100%) 32(100%) 31(96.9%) 28(87.5%) 
2% 3% 4%  32(100%) 32(100%) 31(96.9%) 32(100%) 32(100%) 32(100%) 
Scenario 7 
2% 5% 4% 
 
32(100%) 32(100%) 32(100%) 32(100%) 32(100%) 32(100%) 
Average 32(100%) 31.7(98.9%) 31.7(98.9%) 32(100%) 31.8(99.4%) 31.4(98.1%) 
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Table 3.12: Prediction results for Regimen 3 and Regimen 4 achieved after the 
EFDES-based system learned under condition of learning setting 2 compared with 
expert B’s choices 
Accuracy of  System-prediction Choices 
vs. 
Expert B’s Choices Scenario 
Predicting 
 ∆m ∆x ∆w ∆v 
Regimen 
3 
 using 
Regimen 
1 & 2 
Regimen 
3 
 using 
Regimen 
1 & 4 
Regimen 
3 
 using 
Regimen 
2 & 4 
Regimen 
4 
 using 
Regimen 
1 & 2 
Regimen 
4 
 using 
Regimen 
1 & 3 
Regimen 
4 
 using 
Regimen 
2 & 3 
   6% 32(100%) 31(96.9%) 32(100%) 31(96.9%) 32(100%) 32(100%) 
Scenario 1  
   10% 32(100%) 32(100%) 32(100%) 31(96.9%) 32(100%) 32(100%) 
 3%   32(100%) 32(100%) 32(100%) 32(100%) 32(100%) 32(100%) 
Scenario 2 
 5%   32(100%) 32(100%) 32(100%) 31(96.9%) 32(100%) 32(100%) 
 3% 4%  32(100%) 32(100%) 32(100%) 32(100%) 32(100%) 32(100%) 
Scenario 3 
 5% 4%  32(100%) 32(100%) 32(100%) 31(96.9%) 32(100%) 32(100%) 
1%    32(100%) 32(100%) 32(100%) 31(96.9%) 32(100%) 32(100%) 
Scenario 4 
2%    31(96.9%) 32(100%) 30(93.8%) 32(100%) 32(100%) 32(100%) 
1%   6% 32(100%) 32(100%) 32(100%) 32(100%) 32(100%) 32(100%) 
1%   10% 32(100%) 32(100%) 32(100%) 31(96.9%) 32(100%) 32(100%) 
2%   6% 32(100%) 32(100%) 32(100%) 31(96.9%) 32(100%) 32(100%) 
Scenario 5 
2%   10% 32(100%) 31(96.9%) 32(100%) 32(100%) 32(100%) 32(100%) 
1% 3%   32(100%) 32(100%) 32(100%) 31(96.9%) 32(100%) 32(100%) 
1% 5%   31(96.9%) 32(100%) 32(100%) 32(100%) 32(100%) 32(100%) 
2% 3%   32(100%) 31(96.9%) 32(100%) 32(100%) 32(100%) 32(100%) 
Scenario 6 
2% 5%   32(100%) 32(100%) 28(87.5%) 31(96.9%) 32(100%) 32(100%) 
1% 3% 4%  32(100%) 32(100%) 32(100%) 32(100%) 32(100%) 32(100%) 
1% 5% 4%  32(100%) 32(100%) 32(100%) 30(93.8%) 32(100%) 32(100%) 
2% 3% 4%  32(100%) 32(100%) 32(100%) 32(100%) 32(100%) 32(100%) 
Scenario 7 
2% 5% 4% 
 
32(100%) 32(100%) 32(100%) 32(100%) 32(100%) 32(100%) 
Average 31.9(99.7%) 31.9(99.5%) 31.7(99.1%) 31.5(98.3%) 32(100%) 32(100%) 
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Table 3.13: Prediction results for Regimen 1 and Regimen 2 achieved after the 
EFDES-based system learned under condition of learning setting 2 compared with 
the consensus of experts A & B 
Accuracy of  System-prediction Choices 
vs. 
Consensus of Experts A & B Scenario 
Predicting 
 ∆m ∆x ∆w ∆v 
Regimen 
1 
 using 
Regimen 
2 & 3 
Regimen 
1 
 using 
Regimen 
2 & 4 
Regimen 
1 
 using 
Regimen 
3 & 4 
Regimen 
2 
 using 
Regimen 
1 & 3 
Regimen 
2 
 using 
Regimen 
1 & 4 
Regimen 
2 
 using 
Regimen 
3 & 4 
   6% 29(90.6%) 31(96.9%) 32(100%) 30(93.8%) 30(93.8%) 32(100%) 
Scenario 1  
   10% 29(90.6%) 32(100%) 32(100%) 30(93.8%) 30(93.8%) 31(96.9%) 
 3%   29(90.6%) 32(100%) 32(100%) 29(90.6%) 30(93.8%) 32(100%) 
Scenario 2 
 5%   29(90.6%) 32(100%) 32(100%) 30(93.8%) 30(93.8%) 31(96.9%) 
 3% 4%  29(90.6%) 31(96.9%) 32(100%) 30(93.8%) 30(93.8%) 31(96.9%) 
Scenario 3 
 5% 4%  29(90.6%) 32(100%) 32(100%) 30(93.8%) 30(93.8%) 32(100%) 
1%    28(87.5%) 31(96.9%) 32(100%) 30(93.8%) 30(93.8%) 31(96.9%) 
Scenario 4 
2%    30(93.8%) 31(96.9%) 32(100%) 30(93.8%) 30(93.8%) 32(100%) 
1%   6% 29(90.6%) 31(96.9%) 32(100%) 30(93.8%) 29(90.6%) 31(96.9%) 
1%   10% 29(90.6%) 32(100%) 32(100%) 30(93.8%) 30(93.8%) 32(100%) 
2%   6% 29(90.6%) 32(100%) 32(100%) 30(93.8%) 31(96.9%) 32(100%) 
Scenario 5 
2%   10% 29(90.6%) 31(96.9%) 32(100%) 30(93.8%) 31(96.9%) 31(96.9%) 
1% 3%   30(93.8%) 31(96.9%) 32(100%) 30(93.8%) 30(93.8%) 31(96.9%) 
1% 5%   30(93.8%) 31(96.9%) 32(100%) 30(93.8%) 29(90.6%) 31(96.9%) 
2% 3%   29(90.6%) 32(100%) 32(100%) 30(93.8%) 29(90.6%) 32(100%) 
Scenario 6 
2% 5%   27(84.4%) 31(96.9%) 32(100%) 30(93.8%) 29(90.6%) 32(100%) 
1% 3% 4%  29(90.6%) 31(96.9%) 32(100%) 30(93.8%) 30(93.8%) 32(100%) 
1% 5% 4%  29(90.6%) 32(100%) 32(100%) 30(93.8%) 30(93.8%) 31(96.9%) 
2% 3% 4%  30(93.8%) 31(96.9%) 32(100%) 30(93.8%) 29(90.6%) 32(100%) 
Scenario 7 
2% 5% 4% 
 
30(93.8%) 32(100%) 32(100%) 29(90.6%) 29(90.6%) 31(96.9%) 
Average 29.1(90.9%) 31.5(98.3%) 32(100%) 29.9(93.4%) 29.8(93.1%) 31.5(98.4%) 
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Table 3.14: Prediction results for Regimen 3 and Regimen 4 achieved after the 
EFDES-based system learned under condition of learning setting 2 compared with 
the consensus of experts A & B 
Accuracy of  System-prediction Choices 
vs. 
Consensus of Experts A & B Scenario 
Predicting 
 ∆m ∆x ∆w ∆v 
Regimen 
3 
 using 
Regimen 
1 & 2 
Regimen 
3 
 using 
Regimen 
1 & 4 
Regimen 
3 
 using 
Regimen 
2 & 4 
Regimen 
4 
 using 
Regimen 
1 & 2 
Regimen 
4 
 using 
Regimen 
1 & 3 
Regimen 
4 
 using 
Regimen 
2 & 3 
   6% 28(87.5%) 31(96.9%) 31(96.9%) 31(96.9%) 32(100%) 29(90.6%) 
Scenario 1  
   10% 30(93.8%) 31(96.9%) 32(100%) 31(96.9%) 32(100%) 29(90.6%) 
 3%   30(93.8%) 31(96.9%) 32(100%) 32(100%) 32(100%) 31(96.9%) 
Scenario 2 
 5%   29(90.6%) 31(96.9%) 32(100%) 30(93.8%) 32(100%) 30(93.8%) 
 3% 4%  29(90.6%) 31(96.9%) 32(100%) 32(100%) 32(100%) 29(90.6%) 
Scenario 3 
 5% 4%  30(93.8%) 31(96.9%) 31(96.9%) 30(93.8%) 32(100%) 29(90.6%) 
1%    30(93.8%) 31(96.9%) 32(100%) 29(90.6%) 32(100%) 29(90.6%) 
Scenario 4 
2%    29(90.6%) 31(96.9%) 31(96.9%) 31(96.9%) 32(100%) 31(96.9%) 
1%   6% 29(90.6%) 32(100%) 31(96.9%) 30(93.8%) 32(100%) 32(100%) 
1%   10% 30(93.8%) 31(96.9%) 32(100%) 32(100%) 32(100%) 32(100%) 
2%   6% 30(93.8%) 31(96.9%) 32(100%) 31(96.9%) 32(100%) 31(96.9%) 
Scenario 5 
2%   10% 29(90.6%) 31(96.9%) 32(100%) 30(93.8%) 32(100%) 31(96.9%) 
1% 3%   28(87.5%) 31(96.9%) 31(96.9%) 31(96.9%) 32(100%) 29(90.6%) 
1% 5%   29(90.6%) 31(96.9%) 31(96.9%) 31(96.9%) 32(100%) 28(87.5%) 
2% 3%   30(93.8%) 31(96.9%) 32(100%) 30(93.8%) 32(100%) 31(96.9%) 
Scenario 6 
2% 5%   28(87.5%) 31(96.9%) 32(100%) 30(93.8%) 32(100%) 29(90.6%) 
1% 3% 4%  29(90.6%) 32(100%) 31(96.9%) 31(96.9%) 32(100%) 30(93.8%) 
1% 5% 4%  30(93.8%) 32(100%) 32(100%) 31(96.9%) 32(100%) 29(90.6%) 
2% 3% 4%  30(93.8%) 31(96.9%) 32(100%) 31(96.9%) 32(100%) 28(87.5%) 
Scenario 7 
2% 5% 4% 
 
30(93.8%) 32(100%) 31(96.9%) 30(93.8%) 32(100%) 31(96.9%) 
Average 29.4(91.7%) 31.2(97.5%) 31.6(98.8%) 30.7(95.9%) 31.9(99.8%) 29.9(93.4%) 
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Table 3.15: Prediction results achieved after the EFDES-based system learned 
under condition of learning setting 3 compared with expert A’s choices 
Scenario 
Accuracy of  System-prediction Choices 
vs. 
Expert A’s Choices 
 ∆m ∆x ∆w ∆v 
Predicting 
Regimen 2 
 using 
Regimen 
3 & 4 
Predicting 
Regimen 3 
 using 
Regimen 
2 & 4 
Predicting 
Regimen 4 
using 
Regimen 
2 & 3 
Mean prediction 
   6% 25 (87.1%) 26 (81.3%) 23 (71.9%) 24.7 (77.1%) 
Scenario 1  
   10% 28 (87.5%) 28 (87.5%) 23 (71.9%) 26.3 (82.3%) 
 3%   22 (68.8%) 25 (78.1%) 23 (71.9%) 23.3 (72.9%) 
Scenario 2 
 5%   23 (71.9%) 26 (81.3%) 23 (71.9%) 24.0 (75.0%) 
 3% 4%  25 (78.1%) 24 (75.0%) 23 (71.9%) 24.0 (75.0%) 
Scenario 3 
 5% 4%  21 (65.6%) 24 (75.0%) 23 (71.9%) 22.7 (70.8%) 
1%    25 (78.1%) 25 (78.1%) 23 (71.9%) 24.3 (76.0%) 
Scenario 4 
2%    23 (71.9%) 23 (71.9%) 23 (71.9%) 23.0 (71.9%) 
1%   6% 27 (84.4%) 26 (81.3%) 23 (71.9%) 25.3 (79.2%) 
1%   10% 27 (84.4%) 27 (84.4%) 23 (71.9%) 25.7 (80.2%) 
2%   6% 27 (84.4%) 28 (87.5%) 23 (71.9%) 26.0 (81.3%) 
Scenario 5 
2%   10% 24 (75.0%) 24 (75.0%) 23 (71.9%) 23.7 (74.0%) 
1% 3%   21 (65.6%) 24 (75.0%) 23 (71.9%) 22.7 (70.8%) 
1% 5%   24 (75.0%) 24 (75.0%) 23 (71.9%) 23.7 (74.0%) 
2% 3%   20 (62.5%) 22 (68.8%) 23 (71.9%) 21.7 (67.7%) 
Scenario 6 
2% 5%   23 (71.9%) 23 (71.9%) 23 (71.9%) 23.0 (71.9%) 
1% 3% 4%  21 (65.6%) 23 (71.9%) 23 (71.9%) 22.3 (69.8%) 
1% 5% 4%  25 (78.1%) 29 (90.6%) 23 (71.9%) 25.7 (80.2%) 
2% 3% 4%  23 (71.9%) 24 (75.0%) 23 (71.9%) 23.3 (72.9%) 
Scenario 7 
2% 5% 4% 
 
24 (75.0%) 24 (75.0%) 23 (71.9%) 23.7 (74.0%) 
Average 23.9 (74.7%) 25.0 (78.0%) 23.0 (71.9%) 24.0 (74.8%) 
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Table 3.16: Prediction results achieved after the EFDES-based system learned 
under condition of learning setting 3 compared with expert B’s choices 
Scenario 
Accuracy of  System-prediction Choices 
vs. 
Expert B’s Choices 
 ∆m ∆x ∆w ∆v 
Predicting 
Regimen 2 
 using 
Regimen 
3 & 4 
Predicting 
Regimen 3 
 using 
Regimen 
2 & 4 
Predicting 
Regimen 4 
using 
Regimen 
2 & 3 
Mean prediction 
   6% 23 (71.9%) 25 (78.1%) 26 (81.3%) 24.7 (77.1%) 
Scenario 1  
   10% 26 (81.3%) 26 (81.3%) 22 (68.8%) 24.7 (77.1%) 
 3%   26 (81.3%) 26 (81.3%) 21 (65.6%) 24.3 (76.0%) 
Scenario 2 
 5%   25 (78.1%) 20 (62.5%) 20 (62.5%) 21.7 (67.7%) 
 3% 4%  26 (81.3%) 26 (81.3%) 25 (78.1%) 25.7 (80.2%) 
Scenario 3 
 5% 4%  22 (68.8%) 26 (81.3%) 23 (71.9%) 23.7 (74.0%) 
1%    26 (81.3%) 22 (68.8%) 21 (65.6%) 23.0 (71.9%) 
Scenario 4 
2%    22 (68.8%) 26 (81.3%) 23 (71.9%) 23.7 (74.0%) 
1%   6% 26 (81.3%) 24 (75.0%) 27 (84.4%) 25.7 (80.2%) 
1%   10% 26 (81.3%) 26 (81.3%) 22 (68.8%) 24.7 (77.1%) 
2%   6% 26 (81.3%) 26 (81.3%) 23 (71.9%) 25.0 (78.1%) 
Scenario 5 
2%   10% 26 (81.3%) 26 (81.3%) 29 (90.6%) 27.0 (84.4%) 
1% 3%   26 (81.3%) 26 (81.3%) 22 (68.8%) 24.7 (77.1%) 
1% 5%   22 (68.8%) 26 (81.3%) 23 (71.9%) 23.7 (74.0%) 
2% 3%   23 (71.9%) 26 (81.3%) 19 (59.4%) 22.7 (70.8%) 
Scenario 6 
2% 5%   26 (81.3%) 20 (62.5%) 24 (75.0%) 23.3 (72.9%) 
1% 3% 4%  24 (75.0%) 26 (81.3%) 20 (62.5%) 23.3 (72.9%) 
1% 5% 4%  25 (78.1%) 25 (78.1%) 25 (78.1%) 25.0 (78.1%) 
2% 3% 4%  26 (81.3%) 25 (78.1%) 25 (78.1%) 25.3 (79.2%) 
Scenario 7 
2% 5% 4% 
 
26 (81.3%) 26 (81.3%) 22 (68.8%) 24.7 (77.1%) 
Average 24.9 (77.8%) 25.0 (78.0%) 23.1 (72.2%) 24.3 (76.0%) 
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Table 3.17: Prediction results achieved after the EFDES-based system learned 
under condition of learning setting 3 compared with the consensus of experts A&B 
Scenario 
Accuracy of  System-prediction Choices 
vs. 
Consensus of Experts A & B 
 ∆m ∆x ∆w ∆v 
Predicting 
Regimen 2 
 using 
Regimen 
3 & 4 
Predicting 
Regimen 3 
 using 
Regimen 
2 & 4 
Predicting 
Regimen 4 
using 
Regimen 
2 & 3 
Mean prediction 
   6% 25 (78.1%) 26 (81.3%) 22 (68.8%) 24.3 (76.0%) 
Scenario 1  
   10% 26 (81.3%) 24 (75.0%) 25 (78.1%) 25.0 (78.1%) 
 3%   26 (81.3%) 24 (75.0%) 26 (81.3%) 25.3 (79.2%) 
Scenario 2 
 5%   26 (81.3%) 26 (81.3%) 23 (71.9%) 25.0 (78.1%) 
 3% 4%  26 (81.3%) 26 (81.3%) 23 (71.9%) 25.0 (78.1%) 
Scenario 3 
 5% 4%  23 (71.9%) 21 (65.6%) 22 (68.8%) 22.0 (68.8%) 
1%    26 (81.3%) 26 (81.3%) 24 (75.0%) 25.3 (79.2%) 
Scenario 4 
2%    22 (68.8%) 26 (81.3%) 21 (65.6%) 23.0 (71.9%) 
1%   6% 25 (78.1%) 24 (75.0%) 25 (78.1%) 24.7 (77.1%) 
1%   10% 26 (81.3%) 26 (81.3%) 25 (78.1%) 25.7 (80.2%) 
2%   6% 22 (68.8%) 23 (71.9%) 22 (68.8%) 22.3 (69.8%) 
Scenario 5 
2%   10% 20 (62.5%) 26 (81.3%) 24 (75.0%) 23.3 (72.9%) 
1% 3%   26 (81.3%) 26 (81.3%) 20 (62.5%) 24.0 (75.0%) 
1% 5%   26 (81.3%) 25 (78.1%) 22 (68.8%) 24.3 (76.0%) 
2% 3%   23 (71.9%) 23 (71.9%) 21 (65.6%) 22.3 (69.8%) 
Scenario 6 
2% 5%   26 (81.3%) 21 (65.6%) 22 (68.8%) 23.0 (71.9%) 
1% 3% 4%  26 (81.3%) 21 (65.6%) 20 (62.5%) 22.3 (69.8%) 
1% 5% 4%  25 (78.1%) 26 (81.3%) 22 (68.8%) 24.3 (76.0%) 
2% 3% 4%  26 (81.3%) 25 (78.1%) 20 (62.5%) 23.7 (74.0%) 
Scenario 7 
2% 5% 4% 
 
25 (78.1%) 26 (81.3%) 26 (81.3%) 25.7 (80.2%) 
Average 24.8 (77.5%) 24.6 (76.7%) 22.8 (71.1%) 24.0 (75.1%) 
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Table 3.18: First-choice regimens predicted by the EFDES-based system model 
after regimen 2 was learned using regimens 3 & 4 against the actual regimens 
given to the 35 patients under scenarios 1, 2, 3, 4, and 5   
  Predicted regimens  
after regimen 2 was learned using regimens 3 & 4 
Scenario 1 Scenario 2 Scenario 3 Scenario 4 Scenario 5 
∆v (%) ∆x (%) ∆x, ∆w (%) ∆m (%) ∆m, ∆v (%) 
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B 
6 10 3 5 3,4 5,4 1 2 1,6 1,10 
1 23 4 4 4 4 4 4 4 4 4 4 4 4 4 
2 23 4 4 4 4 4 4 4 4 4 4 4 4 4 
3 10 4 2 2 2 2 2 2 2 2 2 2 2 2 
4 9 4 2 4 4 4 4 4 4 4 4 4 4 4 
5 23 4 4 4 4 4 4 4 4 4 4 4 4 4 
6 23 4 4 4 4 4 4 4 4 4 4 4 4 4 
7 23 4 4 4 4 4 4 4 4 4 4 4 4 4 
8 9 4 2 4 4 4 4 4 4 4 4 4 4 4 
9 10 2 2 2 2 2 2 2 2 2 2 2 2 2 
10 9 4 2 4 4 4 4 4 4 4 4 4 4 4 
11 23 4 4 4 4 4 4 4 4 4 4 4 4 4 
12 23 4 4 4 4 4 4 4 4 4 4 4 4 4 
13 9 4 2 4 4 4 4 4 4 4 4 4 4 4 
14 9 4 2 4 4 4 4 4 4 4 4 4 4 4 
15 10 2 2 2 2 2 2 2 2 2 2 2 2 2 
16 9 4 2 4 4 4 4 4 4 4 4 4 4 4 
17 23 3 4 4 4 4 4 4 4 4 4 4 4 4 
18 23 4 4 4 4 4 4 4 4 4 4 4 4 4 
19 24 4 2 4 4 4 4 4 4 4 4 4 4 4 
20 23 2 4 4 4 4 4 4 4 4 4 4 4 4 
21 23 4 4 4 4 4 4 4 4 4 4 4 4 4 
22 23 4 4 4 4 4 4 4 4 4 4 4 4 4 
23 23 4 4 4 4 4 4 4 4 4 4 4 4 4 
24 23 4 4 4 4 4 4 4 4 4 4 4 4 4 
25 23 4 4 4 4 4 4 4 4 4 4 4 4 4 
26 23 3 4 4 4 4 4 4 4 4 4 4 4 4 
27 23 4 4 4 4 4 4 4 4 4 4 4 4 4 
28 9 4 2 4 4 4 4 4 4 4 4 4 4 4 
29 9 4 2 4 4 4 4 4 4 4 4 4 4 4 
30 23 4 4 4 4 4 4 4 4 4 4 4 4 4 
31 10 2 2 2 2 2 2 2 2 2 2 2 2 2 
32 10 4 2 2 2 2 2 2 2 2 2 2 2 2 
33 23 4 4 4 4 4 4 4 4 4 4 4 4 4 
34 10 3 2 2 2 2 2 2 2 2 2 2 2 2 
35 9 4 2 4 4 4 4 4 4 4 4 4 4 4 
  
109 
Table 3.19: First-choice regimens predicted by the EFDES-based system model 
after regimen 2 was learned using regimens 3 & 4 against the actual regimens 
given to the 35 patients under scenarios 5, 6, and 7   
  Predicted regimens  
after regimen 2 was learned using Regimens 3 & 4 
Scenario 5 Scenario 6 Scenario 7 
∆m, ∆v (%) ∆m, ∆x (%) ∆m, ∆x, ∆w (%) 
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pe
rt 
B 
2,6 2,10 1,3 1,5 2,3 2,5 1,3,4 1,5,4 2,3,4 2,5,4 
1 23 4 4 4 4 4 4 4 4 4 4 4 4 4 
2 23 4 4 4 4 4 4 4 4 4 4 4 4 4 
3 10 4 2 2 2 2 2 2 2 2 2 2 2 2 
4 9 4 2 4 4 4 4 4 4 4 4 4 4 4 
5 23 4 4 4 4 4 4 4 4 4 4 4 4 4 
6 23 4 4 4 4 4 4 4 4 4 4 4 4 4 
7 23 4 4 4 4 4 4 4 4 4 4 4 4 4 
8 9 4 2 4 4 4 4 4 4 4 4 4 4 4 
9 10 2 2 2 2 2 2 2 2 2 2 2 2 2 
10 9 4 2 4 4 4 4 4 4 4 4 4 4 4 
11 23 4 4 4 4 4 4 4 4 4 4 4 4 4 
12 23 4 4 4 4 4 4 4 4 4 4 4 4 4 
13 9 4 2 4 4 4 4 4 4 4 4 4 4 4 
14 9 4 2 4 4 4 4 4 4 4 4 4 4 4 
15 10 2 2 2 2 2 2 2 2 2 2 2 2 2 
16 9 4 2 4 4 4 4 4 4 4 4 4 4 4 
17 23 3 4 4 4 4 4 4 4 4 4 4 4 4 
18 23 4 4 4 4 4 4 4 4 4 4 4 4 4 
19 24 4 2 4 4 4 3 4 4 4 4 4 4 3 
20 23 2 4 4 4 4 4 4 4 4 4 4 4 4 
21 23 4 4 4 4 4 4 4 4 4 4 4 4 4 
22 23 4 4 4 4 4 4 4 4 4 4 4 4 4 
23 23 4 4 4 4 4 4 4 4 4 4 4 4 4 
24 23 4 4 4 4 4 4 4 4 4 4 4 4 4 
25 23 4 4 4 4 4 4 4 4 4 4 4 4 4 
26 23 3 4 4 4 4 4 4 4 4 4 4 4 4 
27 23 4 4 4 4 4 4 4 4 4 4 4 4 4 
28 9 4 2 4 4 4 4 4 4 4 4 4 4 4 
29 9 4 2 4 4 4 4 4 4 4 4 4 4 4 
30 23 4 4 4 4 4 4 4 4 4 4 4 4 4 
31 10 2 2 2 2 2 2 2 2 2 2 2 2 2 
32 10 4 2 2 2 2 2 2 2 2 2 2 2 2 
33 23 4 4 4 4 4 4 4 4 4 4 4 4 4 
34 10 3 2 2 2 2 2 2 2 2 2 2 2 2 
35 9 4 2 4 4 4 4 4 4 4 4 4 4 4 
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Table 3.20: First-choice regimens predicted by the EFDES-based system model 
after regimen 3 was learned using regimens 2 & 4 against the actual regimens 
given to the 35 patients under scenarios 1, 2, 3, 4, and 5   
  Predicted regimens  
after regimen 3 was learned using regimens 2 & 4 
Scenario 1 Scenario 2 Scenario 3 Scenario 4 Scenario 5 
∆v (%) ∆x (%) ∆x, ∆w (%) ∆m (%) ∆m, ∆v (%) 
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B 
6 10 3 5 3,4 5,4 1 2 1,6 1,10 
1 23 4 4 4 4 4 4 4 4 4 4 4 4 4 
2 23 4 4 4 4 4 4 4 4 4 4 4 4 4 
3 10 4 2 2 2 2 2 2 2 2 2 2 2 2 
4 9 4 2 4 4 4 4 4 4 4 4 4 4 4 
5 23 4 4 4 4 4 4 4 4 4 4 4 4 4 
6 23 4 4 4 4 4 4 4 4 4 4 4 4 4 
7 23 4 4 4 4 4 4 4 4 4 4 4 4 4 
8 9 4 2 4 4 4 4 4 4 4 4 4 4 4 
9 10 2 2 2 2 2 2 2 2 2 2 2 2 2 
10 9 4 2 4 4 4 4 4 4 4 4 4 4 4 
11 23 4 4 4 4 4 4 4 4 4 4 4 4 4 
12 23 4 4 4 4 4 4 4 4 4 4 4 4 4 
13 9 4 2 4 4 4 4 4 4 4 4 4 4 4 
14 9 4 2 4 4 4 4 4 4 4 4 4 4 4 
15 10 2 2 2 2 2 2 2 2 2 2 2 2 2 
16 9 4 2 4 4 4 4 4 4 4 4 4 4 4 
17 23 3 4 4 4 4 4 4 4 4 4 4 4 4 
18 23 4 4 4 4 4 4 4 4 4 4 4 4 4 
19 24 4 2 4 3 4 4 4 4 4 4 4 4 4 
20 23 2 4 4 4 4 4 4 4 4 4 4 4 4 
21 23 4 4 4 4 4 4 4 4 4 4 4 4 4 
22 23 4 4 4 4 4 4 4 4 4 4 4 4 4 
23 23 4 4 4 4 4 4 4 4 4 4 4 4 4 
24 23 4 4 4 4 4 4 4 4 4 4 4 4 4 
25 23 4 4 4 4 4 4 4 4 4 4 4 4 4 
26 23 3 4 4 4 4 4 4 4 4 4 4 4 4 
27 23 4 4 4 4 4 4 4 4 4 4 4 4 4 
28 9 4 2 4 4 4 4 4 4 4 4 4 4 4 
29 9 4 2 4 4 4 4 4 4 4 4 4 4 4 
30 23 4 4 4 4 4 4 4 4 4 4 4 4 4 
31 10 2 2 2 2 2 2 2 2 2 2 2 2 2 
32 10 4 2 2 2 2 2 2 2 2 2 2 2 2 
33 23 4 4 4 4 4 4 4 4 4 4 4 4 4 
34 10 3 2 2 2 2 2 2 2 2 2 2 2 2 
35 9 4 2 4 4 4 4 4 4 4 4 4 4 4 
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Table 3.21: First-choice regimens predicted by the EFDES-based system model 
after regimen 3 was learned using regimens 2 & 4 against the actual regimens 
given to the 35 patients under scenarios 5, 6, and 7   
  Predicted regimens  
after regimen 3 was learned using Regimens 2 & 4 
Scenario 5 Scenario 6 Scenario 7 
∆m, ∆v (%) ∆m, ∆x (%) ∆m, ∆x, ∆w (%) 
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B 
2,6 2,10 1,3 1,5 2,3 2,5 1,3,4 1,5,4 2,3,4 2,5,4 
1 23 4 4 4 4 4 4 4 4 4 4 4 4 4 
2 23 4 4 4 4 4 4 4 4 4 4 4 4 4 
3 10 4 2 2 2 2 2 2 2 2 2 2 2 2 
4 9 4 2 4 4 4 4 4 4 4 4 4 4 4 
5 23 4 4 4 4 4 4 4 4 4 4 4 4 4 
6 23 4 4 4 4 4 4 4 4 4 4 4 4 4 
7 23 4 4 4 4 4 4 4 4 4 4 4 4 4 
8 9 4 2 4 4 4 4 4 4 4 4 4 4 4 
9 10 2 2 2 2 2 2 2 2 2 2 2 2 2 
10 9 4 2 4 4 4 4 4 4 4 4 4 4 4 
11 23 4 4 4 4 4 4 4 4 4 4 4 4 4 
12 23 4 4 4 4 4 4 4 4 4 4 4 4 4 
13 9 4 2 4 4 4 4 4 4 4 4 4 4 4 
14 9 4 2 4 4 4 4 4 4 4 4 4 4 4 
15 10 2 2 2 2 2 2 2 2 2 2 2 2 2 
16 9 4 2 4 4 4 4 4 4 4 4 4 4 4 
17 23 3 4 4 4 4 4 4 4 4 4 4 4 4 
18 23 4 4 4 4 4 4 4 4 4 4 4 4 4 
19 24 4 2 4 4 4 3 4 4 4 3 4 4 4 
20 23 2 4 4 4 4 4 4 4 4 4 4 4 4 
21 23 4 4 4 4 4 4 4 4 4 4 4 4 4 
22 23 4 4 4 4 4 4 4 4 4 4 4 4 4 
23 23 4 4 4 4 4 4 4 4 4 4 4 4 4 
24 23 4 4 4 4 4 4 4 4 4 4 4 4 4 
25 23 4 4 4 4 4 4 4 4 4 4 4 4 4 
26 23 3 4 4 4 4 4 4 4 4 4 4 4 4 
27 23 4 4 4 4 4 4 4 4 4 4 4 4 4 
28 9 4 2 4 4 4 4 4 4 4 4 4 4 4 
29 9 4 2 4 4 4 4 4 4 4 4 4 4 4 
30 23 4 4 4 4 4 4 4 4 4 4 4 4 4 
31 10 2 2 2 2 2 2 2 2 2 2 2 2 2 
32 10 4 2 2 2 2 2 2 2 2 2 2 2 2 
33 23 4 4 4 4 4 4 4 4 4 4 4 4 4 
34 10 3 2 2 2 2 2 2 2 2 2 2 2 2 
35 9 4 2 4 4 4 4 4 4 4 4 4 4 4 
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Table 3.22: First-choice regimens predicted by the EFDES-based system model 
after regimen 4 was learned using regimens 2 & 3 against the actual regimens 
given to the 35 patients under scenarios 1, 2, 3, 4, and 5   
  Predicted regimens  
after regimen 4 was learned using regimens 2 & 3 
Scenario 1 Scenario 2 Scenario 3 Scenario 4 Scenario 5 
∆v (%) ∆x (%) ∆x, ∆w (%) ∆m (%) ∆m, ∆v (%) 
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B 
6 10 3 5 3,4 5,4 1 2 1,6 1,10 
1 23 4 4 4 4 4 4 4 4 4 4 4 4 4 
2 23 4 4 4 4 4 4 4 4 4 4 4 4 4 
3 10 4 2 2 2 2 2 2 2 2 2 2 2 2 
4 9 4 2 4 4 4 4 4 4 4 4 4 4 4 
5 23 4 4 4 4 4 4 4 4 4 4 4 4 4 
6 23 4 4 4 4 4 4 4 4 4 4 4 4 4 
7 23 4 4 4 4 4 4 4 4 4 4 4 4 4 
8 9 4 2 4 4 4 4 4 4 4 4 4 4 4 
9 10 2 2 2 2 2 2 2 2 2 2 2 2 2 
10 9 4 2 4 4 4 4 4 4 4 4 4 4 4 
11 23 4 4 4 4 4 4 4 4 4 4 4 4 4 
12 23 4 4 4 4 4 4 4 4 4 4 4 4 4 
13 9 4 2 4 4 4 4 4 4 4 4 4 4 4 
14 9 4 2 4 4 4 4 4 4 4 4 4 4 4 
15 10 2 2 2 2 2 2 2 2 2 2 2 2 2 
16 9 4 2 4 4 4 4 4 4 4 4 4 4 4 
17 23 3 4 4 4 4 4 4 4 4 4 4 4 4 
18 23 4 4 4 4 4 4 4 4 4 4 4 4 4 
19 24 4 2 4 2 2 4 4 2 2 2 4 4 4 
20 23 2 4 4 4 4 4 4 4 4 4 4 4 4 
21 23 4 4 4 4 4 4 4 4 4 4 4 4 4 
22 23 4 4 4 4 4 4 4 4 4 4 4 4 4 
23 23 4 4 4 4 4 4 4 4 4 4 4 4 4 
24 23 4 4 4 4 4 4 4 4 4 4 4 4 4 
25 23 4 4 4 4 4 4 4 4 4 4 4 4 4 
26 23 3 4 4 4 4 4 4 4 4 4 4 4 4 
27 23 4 4 4 4 4 4 4 4 4 4 4 4 4 
28 9 4 2 4 4 4 4 4 4 4 4 4 4 4 
29 9 4 2 4 4 4 4 4 4 4 4 4 4 4 
30 23 4 4 4 4 4 4 4 4 4 4 4 4 4 
31 10 2 2 2 2 2 2 2 2 2 2 2 2 2 
32 10 4 2 2 2 2 2 2 2 2 2 2 2 2 
33 23 4 4 4 4 4 4 4 4 4 4 4 4 4 
34 10 3 2 2 2 2 2 2 2 2 2 2 2 2 
35 9 4 2 4 4 4 4 4 4 4 4 4 4 4 
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Table 3.23: First-choice regimens predicted by the EFDES-based system model 
after regimen 4 was learned using regimens 2 & 3 against the actual regimens 
given to the 35 patients under scenarios 5, 6, and 7   
  Predicted regimens  
after regimen 4 was learned using Regimens 2 & 3 
Scenario 5 Scenario 6 Scenario 7 
∆m, ∆v (%) ∆m, ∆x (%) ∆m, ∆x, ∆w (%) 
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rt 
B 
2,6 2,10 1,3 1,5 2,3 2,5 1,3,4 1,5,4 2,3,4 2,5,4 
1 23 4 4 4 4 4 4 4 4 4 4 4 4 4 
2 23 4 4 4 4 4 4 4 4 4 4 4 4 4 
3 10 4 2 2 2 2 2 2 2 2 2 2 2 2 
4 9 4 2 4 4 4 4 4 4 4 4 4 4 4 
5 23 4 4 4 4 4 4 4 4 4 4 4 4 4 
6 23 4 4 4 4 4 4 4 4 4 4 4 4 4 
7 23 4 4 4 4 4 4 4 4 4 4 4 4 4 
8 9 4 2 4 4 4 4 4 4 4 4 4 4 4 
9 10 2 2 2 2 2 2 2 2 2 2 2 2 2 
10 9 4 2 4 4 4 4 4 4 4 4 4 4 4 
11 23 4 4 4 4 4 4 4 4 4 4 4 4 4 
12 23 4 4 4 4 4 4 4 4 4 4 4 4 4 
13 9 4 2 4 4 4 4 4 4 4 4 4 4 4 
14 9 4 2 4 4 4 4 4 4 4 4 4 4 4 
15 10 2 2 2 2 2 2 2 2 2 2 2 2 2 
16 9 4 2 4 4 4 4 4 4 4 4 4 4 4 
17 23 3 4 4 4 4 4 4 4 4 4 4 4 4 
18 23 4 4 4 4 4 4 4 4 4 4 4 4 4 
19 24 4 2 4 4 4 2 2 4 2 4 2 2 4 
20 23 2 4 4 4 4 4 4 4 4 4 4 4 4 
21 23 4 4 4 4 4 4 4 4 4 4 4 4 4 
22 23 4 4 4 4 4 4 4 4 4 4 4 4 4 
23 23 4 4 4 4 4 4 4 4 4 4 4 4 4 
24 23 4 4 4 4 4 4 4 4 4 4 4 4 4 
25 23 4 4 4 4 4 4 4 4 4 4 4 4 4 
26 23 3 4 4 4 4 4 4 4 4 4 4 4 4 
27 23 4 4 4 4 4 4 4 4 4 4 4 4 4 
28 9 4 2 4 4 4 4 4 4 4 4 4 4 4 
29 9 4 2 4 4 4 4 4 4 4 4 4 4 4 
30 23 4 4 4 4 4 4 4 4 4 4 4 4 4 
31 10 2 2 2 2 2 2 2 2 2 2 2 2 2 
32 10 4 2 2 2 2 2 2 2 2 2 2 2 2 
33 23 4 4 4 4 4 4 4 4 4 4 4 4 4 
34 10 3 2 2 2 2 2 2 2 2 2 2 2 2 
35 9 4 2 4 4 4 4 4 4 4 4 4 4 4 
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Table 3.24: Retrospective evaluation results after the EFDES-based system 
learned under condition of learning setting 4 involving 35 patients treated at AIDS 
Clinic in 2001 
Scenario 
Matching between regimen choices predicted by  EFDES-
based system and regimens prescribed by 
2 experts and 11 non-experts 
 ∆m ∆x ∆w ∆v 
After  
Regimen 2 was 
learned using  
Regimen 
3 & 4 
After  
Regimen 3 was 
learned using  
Regimen 
2 & 4 
After  
Regimen 4 was 
learned using  
Regimen 
2 & 3 
Mean prediction 
   6% 29 (82.9%) 28 (80.0%) 28 (80.0%) 28.3 (81.0%) 
Scenario 1  
   10% 29 (82.9%) 29 (82.9%) 28 (80.0%) 28.7 (81.9%) 
 3%   29 (82.9%) 29 (82.9%) 29 (82.9%) 29.0 (82.9%) 
Scenario 2 
 5%   29 (82.9%) 29 (82.9%) 29 (82.9%) 29.0 (82.9%) 
 3% 4%  29 (82.9%) 29 (82.9%) 28 (80.0%) 28.7 (81.9%) 
Scenario 3 
 5% 4%  29 (82.9%) 29 (82.9%) 28 (80.0%) 28.7 (81.9%) 
1%    29 (82.9%) 29 (82.9%) 28 (80.0%) 28.7 (81.9%) 
Scenario 4 
2%    29 (82.9%) 29 (82.9%) 29 (82.9%) 29.0 (82.9%) 
1%   6% 29 (82.9%) 29 (82.9%) 29 (82.9%) 29.0 (82.9%) 
1%   10% 29 (82.9%) 29 (82.9%) 29 (82.9%) 29.0 (82.9%) 
2%   6% 29 (82.9%) 29 (82.9%) 29 (82.9%) 29.0 (82.9%) 
Scenario 5 
2%   10% 29 (82.9%) 29 (82.9%) 29 (82.9%) 29.0 (82.9%) 
1% 3%   28 (80.0%) 28 (80.0%) 28 (80.0%) 28.0 (80.0%) 
1% 5%   29 (82.9%) 29 (82.9%) 28 (80.0%) 28.7 (81.9%) 
2% 3%   29 (82.9%) 29 (82.9%) 29 (82.9%) 29.0 (82.9%) 
Scenario 6 
2% 5%   29 (82.9%) 29 (82.9%) 28 (80.0%) 28.7 (81.9%) 
1% 3% 4%  29 (82.9%) 28 (80.0%) 29 (82.9%) 28.7 (81.9%) 
1% 5% 4%  29 (82.9%) 29 (82.9%) 28 (80.0%) 28.7 (81.9%) 
2% 3% 4%  29 (82.9%) 29 (82.9%) 28 (80.0%) 28.7 (81.9%) 
Scenario 7 
2% 5% 4% 
 
28 (80.0%) 29 (82.9%) 29 (82.9%) 28.7 (81.9%) 
Average 28.9 (82.6%) 28.85 (82.4%) 28.5 (81.4%) 28.8 (82.1%) 
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Table 3.25: Retrospective evaluation results after the EFDES-based system 
learned under condition of learning setting 4 involving 35 patients against expert 
A’s regimen choices 
Scenario 
Matching between regimen choices predicted by  EFDES-
based system and regimens prescribed by 
expert A 
 ∆m ∆x ∆w ∆v 
After  
Regimen 2 was 
learned using  
Regimen 
3 & 4 
After  
Regimen 3 was 
learned using  
Regimen 
2 & 4 
After  
Regimen 4 was 
learned using  
Regimen 
2 & 3 
Mean prediction 
   6% 4 (100%) 4 (100%) 4 (100%) 4 (100%) 
Scenario 1  
   10% 4 (100%) 4 (100%) 4 (100%) 4 (100%) 
 3%   4 (100%) 4 (100%) 4 (100%) 4 (100%) 
Scenario 2 
 5%   4 (100%) 4 (100%) 4 (100%) 4 (100%) 
 3% 4%  4 (100%) 4 (100%) 4 (100%) 4 (100%) 
Scenario 3 
 5% 4%  4 (100%) 4 (100%) 4 (100%) 4 (100%) 
1%    4 (100%) 4 (100%) 4 (100%) 4 (100%) 
Scenario 4 
2%    4 (100%) 4 (100%) 4 (100%) 4 (100%) 
1%   6% 4 (100%) 4 (100%) 4 (100%) 4 (100%) 
1%   10% 4 (100%) 4 (100%) 4 (100%) 4 (100%) 
2%   6% 4 (100%) 4 (100%) 4 (100%) 4 (100%) 
Scenario 5 
2%   10% 4 (100%) 4 (100%) 4 (100%) 4 (100%) 
1% 3%   4 (100%) 4 (100%) 4 (100%) 4 (100%) 
1% 5%   4 (100%) 4 (100%) 4 (100%) 4 (100%) 
2% 3%   4 (100%) 4 (100%) 4 (100%) 4 (100%) 
Scenario 6 
2% 5%   4 (100%) 4 (100%) 4 (100%) 4 (100%) 
1% 3% 4%  4 (100%) 4 (100%) 4 (100%) 4 (100%) 
1% 5% 4%  4 (100%) 4 (100%) 4 (100%) 4 (100%) 
2% 3% 4%  4 (100%) 4 (100%) 4 (100%) 4 (100%) 
Scenario 7 
2% 5% 4% 
 
4 (100%) 4 (100%) 4 (100%) 4 (100%) 
Average 4 (100%) 4 (100%) 4 (100%) 4 (100%) 
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Table 3.26: Retrospective evaluation results after the EFDES-based system 
learned under condition of learning setting 4 involving 35 patients  against expert 
B’s regimen choices 
Scenario 
Matching between regimen choices predicted by  EFDES-
based system and regimens prescribed by 
expert B 
 ∆m ∆x ∆w ∆v 
After  
Regimen 2 was 
learned using  
Regimen 
3 & 4 
After  
Regimen 3 was 
learned using  
Regimen 
2 & 4 
After  
Regimen 4 was 
learned using  
Regimen 
2 & 3 
Mean prediction 
   6% 8 (100%) 8 (100%) 8 (100%) 8 (100%) 
Scenario 1  
   10% 8 (100%) 8 (100%) 8 (100%) 8 (100%) 
 3%   8 (100%) 8 (100%) 8 (100%) 8 (100%) 
Scenario 2 
 5%   8 (100%) 8 (100%) 8 (100%) 8 (100%) 
 3% 4%  8 (100%) 8 (100%) 8 (100%) 8 (100%) 
Scenario 3 
 5% 4%  8 (100%) 8 (100%) 8 (100%) 8 (100%) 
1%    8 (100%) 8 (100%) 8 (100%) 8 (100%) 
Scenario 4 
2%    8 (100%) 8 (100%) 8 (100%) 8 (100%) 
1%   6% 8 (100%) 8 (100%) 8 (100%) 8 (100%) 
1%   10% 8 (100%) 8 (100%) 8 (100%) 8 (100%) 
2%   6% 8 (100%) 8 (100%) 8 (100%) 8 (100%) 
Scenario 5 
2%   10% 8 (100%) 8 (100%) 8 (100%) 8 (100%) 
1% 3%   8 (100%) 8 (100%) 8 (100%) 8 (100%) 
1% 5%   8 (100%) 8 (100%) 8 (100%) 8 (100%) 
2% 3%   8 (100%) 8 (100%) 8 (100%) 8 (100%) 
Scenario 6 
2% 5%   8 (100%) 8 (100%) 8 (100%) 8 (100%) 
1% 3% 4%  8 (100%) 8 (100%) 8 (100%) 8 (100%) 
1% 5% 4%  8 (100%) 8 (100%) 8 (100%) 8 (100%) 
2% 3% 4%  8 (100%) 8 (100%) 8 (100%) 8 (100%) 
Scenario 7 
2% 5% 4% 
 
8 (100%) 8 (100%) 8 (100%) 8 (100%) 
Average 8 (100%) 8 (100%) 8 (100%) 8 (100%) 
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Table 3.27: Weight vectors optimized by the EFDES-based system model after 
regimen 2 was learned using regimens 3 & 4 regarding to regimen-choice 
prediction against the actual regimens given to the 35 patients under scenarios 1, 
2, 3, 4, and 5   
Optimal weight vectors  
after regimen 2 was learned using regimens 3 & 4 
Scenario 1 Scenario 2 Scenario 3 Scenario 4 Scenario 5 
∆v (%) ∆x (%) ∆x, ∆w (%) ∆m (%) ∆m, ∆v (%) [W1  … W26]T 
6 10 3 5 3,4 5,4 1 2 1,6 1,10 
W1 0.9961 0.9648 0.8984 0.9258 0.5547 0.9063 0.9844 0.9609 0.9063 0.9844 
W2 0.0039 0.0352 0.1016 0.0742 0.4453 0.0938 0.0156 0.0391 0.0938 0.0156 
W3 0.6061 0.5664 0.5938 0.7148 0.3828 0.7148 0.6719 0.2344 0.4258 0.7852 
W4 0.3984 0.4336 0.4063 0.2852 0.6172 0.2852 0.3281 0.7656 0.5742 0.2124 
W5 0.5595 0.2550 0.3576 0.3948 0.1365 0.4167 0.3856 0.1476 0.2471 0.6165 
W6 0.0000 0.2114 0.0766 0.0798 0.0310 0.1173 0.1753 0.1518 0.1174 0.1091 
W7 0.2259 0.0615 0.1429 0.0361 0.0283 0.1335 0.0000 0.0320 0.0000 0.2166 
W8 0.1389 0.2928 0.4778 0.3333 0.2415 0.2014 0.4280 0.1978 0.4431 0.2756 
W9 0.2485 0.3307 0.3527 0.3568 0.4028 0.3464 0.3506 0.7855 0.5563 0.5477 
W10 0.3283 0.2062 0.4125 0.7590 0.7767 0.3552 0.5309 0.4306 0.4838 0.4679 
W11 0.3016 0.4522 0.1646 0.2718 0.6220 0.3819 0.1864 0.6546 0.3098 0.1080 
W12 0.7515 0.4579 0.5708 0.5634 0.5662 0.5363 0.4740 0.0627 0.3263 0.3432 
W13 0.4458 0.7323 0.4447 0.2048 0.1950 0.5113 0.4691 0.5374 0.5162 0.3155 
W14 0.4962 0.2220 0.3063 0.0942 0.4655 0.2884 0.3538 0.2977 0.2920 0.2253 
W15 0.2519 0.3067 0.2584 0.0376 0.1418 0.3352 0.0769 0.3531 0.4734 0.2319 
W16 0.2458 0.1186 0.1062 0.0072 0.1889 0.0000 0.1179 0.0443 0.2704 0.0980 
W17 0.3295 0.4379 0.5023 0.4448 0.3103 0.4775 0.2028 0.3550 0.5487 0.4660 
W18 0.1325 0.2073 0.5084 0.3145 0.3014 0.2700 0.2154 0.0323 0.0000 0.3831 
W19 0.0085 0.4787 0.2080 0.2862 0.1940 0.2072 0.1282 0.3986 0.2704 0.3358 
W20 0.1742 0.3401 0.1914 0.4610 0.2241 0.2340 0.4434 0.3473 0.1593 0.3086 
W21 0.6156 0.4860 0.2331 0.6478 0.5567 0.3948 0.7077 0.6146 0.5266 0.3851 
W22 0.7458 0.4027 0.6858 0.7065 0.6171 0.7928 0.7538 0.5571 0.4591 0.5662 
W23 0.9766 0.9141 0.9023 0.8750 0.9063 0.8867 0.9219 0.9102 0.9180 0.9023 
W24 0.0234 0.0859 0.0977 0.1250 0.0938 0.1133 0.0781 0.0898 0.0820 0.0977 
W25 0.4531 0.5977 0.5234 0.5156 0.5273 0.5078 0.4805 0.4297 0.5977 0.5898 
W26 0.5469 0.4023 0.4766 0.4844 0.4727 0.4922 0.5195 0.5703 0.4023 0.4102 
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Table 3.28: Weight vectors optimized by the EFDES-based system model after 
regimen 2 was learned using regimens 3 & 4 regarding to regimen-choice 
prediction against the actual regimens given to the 35 patients under scenarios 5, 
6, and 7   
Optimal weight vectors  
after regimen 2 was learned using regimens 3 & 4 
Scenario 5 Scenario 6 Scenario 7 
∆m, ∆v (%) ∆m, ∆x (%) ∆m, ∆x, ∆w (%) [W1  … W26]T 
2,6 2,10 1,3 1,5 2,3 2,5 1,3,4 1,5,4 2,3,4 2,5,4 
W1 0.7031 0.6953 0.9414 0.8242 0.9883 0.9570 0.9180 0.8477 0.9844 0.9922 
W2 0.2969 0.3047 0.0586 0.1758 0.0117 0.0430 0.0820 0.1523 0.0156 0.0078 
W3 0.1211 0.5742 0.8906 0.3906 0.8594 0.6875 0.6133 0.4023 0.7031 0.4219 
W4 0.8789 0.4258 0.1094 0.6094 0.1406 0.3125 0.3867 0.5977 0.2969 0.5781 
W5 0.4316 0.5556 0.7041 0.4044 0.4279 0.3481 0.4254 0.3977 0.3657 0.0227 
W6 0.0246 0.1147 0.0000 0.0162 0.0178 0.0706 0.0426 0.0000 0.0063 0.0000 
W7 0.0373 0.0000 0.1028 0.3941 0.0246 0.0860 0.0649 0.1904 0.0205 0.1199 
W8 0.2188 0.0480 0.2633 0.1444 0.0349 0.3038 0.0263 0.2917 0.0926 0.8333 
W9 0.5055 0.2907 0.6184 0.6757 0.8994 0.0118 0.4134 0.2185 0.5104 0.7360 
W10 0.4959 0.4533 0.0356 0.3501 0.4676 0.4507 0.3052 0.4729 0.6404 0.1901 
W11 0.3495 0.3964 0.0325 0.4511 0.5372 0.3481 0.5482 0.3106 0.5417 0.1439 
W12 0.4699 0.5947 0.3816 0.3081 0.0828 0.9176 0.5441 0.7815 0.4833 0.2640 
W13 0.4668 0.5467 0.8617 0.2558 0.5078 0.4633 0.6299 0.3367 0.3390 0.6901 
W14 0.4387 0.0158 0.1241 0.4140 0.3825 0.5850 0.4918 0.5943 0.3907 0.5356 
W15 0.0741 0.1231 0.4124 0.0149 0.1866 0.0333 0.0887 0.0335 0.0472 0.3312 
W16 0.2679 0.1388 0.2339 0.0032 0.2137 0.1229 0.0255 0.0217 0.0758 0.2792 
W17 0.3467 0.6474 0.8459 0.1646 0.3257 0.0751 0.2951 0.2547 0.1589 0.0627 
W18 0.5714 0.1415 0.2372 0.3358 0.2935 0.5917 0.0000 0.5223 0.1635 0.4183 
W19 0.1518 0.0239 0.3387 0.1812 0.1945 0.3455 0.0727 0.2446 0.0000 0.1484 
W20 0.2146 0.3368 0.0301 0.4214 0.2919 0.3399 0.2131 0.1509 0.4505 0.4017 
W21 0.3545 0.7354 0.3504 0.6493 0.5199 0.3750 0.9113 0.4442 0.7893 0.2505 
W22 0.5804 0.8373 0.4274 0.8155 0.5918 0.5316 0.9018 0.7337 0.9242 0.5724 
W23 0.9023 0.9844 0.9570 0.8594 0.9492 0.9648 0.9609 0.9922 0.9063 0.9531 
W24 0.0977 0.0156 0.0430 0.1406 0.0508 0.0352 0.0391 0.0078 0.0938 0.0469 
W25 0.4141 0.3789 0.1250 0.3789 0.6523 0.6484 0.4063 0.4648 0.5078 0.3164 
W26 0.5859 0.6211 0.8750 0.6211 0.3477 0.3516 0.5938 0.5352 0.4922 0.6836 
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Table 3.29: Weight vectors optimized by the EFDES-based system model after 
regimen 3 was learned using regimens 3 & 4 regarding to regimen-choice 
prediction against the actual regimens given to the 35 patients under scenarios 1, 
2, 3, 4, and 5   
Optimal weight vectors  
after regimen 3 was learned using regimens 3 & 4 
Scenario 1 Scenario 2 Scenario 3 Scenario 4 Scenario 5 
∆v (%) ∆x (%) ∆x, ∆w (%) ∆m (%) ∆m, ∆v (%) [W1  … W26]T 
6 10 3 5 3,4 5,4 1 2 1,6 1,10 
W1 0.8516 0.9883 0.8125 0.9961 0.8242 0.9414 0.9531 0.9453 0.9766 0.7422 
W2 0.1484 0.0117 0.1875 0.0039 0.1758 0.0586 0.0469 0.0547 0.0234 0.2578 
W3 0.0117 0.0742 0.5430 0.4180 0.4531 0.3945 0.5664 0.2070 0.2695 0.3633 
W4 0.9883 0.9258 0.4570 0.5820 0.5469 0.6055 0.4336 0.7930 0.7305 0.6367 
W5 0.6284 0.4048 0.4257 0.4668 0.4542 0.4882 0.3830 0.3674 0.3991 0.4671 
W6 0.0764 0.0026 0.0633 0.0000 0.0361 0.0808 0.1182 0.0056 0.0339 0.0160 
W7 0.0118 0.0036 0.1444 0.0857 0.1655 0.1514 0.0320 0.1807 0.2733 0.1963 
W8 0.2020 0.0661 0.4119 0.4487 0.3250 0.1706 0.1491 0.5116 0.2363 0.4362 
W9 0.6545 0.3641 0.6051 0.3307 0.0201 0.4377 0.7389 0.6704 0.2000 0.3590 
W10 0.2835 0.1511 0.5802 0.4514 0.5374 0.2771 0.4160 0.7695 0.4990 0.3458 
W11 0.1696 0.5291 0.1624 0.0845 0.2208 0.3412 0.4679 0.1209 0.3646 0.0967 
W12 0.2691 0.6332 0.3316 0.6693 0.9438 0.4815 0.1429 0.3239 0.7661 0.6250 
W13 0.7047 0.8453 0.2754 0.4629 0.2971 0.5714 0.5520 0.0498 0.2277 0.4579 
W14 0.4092 0.3661 0.4836 0.2043 0.3991 0.4658 0.3410 0.3761 0.4289 0.4008 
W15 0.3584 0.0915 0.0102 0.1754 0.1368 0.1083 0.0975 0.2500 0.0701 0.0436 
W16 0.2158 0.0437 0.0052 0.0867 0.0060 0.1343 0.0947 0.2901 0.0000 0.2964 
W17 0.3175 0.3178 0.0922 0.5489 0.0540 0.1065 0.4276 0.2495 0.4444 0.3175 
W18 0.0050 0.2465 0.2653 0.3578 0.0211 0.4509 0.4665 0.4239 0.4227 0.5047 
W19 0.1612 0.2216 0.1510 0.2704 0.0299 0.0813 0.4474 0.1533 0.3473 0.0240 
W20 0.2733 0.3161 0.4242 0.2468 0.5469 0.4278 0.2314 0.3743 0.1267 0.2817 
W21 0.6366 0.6620 0.7245 0.4668 0.8421 0.4408 0.4359 0.3261 0.5072 0.4517 
W22 0.6230 0.7347 0.8438 0.6429 0.9641 0.7845 0.4579 0.5566 0.6527 0.6796 
W23 0.8984 0.9453 0.8555 0.9297 0.7695 0.8672 0.9609 0.9492 0.9688 0.8711 
W24 0.1016 0.0547 0.1445 0.0703 0.2305 0.1328 0.0391 0.0508 0.0313 0.1289 
W25 0.1719 0.2383 0.4297 0.4766 0.3359 0.4375 0.5469 0.5000 0.3555 0.4336 
W26 0.8281 0.7617 0.5703 0.5234 0.6641 0.5625 0.4531 0.5000 0.6445 0.5664 
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Table 3.30: Weight vectors optimized by the EFDES-based system model after 
regimen 3 was learned using regimens 3 & 4 regarding to regimen-choice 
prediction against the actual regimens given to the 35 patients under scenarios 5, 
6, and 7   
Optimal weight vectors  
after regimen 3 was learned using regimens 3 & 4 
Scenario 5 Scenario 6 Scenario 7 
∆m, ∆v (%) ∆m, ∆x (%) ∆m, ∆x, ∆w (%) [W1  … W26]T 
2,6 2,10 1,3 1,5 2,3 2,5 1,3,4 1,5,4 2,3,4 2,5,4 
W1 0.8750 0.7266 0.9648 0.9375 0.8828 0.8711 0.8750 0.8750 0.9375 0.9805 
W2 0.1250 0.2734 0.0352 0.0625 0.1172 0.1289 0.1250 0.1250 0.0625 0.0195 
W3 0.1719 0.2266 0.4570 0.6055 0.7813 0.4727 0.6289 0.5625 0.6016 0.5156 
W4 0.8281 0.7734 0.5430 0.3945 0.2188 0.5273 0.3711 0.4375 0.3984 0.4844 
W5 0.5457 0.4128 0.3730 0.4104 0.2670 0.3711 0.4530 0.4497 0.3198 0.4990 
W6 0.0126 0.0659 0.0453 0.1703 0.0664 0.0204 0.0041 0.1039 0.0080 0.0233 
W7 0.2527 0.1480 0.0282 0.2188 0.1159 0.0409 0.2143 0.1884 0.0676 0.1474 
W8 0.3370 0.0000 0.5000 0.3918 0.5668 0.3377 0.4384 0.3073 0.4291 0.1598 
W9 0.7573 0.4516 0.4887 0.1731 0.7345 0.3852 0.1317 0.0390 0.4987 0.4067 
W10 0.6374 0.3935 0.1975 0.0997 0.3123 0.3534 0.5652 0.1594 0.1351 0.1579 
W11 0.1174 0.5872 0.1270 0.1978 0.1662 0.2913 0.1086 0.2430 0.2510 0.3412 
W12 0.2301 0.4826 0.4660 0.6566 0.1991 0.5944 0.8642 0.8571 0.4933 0.5699 
W13 0.1099 0.4585 0.7743 0.6814 0.5718 0.6058 0.2205 .06522 0.7973 0.6947 
W14 0.3353 0.3646 0.4517 0.2121 0.3997 0.5395 0.3822 0.0868 0.4016 0.5195 
W15 0.0279 0.0996 0.0215 0.1189 0.1881 0.1447 0.0174 0.0404 0.1041 0.1689 
W16 0.0078 0.0000 0.0979 0.1406 0.0718 0.0000 0.0699 0.0090 0.0123 0.1667 
W17 0.4651 0.4827 0.2437 0.5939 0.2147 0.2719 0.3030 0.6497 0.3951 0.1273 
W18 0.0906 0.5125 0.5161 0.3351 0.0321 0.0675 0.0348 0.1324 0.0372 0.3406 
W19 0.0196 0.3649 0.2723 0.1484 0.2241 0.0000 0.0294 0.0135 0.1399 0.0349 
W20 0.1996 0.1527 0.3046 0.1939 0.3856 0.1886 0.3149 0.2635 0.2033 0.3532 
W21 0.8815 0.3879 0.4624 0.5459 0.7798 0.7878 0.9478 0.8272 0.8587 0.4905 
W22 0.9725 0.6351 0.6298 0.7109 0.7040 1.0000 0.9007 0.9776 0.8477 0.7984 
W23 0.9688 0.8984 0.9375 0.8633 0.8672 0.9727 0.8633 0.8047 0.9531 0.9531 
W24 0.0313 0.1016 0.0625 0.1367 0.1328 0.0273 0.1367 0.1953 0.0469 0.0469 
W25 0.1758 0.3945 0.4883 0.5273 0.6016 0.4336 0.3906 0.3906 0.4844 0.4961 
W26 0.8242 0.6055 0.5117 0.4727 0.3984 0.5664 0.6094 0.6094 0.5156 0.5039 
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Table 3.31: Weight vectors optimized by the EFDES-based system model after 
regimen 4 was learned using regimens 3 & 4 regarding to regimen-choice 
prediction against the actual regimens given to the 35 patients under scenarios 1, 
2, 3, 4, and 5   
Optimal weight vectors  
after regimen 4 was learned using regimens 3 & 4 
Scenario 1 Scenario 2 Scenario 3 Scenario 4 Scenario 5 
∆v (%) ∆x (%) ∆x, ∆w (%) ∆m (%) ∆m, ∆v (%) [W1  … W26]T 
6 10 3 5 3,4 5,4 1 2 1,6 1,10 
W1 0.8125 0.8242 0.8281 0.9883 0.9805 0.9766 0.8633 0.9180 0.7188 0.9336 
W2 0.1875 0.1758 0.1719 0.0117 0.0195 0.0234 0.1367 0.0820 0.2812 0.0664 
W3 0.7266 0.6758 0.6055 0.7656 0.8359 0.9453 0.7773 0.4102 0.3047 0.6641 
W4 0.2734 0.3242 0.3945 0.2344 0.1641 0.0547 0.2227 0.5898 0.6953 0.3359 
W5 0.1103 0.0435 0.2248 0.2010 0.1006 0.0963 0.0725 0.3196 0.1304 0.3399 
W6 0.2015 0.0946 0.1986 0.0475 0.1374 0.0495 0.2115 0.1010 0.0222 0.0891 
W7 0.1522 0.0559 0.0763 0.0401 0.1072 0.1141 0.0279 0.0000 0.0314 0.0000 
W8 0.4766 0.1706 0.0906 0.1127 0.4043 0.5652 0.4352 0.5434 0.3681 0.4644 
W9 0.7839 0.7027 0.4513 0.4727 0.7863 0.4346 0.7038 0.7981 0.5817 0.7442 
W10 0.6505 0.5155 0.4322 0.4114 0.4239 0.3747 0.2351 0.8659 0.2780 0.1307 
W11 0.4131 0.7860 0.6846 0.6863 0.4951 0.3385 0.4923 0.1370 0.5014 0.1957 
W12 0.0147 0.2027 0.3502 0.4798 0.0763 0.5159 0.0846 0.1010 0.3961 0.1667 
W13 0.1972 0.4286 0.4915 0.5485 0.4688 0.5112 0.7371 0.1341 0.6906 0.8693 
W14 0.1117 0.1852 0.0729 0.3145 0.3441 0.6675 0.4222 0.0417 0.4425 0.1532 
W15 0.4390 0.0306 0.0000 0.1701 0.0952 0.4986 0.0765 0.0969 0.2831 0.3710 
W16 0.2149 0.3484 0.1284 0.2900 0.1107 0.2730 0.4563 0.0028 0.2874 0.2072 
W17 0.7011 0.7444 0.3576 0.3585 0.2847 0.0157 0.2997 0.4091 0.1692 0.5065 
W18 0.0528 0.4311 0.4144 0.5773 0.2143 0.0220 0.4074 0.2602 0.3108 0.1734 
W19 0.2829 0.2628 0.1318 0.1382 0.4777 0.1009 0.1944 0.3583 0.0323 0.3750 
W20 0.1872 0.0704 0.5694 0.3270 0.3713 0.3168 0.2781 0.5492 0.3883 0.3403 
W21 0.5081 0.5383 0.5856 0.2526 0.6905 0.4793 0.5160 0.6429 0.4062 0.4556 
W22 0.5022 0.3888 0.7399 0.5718 0.4117 0.6261 0.3492 0.6389 0.6804 0.4178 
W23 0.8555 0.9258 0.7031 0.9258 0.8945 0.9922 0.9023 0.8750 0.8281 0.8984 
W24 0.1445 0.0742 0.2969 0.0742 0.1055 0.0078 0.0977 0.1250 0.1719 0.1016 
W25 0.0547 0.5977 0.4766 0.7539 0.2773 0.1328 0.2813 0.4492 0.4570 0.6523 
W26 0.9453 0.4023 0.5234 0.2461 0.7227 0.8672 0.7188 0.5508 0.5430 0.3477 
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Table 3.32: Weight vectors optimized by the EFDES-based system model after 
regimen 4 was learned using regimens 3 & 4 regarding to regimen-choice 
prediction against the actual regimens given to the 35 patients under scenarios 5, 
6, and 7   
Optimal weight vectors  
after regimen 4 was learned using regimens 3 & 4 
Scenario 5 Scenario 6 Scenario 7 
∆m, ∆v (%) ∆m, ∆x (%) ∆m, ∆x, ∆w (%) [W1  … W26]T 
2,6 2,10 1,3 1,5 2,3 2,5 1,3,4 1,5,4 2,3,4 2,5,4 
W1 0.6328 0.9844 0.8125 0.8906 0.9844 0.9141 0.8945 0.8125 0.9688 0.9844 
W2 0.3672 0.0156 0.1875 0.1094 0.0156 0.0859 0.1055 0.1875 0.0312 0.0156 
W3 0.3906 0.5234 0.7344 0.8711 0.8008 0.8906 0.8555 0.7578 0.8711 0.7539 
W4 0.6094 0.4766 0.2656 0.1289 0.1992 0.1094 0.1445 0.2422 0.1289 0.2461 
W5 0.1525 0.4122 0.0136 0.1303 0.2735 0.0305 0.1353 0.0841 0.1696 0.2374 
W6 0.0823 0.1280 0.0132 0.1586 0.1527 0.0173 0.0352 0.0389 0.1449 0.0913 
W7 0.0102 0.0604 0.0282 0.0316 0.0600 0.1000 0.0870 0.0997 0.1461 0.0202 
W8 0.4159 0.2020 0.2678 0.2515 0.2531 0.3807 0.4244 0.4425 0.3743 0.0091 
W9 0.3591 0.2720 0.8987 0.3793 0.4466 0.5446 0.5352 0.8198 0.6996 0.3053 
W10 0.5563 0.5165 0.3548 0.5854 0.2067 0.0688 0.5761 0.3196 0.5205 0.1869 
W11 0.4315 0.3857 0.7186 0.6182 0.4735 0.5888 0.4403 0.4735 0.4561 0.7534 
W12 0.5586 0.6000 0.0881 0.4621 0.4008 0.4381 0.4297 0.1413 0.1555 0.6034 
W13 0.4334 0.4231 0.6169 0.3829 0.7333 0.8313 0.3370 0.5806 0.3333 0.7929 
W14 0.3877 0.2899 0.4574 0.1287 0.1319 0.5753 0.3351 0.0874 0.0853 0.3803 
W15 0.0815 0.2000 0.0435 0.3725 0.2417 0.4884 0.1198 0.0986 0.1671 0.3565 
W16 0.2686 0.1837 0.2763 0.0344 0.1010 0.0240 0.1596 0.0956 0.2042 0.1923 
W17 0.3111 0.3445 0.1064 0.3458 0.5852 0.2226 0.2193 0.5336 0.4167 0.2356 
W18 0.5778 0.2833 0.0725 0.0196 0.2384 0.2300 0.4392 0.0563 0.1813 0.0783 
W19 0.3039 0.2493 0.2538 0.5413 0.2500 0.7560 0.3245 0.4886 0.2222 0.3487 
W20 0.3012 0.3655 0.4362 0.5255 0.2830 0.2021 0.4456 0.3789 0.4980 0.3840 
W21 0.3407 0.5167 0.8841 0.6078 0.5199 0.2817 0.4410 0.8451 0.6516 0.5652 
W22 0.4275 0.5669 0.4699 0.4243 0.6490 0.2200 0.5160 0.4158 0.5736 0.4590 
W23 0.7813 0.8945 0.8750 0.8438 0.8359 0.9922 0.8398 0.7852 0.7813 0.8906 
W24 0.2188 0.1055 0.1250 0.1563 0.1641 0.0078 0.1602 0.2148 0.2188 0.1094 
W25 0.6055 0.5078 0.3398 0.2109 0.6250 0.0781 0.7383 0.5078 0.2852 0.7227 
W26 0.3945 0.4922 0.6602 0.7891 0.3750 0.9219 0.2617 0.4922 0.7148 0.2773 
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3.4  Discussion  
Two different sets of weight rankings made by two AIDS physician experts 
individually involved in the prediction results were used in learning by the systems 
to optimize their regimen choices to match expert A and B individually. 
Additionally, the prediction result involved used a consensus set of weight 
rankings that systems learned and predicted best match the consensus of the two 
experts. Each prediction result in Tables 3.6-3.18 was the highest match of three 
prediction results obtained using three different random initials. The prediction 
accuracy is defined as the ratio of the number of choices on which the system 
made right predictions as compared to the expert’s choices and the total number 
of the prediction choices.  
There were seven scenarios under the self-learning EFDES experiments. 
The descriptions on the tables made the prediction results with understandable 
contents. The overall prediction results were high levels of satisfaction that the 
models could provide under the variety of the seven scenarios with the different 
learning settings.  The prediction results using data-learning setting 1 provided the 
mean accuracy from 84.1% to 98.4% with the overall mean being 92.4% and from 
95.8% to 99.1%, with the overall mean being 95.8% as compared to expert A’s 
choices and expert B’s choices, respectively. The prediction accuracy depended 
on which regimens were used in learning. The system  learning by using regimen 
1, regimen 2, and regimen 4 would provide the best prediction result as compared 
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to the expert A’s choices, but using regimen 2, regimen 3, and regimen 4 would 
provide the best one as compared to expert B’s choices.   
The prediction results as compared to the consensus choices of the two 
experts under the condition of data-learning setting 1 came with the accuracy from 
90.8% to 95.8% with the overall mean being 93.9%, while their exact agreement 
rate was 43.8%. As compared to the consensus choices of the two experts under 
the conditions of data learning-setting 3, only ten of the 32 treatment objectives 
were contributed to the system learning that would lead to the lower mean 
prediction accuracy of 75.1% in Table 3.17, as compared to those mean 
prediction accuracy of 93.9% and 96.0% under the condition of data-learning 
setting 1 and data-learning setting 2, respectively. The prediction results using 
data-learning setting 3 provided the mean accuracy from 71.9% to 78.0%, with the 
overall mean being 74.8% and from 72.2% to 78.0%, with the overall mean being 
76.0% as compared to expert A’s choices and expert B’s choices, respectively. 
The fewer numbers of treatment objectives used in the system learning that 
contained information of the expert’s preferred choices would cause the lower 
mean prediction accuracy results either for the consensus of experts or an 
individual. 
The retrospective evaluation results of the 35 historical patient cases shown 
in Table 3.18-3.23 were obtained by providing the system with data-learning 
setting 4 including regimen 2, regimen 3, and regimen 4. The system optimized 
weight vectors from learning each regimen using other two regimens to predict the 
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regimen-choices for the 35 retrospective patients. The average agreement rates 
for seven scenarios were from 81.4% to 82.6%, with the overall average 
agreement rate of 82.1% for the 35 patients treated by 13 AIDS physicians. The 
overall mean agreement rate was 100% for expert A and expert B individually, 
while the agreement rate for the remaining 11 AIDS physicians was 72.8%. The 
exact agreement the system could provide was a high level of satisfaction above 
80%.  
 Seven patients with mismatching regimens assigned by the system were 
treated by non-system AIDS physicians. Three patients were classified with “high” 
potency that the system assigned regimen 2. It should be the appropriate regimen 
choice because regimen 2 could provide the most expected potency agreed with 
two AIDS experts’ regimen choice. Similarly, the system assigned regimen 4 as 
the same regimen two AIDS experts selected for other three patients classified 
with “medium” potency and “high” future drug options. Regimen 4 provided the 
lowest expected potency and the most expected future drug options that would be 
considered as a better regimen choice the system selected. Only one patient was 
the system assigned the right regimen choice rated from 50% to 90% under the 
seven scenarios.  
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CHAPTER 4 
SUMMARY AND FUTURE DIRECTIONS 
 
4.1  Summary and Conclusion 
The HIV/AIDS-EFDES system was based on applying the extended fuzzy 
discrete event system theory for optimal decision-making in HIV/AIDS treatment 
regimen selection. The system extended the FDES framework for HIV/AIDS 
treatment regimen selection, especially in the case of the initial round of 
combination antiretroviral therapy for HIV/AIDS. In the new EFDES framework, the 
type-2 fuzzy set was employed in representing the expert domain of knowledge 
and experiences with imprecision and uncertainties. All system parameters with 
intuitive meaning used in the FDES framework were contributed in the EFDES 
framework as well. The EFDES-based system would keep simple and 
understandable steps of the procedures from the beginning through to the final 
step of the decision-making. The change from one state to another in the sense of 
the forward-looking tree provides the treatment with a dynamic optimization 
process. The representations of experts’ knowledge and regimen information in 
the terms of type-2 fuzzy sets would be more flexible as consensus of diverse 
opinions with equal respect. Adding or updating clinical parameters could be done 
with ease.  
HIV/AIDS treatment is a complicated strategy involving not only the 
patient’s clinical participation but drug resistances. Frequent updating of treatment 
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guidelines many times in the past few years reflected the fast evolution of 
scientific knowledge on HIV/AIDS as a complex and severe disease. Research on 
developing HIV/AIDS drugs is on the fast track. Optimizing new weight vectors for 
a new HIV/AIDS regimen can be readily achieved when clinical parameter 
information on the potency, adherence, adverse events, and future drug options 
are provided by the HIV/AIDS experts. The system needs little time to be updated 
as new regimens become accessible. 
The HIV/AIDS-EFDES system provided impassive decision-making on 
selecting proper regimens for the retrospective patients in the initial round of the 
HIV/AIDS treatment. Twenty eight of 35 patients with the correctly selected 
regimens were in overall exact agreement under seven scenarios. Two HIV/AIDS 
physician experts were involved in the system development with three regimens in 
treatment.  
Self-learning is another significant feature of the HIV/AIDS-EFDES system. 
The self-learning system is able to predict outcomes for a new regimen with little 
required information on clinical trials. For example, only the potency, adherence, 
adverse events, and future drug options are required for the system to predict 
decision-making on a new fourth regimen among three other existing regimens. 
The retrospective performances of the HIV/AIDS-EFDES system’s self-learning 
provided an overall mean prediction rate under seven scenarios about 28 out of 
35 given prescriptions. These system predictions were obtained under 
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experimental environments of weak experts’ consensus and uncertainties of 
knowledge represented in the term of type-2 fuzzy sets. 
In conclusion, we applied the extended fuzzy discrete event theory for 
optimal decision-making on treatment regimen selection for naïve HIV/AIDS 
patients with highly active antiretroviral therapy. This HIV/AIDS EFDES system 
extended the FDES framework with use of the type-2 fuzzy sets to represent the 
uncertainties of clinical domains of diverse experts’ knowledge and experiences. 
Historically, three treatment regimens used in the model evaluation generated the 
agreement between experts and models with better results as compared to the 
agreement among experts. The retrospective performance of the system with the 
real patients treated in AIDS Clinic in 2001 provided the impassive promising 
results. The performance of the system’s self-learning was tested under various 
clinically possible settings for seven different scenarios involving four historical 
treatment regimens. The results show that in some certain circumstances, 
depending on which treatment regimens were learned, the models’ average 
prediction would be more accurate at the satisfaction level of more than 99%. The 
retrospective performance of the system provided overall mean accuracy around 
82% (28.8/35). That result was as good as the FDES-based system’s 
performance. However, the EFDES-based system would earn a benefit on the 
management of diverse and uncertainty of the experts’ knowledge and expertise. 
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4.2  Future Directions 
In the application of the EFDES theory to HIV/AIDS treatment regimen 
selection system, Type-2 fuzzy sets were allowed to play important role in 
extracting the expert’s knowledge and experiences into useable forms. The 
effectiveness measure was only used for online optimal control synthesis of the 
system to provide an appropriated treatment therapy. In realistic, there is an 
expense of the treatment therapy. What the treatment therapy a patient receives 
depends on his financial support. The cost of treatment therapy will then be 
needed to consider along with the treatment effectiveness measure for the system 
optimal control.  
There was an optimization problem in maximizing the overall matching 
between the treatment regimens assigned by the system and those regimens 
assigned by two AIDS experts for the 32 treatment objectives. The genetic 
algorithm in MATLAB’s Direct Search Toolbox was employed to solve that kind of 
problem through adjusting 26 weights for four clinical parameters for all of the 32 
treatment objectives. Other optimization approaches such as particle swarm 
optimization approach, simulated annealing method, etc., would be considered to 
be experimental search engines for the time-consuming task of optimizing the 26-
dimensional vector space. 
Finally, the challenge is the implementation of the EFDES-based system on 
the HIV/AIDS treatment selection for patients with the second round treatment. 
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HIV/AIDS is a global problem. Its treatment is dependent on the physician 
experts’ opinion. A system which is capable of supporting the treatment decision 
will be desired. Recently, the HIV/AIDS treatment regimen selection system 
appeared in literature that utilized theory of fuzzy discrete event system (FDES) to 
capture the meaning of experts’ knowledge; a form of consensus involving 
estimated points and type-1 fuzzy sets. The goal was to assign exact matching 
regimens as close as possible to those regimens preferred by the experts for 
patients. The system performance was 80% of satisfaction level with the 35 
retrospective patients. Extracting experts’ knowledge into the consensus forms 
would not be possible without being compromised by the experts. With equal 
respective experts, if one insists on his/her values, then the consensus would not 
be achieved. Conversely, the FDES theory would be no longer to handle such 
conflict. The theory of extended fuzzy discrete event system (EFDES) extended 
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the FDES theory that type-2 fuzzy sets would be allowed to be used in the system. 
This dissertation is to apply the EFDES theory to the HIV/AIDS treatment regimen 
selection system. Seven scenarios of the diversity of experts’ knowledge 
representation were categorized for the system. The MATLAB was implemented 
to model the system. Genetic algorithm in MATLAB’s Direct Search Toolbox was 
used to search an optimal vector of 26 weights for system parameters regarding 
the experts’ regimen-choices. As the same input of the retrospective patient data 
for the FDES-based system, the overall means of simulation results of EFDES-
based system demonstrated the degree of matching regimens being 80%. That 
result would be the same performance level of the FDES-based system as well. 
The EFDES-based system performance with self-learning provided the overall 
satisfaction level of above 80%. Moreover, the EFDES-based system with use of 
the type-2 fuzzy set gained the benefit on the extraction of diverse and uncertainty 
experts’ knowledge and expertise.  
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